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Abstract 
Eukaryotic initiation factor 2 (eIF2) is a G protein comprised of 3 subunits (α, β and γ) 
that is critical for translation. It is tightly regulated in the integrated stress response 
(ISR) via the phosphorylation of its α subunit following the induction of cellular stress. 
In its phosphorylated form eIF2α inhibits the guanine nucleotide exchange factor (GEF) 
eukaryotic initiation factor 2B (eIF2B), resulting in the attenuation of global protein 
synthesis. eIF2B is a multisubunit protein comprised of regulatory and catalytic 
subunits. The catalytic subunits are responsible for the GEF activity whereas the 
regulatory subunits mediate inhibition by phosphorylated eIF2α. Through studying the 
localisation of eIF2B subunits, cytoplasmic eIF2B bodies were identified in mammalian 
cells. A relationship between body size and the eIF2B subunits localising to them exists; 
larger bodies contain all subunits and smaller bodies contain predominantly catalytic 
subunits. eIF2 localises to eIF2B bodies and moves through these bodies in a manner 
that correlates with eIF2B GEF activity. Upon the induction of cellular stress 
phosphorylated eIF2α localises predominately to larger eIF2B bodies which contain 
regulatory subunits and a decrease in the movement of eIF2 through these bodies is 
observed. Interestingly, drugs that inhibit the ISR can rescue the movement of eIF2 
through these eIF2B bodies, in a manner that correlates to cellular levels of 
phosphorylated eIF2α. In contrast, smaller eIF2B bodies, which contain predominately 
catalytic subunits, show increased movement of eIF2 during cellular stress. This 
increase in movement is accompanied by an increase in the localisation of eIF2Bδ to 
these bodies, suggesting the formation of a novel eIF2B subcomplex. This response is 
mimicked by ISR-inhibiting drugs, providing insight into their potential mechanisms of 
action. This study provides the first evidence that the composition and function of 
mammalian eIF2B bodies is regulated by the ISR and the drugs that control it.  
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1. Introduction 
1.1 General Introduction 
Different cell types exhibit distinct gene expression profiles which are rapidly 
modulated in response to internal and external stimuli. Genes are transcribed into 
mRNA molecules in the nucleus and then transported to the cytoplasm where they are 
translated into proteins. The initiation step of translation is rate limiting and therefore 
modulation of this step provides a control point in gene expression. The protein 
eukaryotic initiation factor 2 (eIF2) in its active guanosine triphosphate (GTP) bound 
form is essential for translation initiation. Following subsequent rounds of translation 
eIF2B acts as a guanine nucleotide exchange factor (GEF) and is required to replenish 
eIF2-GTP within the cell (Panniers and Henshaw, 1983). Recognition of adverse stimuli 
by a number of cellular pathways can lead to the inhibition of eIF2B via a common 
pathway termed the integrated stress response (ISR).  Tight control of eIF2B by the ISR 
is particularly important in allowing the cell to respond to adverse conditions that 
induce cellular stress. 
In yeast eIF2B has been found to localise to cytoplasmic foci termed, eIF2B bodies 
(Campbell et al., 2005; Moon and Parker, 2018; Noree et al., 2010; Taylor et al., 2010). 
These foci appear to be sites of GEF activity that can be regulated by conditions of 
cellular stress (Campbell et al., 2005; Taylor et al., 2010). The localisation of eIF2B has 
not previously been investigated in mammalian cells. Mutations in mammalian eIF2B 
are causative of the neurodegenerative disease, leukoencephalopathy with vanishing 
white matter (VWM). The pathophysiology of VWM is unclear and therefore 
investigating the cellular localisation of eIF2B may provide a platform to better 
understand disease mechanisms. This thesis aims to characterise mammalian eIF2B 
localisation and explore the role of this localisation with respect to the ISR.  
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1.2 Translation 
Eukaryotic genomes encode thousands of proteins and through the process of 
translation; the cell can rapidly control gene expression. Messenger RNA (mRNA) 
molecules are transcribed from genes and provide a template to synthesise a 
polypeptide chain complementary to the DNA sequence of the gene. The structure of a 
mRNA molecule is shown in Figure 1.1. Structurally the 5' end of a mRNA molecule 
encodes an untranslated region (5' UTR). The UTR serves as a ribosome binding site 
and can also contain upstream open reading frames (uORFs) for non-canonical 
methods of translation (Young and Wek, 2016). The far 5' nucleotide of the mRNA is 
bound to the mRNA by a triphosphate bond and methylated at position 7 (Shatkin, 
1976). This nucleotide is referred to as the cap structure and is required for cap-
dependent translation (Section 1.2.1.2.1). The coding sequence of the mRNA contains 
a number of codons that encode the amino-acid sequence for the protein and a start 
codon for the initiation of translation and a stop codon for termination. Following the 
coding region the mRNA has a 3' UTR which often contains binding sites for regulatory 
proteins (Barrett et al., 2012). A poly(A) tail (stretch of adenine bases) is added to the 
far 3' end of mature mRNA molecules, providing protection against degradation and 
also enhancing cap-dependent translation (Dreyfus and Régnier, 2002).  
Through the process of translation mRNAs are selectively translated into proteins. 
Tight regulation of the translation pathway controls the cellular abundance of specific 
proteins to promote cellular homeostasis. Central to the process of translation is the 
ribosome. Ribosomes from all species consist of two subunits both of which are 
formed from numerous ribosomal proteins and ribosomal RNA molecules 
(Ramakrishnan, 2011). The complete 80S eukaryotic ribosome is formed from a smaller 
40 S subunit, responsible for decoding the mRNA sequence and a larger 60 S subunit, 
which catalyses peptide bond formation (Doudna and Rath, 2002). The translation 
pathway can be divided into three stages: initiation, elongation and termination. 
During the initiation phase, the 80 S ribosome is assembled at the start codon of a 
target mRNA molecule, mediated by a number of eukaryotic initiation factors (eIFs) 
(Hinnebusch and Lorsch, 2012). During the elongation phase, the ribosome 
translocates each codon of the target mRNA molecule in turn (Doudna and Rath, 
2002). Transfer ribonucleic acid (tRNA) molecules carrying amino acids selectively 
17 
 
interact with the ribosome through complementary binding of the tRNA anticodon and 
mRNA codons positioned within the ribosome (Dever and Green, 2012). The ribosome 
catalyses the formation of peptide bonds between the amino acids carried by the 
tRNAs (Doudna and Rath, 2002). As the ribosome translocates the mRNA a polypeptide 
chain is selectively synthesised. In the final step of translation, the termination step, 
the polypeptide chain is released from the ribosome and the translational machinery 
disassembles, ready to facilitate subsequent rounds of translation.  
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Figure 1.1 The structure of a mRNA molecule.  
The sequence of a mRNA transcript can be divided into five sections. In a 5' to 3' 
direction these are: The cap structure, the 5' untranslated region (UTR), the coding 
sequence, the 3' UTR and the poly(A) tail. The coding sequence encodes a template for 
the amino acid sequence of a protein. The 5' and 3' UTR do not encode the protein 
sequence but are important for the regulation of the protein translation. The cap 
structure and the poly(A) tail protect the mRNA from degradation and facilitate its 
translation.  
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1.2.1 Translation initiation 
The complex process by which ribosomes are recruited to the mRNA and the 
appropriate start codon is selected, is defined as translation initiation. In eukaryotes, 
the highly conserved heterotrimeric G-protein eIF2 is essential for this process. In its 
active GTP bound form, eIF2 binds to a methionyl initiator transfer RNA (Met-tRNAi) 
molecule to form a ternary complex. The ternary complex is loaded onto the small 
(40S) ribosomal subunit facilitated by the binding of other eIFs, to form a 43S pre-
initiation complex (PIC) (Hinnebusch and Lorsch, 2012). The PIC is recruited to the 5'-
end of a target mRNA molecule, and scans the mRNA sequence for an appropriate 
start codon (Hinnebusch and Lorsch, 2012). During the scanning process, eIF2-GTP is 
hydrolysed, mediated by the GTPase-activating protein eIF5 (Huang et al., 1997). Upon 
start codon recognition eIF2-GDP is released in combination with eIF5, and the 60S 
ribosomal subunit interacts with the 40S ribosomal subunit. This initiation process 
generates a full 80S ribosome with an appropriately positioned Met-tRNAi at the start 
codon of a mRNA ready to enter the translation elongation phase (Hinnebusch and 
Lorsch, 2012).   
1.2.1.1 Formation of the 43 S Preinitiation complex 
In the first step of translation initiation, a ternary complex comprised of eIF2-GTP and 
a Met-tRNAi is loaded onto the 40 S ribosomal subunit to form a 43 S PIC (Hinnebusch 
and Lorsch, 2012). In its GTP-bound form, eIF2 has high affinity for Met-tRNAi and 
interacts to form the ternary complex (Erickson and Hannig, 1996; Kapp and Lorsch, 
2004; Levin et al., 1973; Safer et al., 1975). eIF2 is comprised of three non-identical 
subunits, α, β and γ. The γ subunit of eIF2 binds the Met-tRNAi and the α and β 
subunits appear to stabilise this interaction (Naveau et al., 2010; Nika et al., 2001; 
Yatime et al., 2004). 
The loading of the ternary complex onto the 40 S ribosomal subunit is facilitated by 
eIFs 1, 1A, 3 and 5. eIF1 and 1A induce a conformational change in the 40 S ribosomal 
subunit which promotes the association of the ternary complex (Passmore et al., 
2007). Binding of eIF1 to the 40 S ribosomal subunit requires the presence of eIF3, and 
additionally binding of eIF1A to the 40 S ribosomal subunit requires the presence of 
both eIF1 and eIF3 (Majumdar et al., 2003). eIF5 has a role bridging the interaction 
between eIF2 and eIF3 (Asano et al., 2000). Interestingly, eIF1, 2, 3 and 5 have been 
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shown to form a stable multifactorial complex (MFC) complex in yeast (Asano et al., 
2000) and more recently in mammalian cells (Sokabe et al., 2012). The rate in which 
the Met-tRNAi is delivered to the 40 S ribosomal subunit is independent of whether it 
is complexed with eIF2-GTP alone as a ternary complex (which interacts with eIF1, 3 
and 5 already bound to the 40 S subunit) or in combination with eIF1, 3 and 5 as a MFC 
(Sokabe et al., 2012). The role of the MFC in the initiation of translation therefore 
appears to be of little significance for the formation of the 43 S PIC. Recent data has 
suggested the MFC may have a more apparent role in the assembly of the 80 S 
ribosome complex through promoting eIF2 release from the Met-tRNAi (Sokabe et al., 
2012).   
1.2.1.2 mRNA recruitment and scanning 
1.2.1.2.1 Cap-dependent initiation 
The 43 S PIC is loaded onto the 5' end of a target mRNA molecule facilitated by the cap 
complex, eIF4F, formed of eIF4E, eIF4A and eIF4G (Figure 1.2). The attachment of the 
ribosome is impeded by secondary structures in the mRNA 5' UTR. In order to facilitate 
the 43 S PIC binding to mRNAs with structured 5' UTRs, eIF4A exerts helicase activity to 
produce a single stranded binding site near the 5' cap of the mRNA (Rogers et al., 
1999). eIF4A lacks RNA-binding domains and only weakly interacts with single stranded 
mRNA (Lorsch and Herschlag, 1998). eIF4E however can recognise and interact with 
the mRNA cap structure, and is responsible for recruiting eIF4A to the 5' UTR of the 
target mRNA (Rogers et al., 2001). This interaction of eIF4E with the mRNA cap is 
enhanced by eIF4G (Gross et al., 2003), which also acts as a scaffold protein orientating 
eIF4A in the correct position to unwind the mRNA structure (Hilbert et al., 2011; 
Oberer et al., 2005; Schutz et al., 2008). eIF4G also stabilises the binding of the 43 S PIC 
on to the mRNA molecule through interactions with eIF3 (Villa et al., 2013). 
Additionally, eIF4G can interact with the poly(A)-binding protein (PABP) present at the 
3' end of a mRNA molecule (Tarun and Sachs, 1996) to produce a closed loop structure 
that is thought to enhance translation efficiency and ribosome re-initiation (Michel et 
al., 2000; Wells et al., 1998). 
Once bound the 43 S PIC complex scans the mRNA in a 5' to 3' direction until a start 
codon is detected through complementarity to the anticodon of the Met-tRNAi (Figure 
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1.2). eIF1 and eIF1A promote a scanning-competent conformation of the 40 S 
ribosomal subunit (Passmore et al., 2007) and ATP-dependent helicase activity of 
eIF4A melts secondary structures of the mRNA allowing the 43 S PIC to translocate 
along it. The requirement of eIF4A is proportional to the degree of secondary structure 
(Jackson, 1991; Svitkin et al., 2001), and for moderately structured mRNA molecules 
eIF4B is required as a co-factor of eIF4A to stimulate its helicase activity (Dmitriev et 
al., 2003; Özeş et al., 2011; Rozovsky et al., 2008). In the case of highly stable 
secondary structures the helicase activity of eIF4A is not sufficient and the helicase 
DHX29 is required (Pisareva et al., 2008). 
1.2.1.2.2 Cap-independent initiation 
Although 95 % of mRNAs are translated via cap-dependent initiation (Merrick, 2004), 
cap-independent initiation also occurs in eukaryotic cells. Cap-independent initiation 
bypasses the requirement for cap-dependent ribosome scanning. It relies on the 
presence of internal ribosome entry sites (IRES) in the mRNA sequence that allow for 
the direct recruitment of the 40 S ribosome subunit to the vicinity of the start codon 
(Van Eden et al., 2004). The involvement of eIFs in cap-independent initiation varies 
between mRNA transcripts and it is believed that the secondary structures of IRES can 
facilitate interactions between the mRNA and the translational apparatus (Pisarev et 
al., 2005).  
1.2.1.3 Start codon selection and 80 S ribosome assembly  
The 43 S PIC scans the mRNA until a start codon, most commonly AUG, is detected 
through complementary binding of the Met-tRNAi anticodon (Figure 1.2). The α 
subunit of eIF2 and the 18 S ribosomal RNA (rRNA) component of the small 40 S 
ribosomal subunit, interact with specific nucleotides surrounding the start codon, 
increasing the efficiency for selection of start codons in optimal context (Kozak, 1986; 
Pisarev et al., 2006). During ribosome scanning eIF2-GTP is hydrolysed, promoted by 
the GTPase-activator protein eIF5 (Huang et al., 1997). The subsequent GDP and 
inorganic phosphate (Pi) molecules are not released from eIF2 keeping it in a scanning-
competent conformation. Upon start codon selection, the 43 S PIC undergoes a large 
conformational change, eIF5 promotes the displacement of eIF1 (Algire et al., 2005; 
Maag et al., 2005; Nanda et al., 2009) and subsequently the Pi molecule from eIF2 is 
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released (Algire et al., 2005) (Figure 1.2). The conformation adopted by the 43 S PIC 
triggers scanning arrest. In its GDP-bound form eIF2 has reduced affinity for the Met-
tRNAi (Erickson and Hannig, 1996; Kashiwagi et al., 2019) and this affinity is further 
reduced by the association of the PIC components eIF5 and eIF3 (Sokabe et al., 2012). 
eIF2-GDP is released from the 43 S PIC in complex with eIF5 (Algire et al., 2005; Singh 
et al., 2006), allowing for eIF5B-GTP to bind (Figure 1.2). eIF5B-GTP interacts with 
eIF1A (Marintchev et al., 2003) recruiting it to the 40 S ribosomal subunit where it 
accelerates the joining of the 60 S ribosomal subunit, stimulating the release of eIF1 
and eIF3 (Unbehaun et al., 2004) and forming the complete 80 S ribosomal complex 
(Acker et al., 2006) (Figure 1.2). eIF5B hydrolyses GTP to induce a conformational 
change which is accompanied by the release of eIF5B and eIF1A (Figure 1.2), 
positioning the 80 S ribosomal subunit ready for translation elongation (Fringer et al., 
2007).  
1.2.1.4 Recycling of eIF2-GTP   
In order for subsequent rounds of translation initiation to occur within the cell, eIF2-
GTP must be replenished. eIF2 has a higher affinity for GDP (Erickson and Hannig, 
1996), and thus the GEF, eukaryotic initiation factor 2B (eIF2B), is required for the 
recycling of eIF2-GDP to its GTP bound form (Figure 1.2). In yeast eIF2B acts as a dual 
functioning protein (Jennings et al., 2013). eIF2-GDP is released from the 43 S PIC in 
complex with eIF5, which functions as a GDP dissociation inhibitor (GDI) (Jennings and 
Pavitt, 2010). eIF2B acts as a GDI displacement factor (GDF) to release eIF2-GDP from 
eIF5 (Jennings et al., 2013), prior to performing its GEF activity. In mammalian cells the 
role of eIF2B as a GDF has not currently been evaluated however unlike in yeast, 
mammalian eIF5 does not appear to have GDI activity (Sokabe et al., 2012). The GEF 
activity of eIF2B is tightly regulated within the cell. The structure and role of eIF2B will 
be further reviewed in Section 1.4.  
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Figure 1.2 Translation initiation pathway.  
A ternary complex formed of eIF2-GTP and a methionylated initiator tRNA, is recruited 
to the 40S ribosomal subunit by various eIFs to form a 43 S PIC. Facilitated by other 
eIFs, the 43 S PIC is loaded onto a target mRNA molecule and scans the mRNA 
sequence for a start codon. Upon recognition of a start codon, eIF2-GTP is hydrolysed 
and released in complex with eIF5. eIF5B accommodates the binding of the 60S 
ribosomal subunit to the 40S subunit forming the elongation ready 80S ribosome. eIF2-
GDP-eIF5 is recycled to eIF2-GTP by eIF2B.  
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1.2.2 Translation elongation 
During the elongation phase of translation, a nascent polypeptide chain 
complementary to the mRNA coding sequence is synthesised. This reaction is catalysed 
by the 80 S ribosome. Through a series of conformational changes mediated by 
eukaryotic elongation factors (eEFs), the 80 S ribosome facilitates the sequential 
joining of each amino acid in the chain. The process of translation elongation is highly 
conserved between eukaryotes and bacteria and mechanistic insights to this process 
have been largely generated in bacterial systems (Rodnina and Wintermeyer, 2009).  
The 80S ribosome has three tRNA-binding sites, the A-site, the P-site and the E-site 
(Ben-Shem et al., 2011). Following translation initiation the 80S ribosome is positioned 
with the Met-tRNAi located in the P-site, stabilised through complementary binding of 
its anticodon to the start codon (Figure 1.3). In the first step of elongation, termed 
decoding, the ribosome selects a tRNA with an anticodon that is complementary to the 
second codon in the open reading frame which resides in the A site of the ribosome.  
The eukaryotic elongation factor 1A (eEF1A), in its GTP-bound form, delivers the 
aminoacyl-tRNA to the ribosomal A-site. Upon complementary base pairing of an 
aminoacyl-tRNA anticodon and the mRNA codon, eEF1A is hydrolysed, releasing the 
factor and depositing the aminoacyl-tRNA in the A-site (Figure 1.3) (Dever and Green, 
2012). The peptidyl transferase centre of the large ribosomal subunit catalyses the 
rapid formation of a peptide bond between this aminoacyl-tRNA and the aminoacyl-
tRNA located in the P-site of the ribosome (Beringer and Rodnina, 2007), transferring 
the growing peptidyl chain onto the A-site of the ribosome and leaving the 
deaminoacylated-tRNA in the P-site (Figure 1.3). The ribosome then undergoes a 
conformational rearrangement, rotating both subunits (Frank and Agrawal, 2000; 
Zhang et al., 2009), positioning the acceptor ends of the tRNA molecules currently 
located in the P-site and the A-site of the ribosome to the E-site and P-site respectively 
(Moazed and Noller, 1989; Munro et al., 2007). eEF2 in its GTP-bound form is 
responsible for stabilising this rotated conformation (Agirrezabala et al., 2008) (Figure 
1.3). Through its hydrolysis, eEF2 promotes the translocation of the mRNA, positioning 
the third codon of the open reading frame in the A-site and the first and second 
codons accompanied by the bound tRNAs to the E-site and P-site respectively (Figure 
1.3) (Ratje et al., 2010). The ribosome subunits then rotate back to their original 
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conformation (Gao et al., 2009) ready for the next cycle of elongation. Through 
repetition of this process a polypeptide chain complementary to the mRNA coding 
sequence is synthesised.  
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Figure 1.3 Translation elongation pathway.  
Following translation initiation the Met-tRNAi is positioned in the ribosomal P site. 
eEF1A-GTP delivers a tRNA carrying a specific amino acid to the ribosomal A site where 
it binds through complementary binding of the tRNA anticodon to the mRNA codon. 
The 60S ribosomal subunit catalyses the formation of a peptide bond between the 
amino acid held in the P site and the A site. eEF2-GTP stimulates the translocation of 
the ribosome along the mRNA positioning the next codon of the mRNA sequence into 
the ribosomal A site. The tRNA is released from the E site and the process repeats until 
a stop codon is reached.  
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1.2.3 Translation termination and ribosome recycling 
The ribosome continues to translocate along the mRNA catalysing the formation of the 
polypeptide chain until a stop codon, UAA, UGA, or UAG, enters the A site (Capone et 
al., 1986). Recognition of a stop codon triggers the release of the polypeptide chain 
and recycling of the ribosome for subsequent rounds of translation in a process 
mediated by the eukaryotic release factors (eRF), eRF1 and eEF3 (Zhouravleva et al., 
1995).  
eRF1 binds to eRF3-GTP and acts as a GTP dissociation inhibitor (Pisarev et al., 2006). 
eRF3 directs eRF1 to the ribosome (Bertram et al., 2000), and interaction with the 
ribosome promotes the hydrolysis of eRF3-GTP (Frolova et al., 1996). Hydrolysis of 
eRF3 induces conformational changes in eRF1, positioning eRF1 in the peptidyl 
transferase centre of the ribosome, coupling stop codon recognition and peptide 
release (Alkalaeva et al., 2006; Fan-Minogue et al., 2008). Once the completed 
polypeptide chain has been released, the 80S ribosome must dissociate from eRF1 
(Pisarev et al., 2007), the mRNA and the de-acylated tRNA in order to initiate 
translation of other mRNA molecules. In some cases the ribosome may only partially 
dissociate, allowing for re-initiation of translation on the same mRNA transcript. This 
process relies upon the binding of eIF4F and PABP during initiation to bring the 5' and 
3' ends of a mRNA into close proximity (Tarun and Sachs, 1996), and occurs most 
commonly for transcripts that contain short open reading frames upstream of the 
main coding sequence (Gunišová et al., 2018). 
eRF1 and eRF3 have been shown to promote ribosomal subunit dissociation, however 
this occurs at a slow rate and is not sufficient to account for the rate at which a cell can 
reinitiate translation (Shoemaker et al., 2010). Translation initiation factors can 
mediate the recycling of the ribosome at specific concentrations of Mg2+ (Pisarev et al., 
2007). Binding of eIF3 to the 40S ribosomal subunit promotes disassembly into the 60S 
subunit and the 40S subunit bound to the mRNA and de-acylated tRNA (Siridechadilok 
et al., 2005). eIF1 then induces release of the de-acylated tRNA, followed by  eIF3 
mediated dissociation of the mRNA (Pisarev et al., 2010). More recently the protein 
ABCE1 was identified to promote ribosome recycling and is important for facilitating 
the process in a wider range of Mg2+ concentrations (Barthelme et al., 2011; Pisarev et 
al., 2010). 
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Figure 1.4 Translation termination and ribosome recycling pathway.  
The presence of a stop codon in the ribosomal A site triggers termination of 
translation. eRF3-GTP directs eRF1 to the ribosomal A site. eRF3-GTP hydrolysis 
stimulates binding of eRF1 to the stop codon and subsequent release of the 
polypeptide chain. eIF3 binds the 40S ribosomal subunit and mediates the release of 
the 60S ribosomal subunit. eIF1 then mediates the release of the mRNA and tRNA 
molecule freeing the 40S ribosomal subunit.  
  
29 
 
1.3 Regulation of translation initiation during cellular stress 
The process of translation involves a significant amount of cellular energy and 
therefore tight regulation is crucial in response to adverse cellular conditions. The cell 
must establish an impeccable balance between energy conservation and the synthesis 
of stress responsive proteins in order to restore cellular homeostasis. There are a 
number of pathways through which the cell can regulate translation initiation during 
cellular stress including, eIF4E-BP dephosphorylation (Patel et al., 2002) and eIF4G 
cleavage (Gradi et al., 1998; Svitkin et al., 1999). However, one of the best studied and 
most diverse mechanisms of translational control in response to cellular stress is the 
ISR; a series of stress sensing pathways that regulate translation through the common 
mechanism of eIF2 phosphorylation.  
1.3.1 The integrated stress response 
eIF2 plays a pivotal role in the initiation of translation and therefore serves as an 
important target for regulation. The core event of the ISR is the phosphorylation of 
eIF2α at serine residue 51 by stress-responsive eIF2α kinases, which leads to the 
inhibition of eIF2B. Once inhibited eIF2B cannot replenish eIF2-GTP within the cell and 
global translation is attenuated. Paradoxically, the translation of a number of stress-
responsive proteins is upregulated, conserving energy and favouring homeostatic 
reprogramming.  
1.3.1.1 Activation of the ISR and attenuation of global protein 
synthesis 
Through control of the guanine nucleotide status of eIF2, global translation levels can 
be manipulated as part of the ISR. Under normal cellular conditions, in its GTP-bound 
form, eIF2 forms a ternary complex with a Met-tRNAi. The ternary complex facilitates 
the delivery of the Met-tRNAi to the ribosome, and assists ribosomal translocation to 
an appropriate start codon, where complementary binding of the Met-tRNAi anticodon 
initiates translation. eIF2 is released in its inactive GDP-bound form, in combination 
with another initiator factor, eIF5. In order for subsequent rounds of translation to 
occur eIF2 must be released from eIF5 and replenished in its active GTP-bound form. 
This reaction is catalysed by eIF2B and therefore eIF2B provides a critical controlled 
point in the translation initiation pathway. A more detailed description of translation 
initiation can be found in Section 1.2.1. In response to various cellular stress stimuli, 
30 
 
stress-sensing pathways become activated and promote the induction of the ISR 
through the common down-stream mechanism of eIF2α phosphorylation (Brostrom 
and Brostrom, 1998; Dever et al., 1992). In its phosphorylated form eIF2 becomes a 
competitive inhibitor of eIF2B activity (Dever et al., 1995; Rowlands et al., 1988); 
subsequently levels of eIF2-GTP are depleted within the cell, leading to a global 
attenuation of protein synthesis (Figure 1.5). The precise mechanism of eIF2B 
inhibition by phosphorylated eIF2α is discussed in Section 1.4.3.1.  
In yeast a single eIF2α kinase, GCN2 (general amino acid control nonderepressible 2), is 
responsible for phosphorylating eIF2α and inducing the ISR in response to amino acid 
deprivation in order to reduce the cellular demand for amino acids (Vazquez de Aldana 
et al., 1994) (Figure 1.5). GCN2 is highly conserved from yeast to mammalian cells 
(Castilho et al., 2014), however in mammalian cells three additional eIF2α kinases 
which phosphorylate the same single serine residue of eIF2α exist (Donnelly et al., 
2013). These kinases are termed: PKR (protein kinase R), PERK (protein kinase RNA-like 
endoplasmic reticulum kinase), and HRI (heme-regulated inhibitor) (Castilho et al., 
2014) (Figure 1.5). The mammalian eIF2α kinases share extensive homology in their 
catalytic domains, which contain a dimerization interface, crucial for kinase activation 
and catalytic function. Each kinase however harbours a unique regulatory domain that 
allows for activation of the ISR by a range of cellular stresses (Berlanga et al., 1998; 
Chen et al., 1991; Harding et al., 1999; Meurs et al., 1990; Shi et al., 1998). PKR is 
activated mainly by double-stranded RNA (dsRNA) during viral infection and promotes 
survival by reducing the translation of viral mRNAs (Clemens and Elia, 1997; Lemaire et 
al., 2008). PERK is principally activated in response to endoplasmic reticulum (ER) 
stress, commonly caused by the accumulation of unfolded proteins in the ER. PERK 
activation alleviates this stress by decreasing the level of proteins localising to the ER 
(Harding et al., 2000; Patil and Walter, 2001). Unlike the other kinase molecules which 
are globally expressed, HRI is predominately expressed in erythroid cells and protects 
the cell against toxic globin aggregates. When heme is unavailable to form 
hemoglobin, HRI mediates the downregulation of protein synthesis, decreasing the 
translation of globin and preventing the formation of toxic globin aggregates (Han 
2001, Lu 2001). HRI has also been shown to be activated in non-erythroid cells in 
31 
 
response to arsenite induced oxidative stress and is required to promote cellular 
recovery through ISR signalling (McEwen et al., 2005).  
In addition to natural stimuli, the ISR can be induced chemically. Two chemicals 
commonly used to induce the ISR for experimental studies are Thapsigargin (Tg) and 
sodium arsenite (SA) (Figure 1.5). Tg is a potent inducer of ER stress, it inhibits the 
sarcoplasmic/ER Ca2+ ATPase (SERCA) causing a decrease in ER calcium levels. Depleted 
calcium levels within the ER leads to the inactivation of calcium-dependent chaperones 
required for protein folding (Hebert and Molinari, 2007; Oslowski and Urano, 2011). 
The accumulation of misfolded proteins in the ER results in the activation of the eIF2α 
kinase, PERK. SA is a potent inducer of oxidative stress. Treatment of cells with SA 
increases intracellular levels of reactive oxygen species (ROS) (Chen et al., 1998). 
Increased levels of intracellular ROS result in the activation of the eIF2α kinase HRI 
(Han et al., 2001; McEwen et al., 2005).   
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Figure 1.5 Activation of the ISR pathway.  
In response to various cellular stress stimuli eIF2α kinase molecules are activated 
through dimerization. eIF2α kinase molecules phosphorylate the α subunit of eIF2. In 
its phosphorylated form, eIF2 is a competitive inhibitor of eIF2B activity preventing 
replenishment of eIF2-GTP within the cell and inhibiting translation initiation.  
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1.3.1.1.1 Formation of stress granules 
Decreased levels of cellular eIF2-GTP leads to the formation of eIF2-GTP-deficient, and 
therefore non-productive preinitiation complexes. In the absence of productive 
preinitiation complexes, fewer ribosomes are loaded onto mRNA transcripts and as 
elongating ribosomes reach stop codons, global translation is down-regulated. Stalled 
complexes of mRNA molecules bound by non-productive preinitiation complexes can 
be recruited to large cytoplasmic granules, termed stress granules (SG) (Figure 1.6) 
(Kedersha et al., 1999; Kimball et al., 2003). In mammalian cells, SG assembly is 
mediated by RNA binding proteins including T-cell intracellular antigen 1 (TIA1), and 
GTPase activating protein binding protein 1 (G3BP) (Kedersha et al., 1999; Kimball et 
al., 2003). Through self-aggregation (Gilks et al., 2004; Tourrière et al., 2003), these 
RNA binding proteins promote the formation of a stable core structure containing 
mRNAs and non-productive preinitiation complexes, in addition to other proteins (Jain 
et al., 2016) . Recent evidence suggests that RNA-RNA interactions also promote the 
assembly of these core structures and contribute to their stability (Treeck et al., 2018). 
These core structures become rapidly surrounded by a more dynamic shell, formed 
through interactions of intrinsically disordered regions of RNA binding proteins (Jain et 
al., 2016). Studies have shown that SG components can rapidly shuttle through SGs, 
and it is suggested that the shell provides a scaffold for this dynamic exchange, with 
the transition of components between the core and shell modulated by numerous 
protein and RNA remodelling complexes (Buchan, 2014; Jain et al., 2016; Kedersha et 
al., 2000). It is currently believed that SGs provide a hub in which mRNAs can be sorted 
and then stored for translational re-initiation upon restoration of cellular homeostasis 
or instead be directed for decay (Anderson and Kedersha, 2006; Jain et al., 2016).  
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Figure 1.6 Stress granule formation pathway.  
Under normal cellular conditions eIF2B recycles eIF2-GDP into its GTP-bound form. 
eIF2-GTP along with a number of other eIFs form pre-initiation complexes with target 
mRNA molecules and the 40S ribosomal subunit. Translation of these pre-initiation 
complexes is initiated through hydrolysis of eIF2-GTP which promotes binding of the 
large ribosomal subunit. In response to conditions of cellular stress, eIF2 is 
phosphorylated and becomes a competitive inhibitor of eIF2B activity, preventing eIF2-
GTP recycling. Pre-initiation complexes form in the absence of eIF2-GTP. Joining of the 
large ribosome subunit is thus less favourable and translation becomes stalled. RNA 
binding proteins including G3BP and TIA1 mediate the aggregation of stalled pre-
initiation complexes to form SGs.  
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1.3.1.2 Cellular recovery signalling 
The length and severity of ISR induction determine the fate of a cell. During episodes 
of acute or short lived cellular stress, the ISR promotes cellular recovery signalling. 
However, in cases of severe or long lived cellular stress, where ISR signalling is unable 
to restore cellular homeostasis, the ISR can induce cell death signalling (Rutkowski et 
al., 2006). In addition to the down-regulation of global protein synthesis, the ISR 
induces translational up-regulation of specific mRNAs which mediate these signalling 
pathways. The translation of these mRNAs is most commonly regulated by the 
presence of upstream open reading frames (uORFs) in their 5' UTR. uORFs are 
generally inhibitory for the translation of a mRNA transcript under normal cellular 
conditions, however during episodes of cellular stress, they can promote the 
translation of a mRNA.  Under normal cellular conditions the circularisation of a mRNA 
through interactions between eIF4F and PABP promotes re-initiation of the scanning 
ribosome. Upon stop codon recognition, the 60S ribosome dissociates whereas the 40S 
ribosome remains associated. Binding of a ternary complex to the scanning 40S 
ribosome allows for consecutive rounds of translation of the mRNA transcript. When 
ternary complexes are present in abundance, translation is initiated at uORFs, however 
when ternary complex levels are depleted, the scanning ribosome is unlikely to bind a 
ternary complex by the time it reaches a uORF. As the ribosome will continue to scan 
the transcript until a ternary complex joins, it is more likely the ribosome will bypass 
any uORFs and initiate translation at the coding ORF, in a process termed leaky 
scanning, as shown in Figure 1.7. GCN4 in yeast was the first mRNA shown to be 
regulated by the ISR through the presence of uORFs (Mueller and Hinnebusch, 1986). 
Although there is no GCN4 ortholog in mammalian cells, the best characterised mRNA 
regulated via this mechanism is the transcription factor Activating transcription factor 
4 (ATF4). ATF4 mRNA is ubiquitously expressed; however under normal cellular 
conditions protein levels are low (Harding et al., 2000; Vallejo et al., 1993). The human 
ATF4 mRNA contains three uORFs (Harding et al., 2000) (Figure 1.7). Under normal 
cellular conditions, the first two uORFs which encode short polypeptides (3 amino 
acids and 12 amino acids in length respectively) are translated (Ameri and Harris, 
2008). The up-stream uORFs in mammalian ATF4 act as re-initiation uORFs; upon stop 
codon recognition, the 60S ribosome dissociates whereas the 40S ribosome remains 
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associated. When ternary complexes are readily available, the scanning 40 S ribosome 
acquires a new ternary complex in sufficient time to reinitiate translation at the next 
uORF. The final uORF sequence overlaps with the coding sequence of ATF4 in an out-
of-frame manner and therefore the translation of uORF3 inhibits the translation of 
ATF4 (Figure 1.7) (Lu et al., 2004b; Vattem and Wek, 2004).    
ATF4 can activate pro-survival mechanisms within the cell through a number of 
different pathways. Both PERK and GCN2 induced phosphorylation of eIF2α have been 
shown to induce ATF4 mediated autophagy (B’chir et al., 2013). Autophagy is a highly 
conserved cellular process that serves to recycle cytoplasmic materials in order to 
maintain cellular energy levels, metabolism and levels of amino acids (Mizushima and 
Komatsu, 2011). Additionally, PERK induced ATF4 signalling can alleviate ER stress that 
has been induced by the accumulation of unfolded proteins in the ER. ATF4 signalling 
activates two distinct signalling pathways, mediated by ATF6 and IRE1. ATF6 increases 
the ER protein folding capacity whereas IRE1 induces mRNA decay factors, reducing 
the protein folding load (Ron and Walter, 2011). If ISR signalling leads to the 
restoration of cellular homeostasis, ATF4-mediated activation of the transcription 
factor C/EBP homologous protein (CHOP), can contribute to the restoration of global 
translation. CHOP induces the transcription of Growth arrest and DNA damage-
inducible protein (GADD34), an eIF2α phosphatase regulatory subunit which 
contributes to the dephosphorylation of eIF2α (Brush et al., 2003). In cases of severe 
cellular stress where the pro-survival mechanisms induced by the ISR are unsuccessful 
in restoring homeostasis, the ISR promotes cell death signalling. One of the best 
studied mechanisms of ISR-induced cell death also involves ATF4-mediated activation 
of CHOP. CHOP has been shown to induce apoptosis via a number of mechanisms 
including, repression of anti-apoptotic proteins (McCullough et al., 2001) and 
upregulation of death receptors (Yamaguchi and Wang, 2004). Hence ATF4 and CHOP 
have extensive roles in the ISR and function as common mediators to produce tailored 
responses, both pro- and anti-survival dependent on the cellular stress stimuli.  
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Figure 1.7 Regulation of ATF4 expression by Leaky Scanning.  
ATF4 expression is regulated by the presence of three uORFs. Under normal cellular 
conditions levels of ternary complex are abundant within the cell. Scanning ribosomes 
readily associate with a ternary complex, initiating translation at the uORFs of ATF4. In 
response to conditions of cellular stress, levels of ternary complex are reduced within 
the cell and scanning ribosomes more commonly reach the coding region of ATF4 
before associating with a ternary complex.  
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1.3.2 Small molecule modulation of the ISR 
The ISR provides a central network for maintaining cellular homeostasis and therefore 
the dysregulation of ISR signalling has numerous pathological consequences and has 
been linked to conditions such as: cancer, diabetes, cardiovascular disease and 
neurodegeneration (Bi et al., 2005; Eizirik et al., 2008; Prahlad and Morimoto, 2009; 
Santos-Ribeiro et al., 2018). The ISR can induce both cell survival signalling and cell 
death signalling and maintaining a balance between these two signalling pathways is 
crucial. The phosphorylation of eIF2 is the core event through which all signalling 
pathways that stimulate the ISR converge, and therefore is an appealing therapeutic 
target. 
1.3.2.1 GSK2606414 
In neurodegenerative diseases, both ISR signalling enhancers and inhibitors can be 
neuroprotective, dependent on the underlying molecular mechanisms of the disease. 
Sephin 1, which indirectly prevents eIF2α dephosphorylation through the inhibition of 
GADD34, delays the onset of clinical symptoms in multiple sclerosis mouse models 
(Chen et al., 2019). Similarly the upregulation of PERK has also been shown to prevent 
clinical symptoms (Lin et al., 2007). In multiple sclerosis, the translation of ISR-
responsive-proteins reduces the cytotoxic impact of inflammation on oligodendrocytes 
reducing disease associated oligodendrocyte loss (Chen et al., 2019). Somewhat 
paradoxically, PERK inhibition can also reduce clinical symptoms of neurodegenerative 
disease. Increased levels of PERK and phosphorylated eIF2α have been documented in 
Parkinson's disease patients (Hoozemans et al., 2007). This is hardly surprising as the 
key pathological hallmark of Parkinson's is the aggregation of misfolded α-synuclein 
proteins into abnormal cellular deposits, termed Lewy bodies (Power et al., 2017). 
Although ISR-induced PERK signalling can be protective in reducing the load of 
misfolded proteins, chronic PERK activation (as in Parkinson's) prevents global 
translation and stimulates cell death. Treatment of Parkinson's disease mice with the 
PERK inhibitor GSK2606414 promotes survival of dopaminergic neurons and improves 
motor function, likely through restoring levels of synaptic proteins (Mercado et al., 
2018).  
Over the last decade, unfolded proteins in the brains of patients suffering from 
neurodegenerative or memory compromising diseases has been increasingly 
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documented (Scheper and Hoozemans, 2015). As a result, pharmaceutical modulation 
of PERK has gained significant interest over the last few years. In addition to 
Parkinson's disease, GSK2606414 also appears promising in preventing 
neurodegeneration in prion-disease, frontotemporal dementia and Marinesco-Sjögren 
syndrome (Grande et al., 2018; Moreno et al., 2013; Radford et al., 2015). GSK2606414 
however has poor pharmacokinetic properties. The specificity of GSK2606414 is 
limited with recent studies demonstrating it also inhibits Receptor-interacting 
serine/threonine-protein kinase 1 (RIPK1), a kinase involved in inflammatory signalling 
(Rojas-Rivera et al., 2017). Furthermore, in mouse models, GSK2606414 induces 
pancreatic toxicity (Moreno et al., 2013), likely due to pancreatic cells requiring some 
level of ISR induction to regulate high levels of protein synthesis for their endocrine 
function. These results highlight the requirement of tailored ISR targeting in different 
cell types.   
1.3.2.2 ISRIB 
Recently the small molecule ISRIB (ISR InhiBitor) was identified in a cell-based screen 
for inhibitors of PERK activity (Sidrauski et al., 2013). ISRIB reverses phosphorylated 
eIF2α induced translational repression (Halliday et al., 2015; Sidrauski et al., 2013; 
Sidrauski et al., 2015a), through restoration of eIF2B activity (Sekine et al., 2015; 
Sidrauski et al., 2015b). The mechanisms through which ISRIB enhances eIF2B activity 
will be discussed further in Section 1.4.3.2. Like GSK2606414, ISRIB is neuroprotective 
(Sidrauski et al., 2013), however it presents as a more promising therapeutic as it does 
not induce pancreatic toxicity (Halliday et al., 2015). This is likely due to the fact ISRIB 
only has a defined window of activation, and above a certain threshold of eIF2α 
phosphorylation ISRIB no longer inhibits the ISR (Rabouw et al., 2019; Sidrauski et al., 
2015a). This mechanism allows ISRIB to prevent low levels of ISR induction which may 
contribute to neurodegeneration, while retaining the cell’s ability to promote the 
cytoprotective effects of ISR activation in response to higher levels of cellular stress.  
1.3.2.3 DBM and Trazodone 
Similarly to ISRIB, the FDA-approved drugs dibenzoylmethane (DBM) and trazodone 
are also able to partially reverse stress-induced translational repression (Halliday et al., 
2017). The mechanism though which these drugs reverse the effects of the ISR is 
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currently unknown. Future studies into the mechanisms of these drugs could improve 
their therapeutic potential for neurological disease.  
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1.4 eukaryotic Initiation Factor 2B 
eIF2B is the guanine nucleotide exchange factor for eIF2 and therefore plays a 
fundamental role in the initiation of translation (described in Section 1.2.1). Although 
functionally similar to other guanine nucleotide exchange factors, eIF2B exhibits a 
greater level of complexity within its quaternary structure. It is composed of five non-
identical subunits, termed α through to ε, encoded in human cells by the genes EIF2B1-
5 respectively. In its native form eIF2B exists as a heterodecamer composed of two 
copies of each of its five subunits (Gordiyenko et al., 2014; Wortham et al., 2014), 
however within mammalian cells, eIF2B has also been documented to form sub-
complexes which contain varying degrees of the individual eIF2B subunits (Liu et al., 
2011; Wortham et al., 2014). The γ and ε subunits catalyse the guanine nucleotide 
exchange activity of eIF2B, whereas the α, β and δ subunits are required to regulate 
this activity in response to various cellular signals (Kimball et al., 1998; Pavitt et al., 
1997; Pavitt et al., 1998; Williams et al., 2001). Through its regulation, eIF2B provides a 
critical controlled point in the translation initiation pathway such that in response to 
adverse conditions the cell can down-regulate global translation to preserve energy. In 
yeast eIF2B localises to cytoplasmic bodies, termed eIF2B bodies. These foci represent 
sites where eIF2B catalytic activity occurs and is also regulated (Campbell et al., 2005). 
The cytoplasmic organisation of mammalian eIF2B complexes has not previously been 
investigated.  
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1.4.1 eIF2B subunit function  
The eIF2B catalytic subunits, eIF2Bɛ and eIF2Bγ, are responsible for the GEF activity of 
eIF2B. The C terminal domain of eIF2Bɛ facilitates binding of eIF2 and through its HEAT 
domain can catalyse eIF2 nucleotide exchange; however the rate of this exchange is 
greatly enhanced through joining of the other eIF2B subunits (Gomez and Pavitt, 
2000). eIF2Bγ enhances eIF2B activity through binding to GTP  (Williams et al. 2001; 
Gordiyenko et al. 2014), but also by facilitating the displacement of eIF5 from eIF2-GDP 
to allow for guanine nucleotide exchange, following the initiation of translation 
(Jennings and Pavitt, 2014). The eIF2B regulatory subunits are responsible for 
mediating levels of eIF2B activity, dependent on the cellular environment. As eIF2 has 
a higher affinity for GDP (Erickson and Hannig, 1996) the level of guanine nucleotide 
exchange activity of eIF2B within the cell can determine global translation rates. In 
response to conditions of cellular stress eIF2 becomes phosphorylated, converting eIF2 
from a substrate, to a competitive inhibitor of eIF2B GEF activity, stimulating the ISR 
(Dever et al., 1995; Rowlands et al., 1988) (Section 1.3.1). This phosphorylation 
induced inhibition is conferred by the eIF2B regulatory subunits. eIF2Bα in particular is 
required to confer this inhibition however mutational analysis of eIF2Bβ and eIF2Bδ 
suggests these subunits also contribute (Dev et al., 2010; Dever et al., 1993; Elsby et 
al., 2011; Fabian et al., 1997; Hannig et al., 1990; Kimball et al., 1998; Krishnamoorthy 
et al., 2001; Pavitt et al., 1997; Siekierka et al., 1982).  
1.4.2 eIF2B structural arrangement 
Prior to 2014, eIF2B was believed to be a pentameric complex comprised of one copy 
of each of its subunits, however mass spectrometry has revealed that eIF2B is actually 
a decameric complex comprised of two copies of each of its subunits (Gordiyenko et 
al., 2014; Wortham et al., 2014). The crystal structure of decameric eIF2B, solved for 
Schizosaccharomyces pombe (S. pombe) (Kashiwagi et al., 2016) and later solved for 
mammalian cells (Tsai et al., 2018; Zyryanova et al., 2018), revealed a central core 
composed of a hexameric arrangement of two copies of each of the regulatory 
subunits, flanked at opposite sides by a heterodimer of the catalytic subunits (Figure 
1.8). Expression of eIF2Bγ is required to stabilise the expression of eIF2Bɛ within the 
cell and the formation of a heterodimeric complex of these two subunits is believed to 
be the first step in decameric formation (Figure 1.9) (Wang et al., 2012; Wortham and 
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Proud, 2015). eIF2Bγ and eIF2Bɛ contain homologous domains with sequence 
similarity to nucleotidyl transferases (NT) and acyl transferases (AT) (Figure 1.10) 
(Koonin, 1995). Genetic manipulation of these domains in mammalian systems has 
revealed a requirement for the NT-like domain of both proteins to facilitate their 
binding, and also the binding of the regulatory subunits. The AT-like domain of eIF2Bɛ 
also facilitates association with the regulatory subunits; however the AT-like domain of 
eIF2Bγ is not required (Wang et al., 2012). The regulatory subunits of eIF2B reside 
within the centre of the decamer (Figure 1.8). It has been proposed that first a 
heterodimer of eIF2Bβ and eIF2Bδ bind the catalytic heterodimer, through interactions 
between eIF2Bβ and eIF2Bɛ, and eIF2Bδ and eIF2Bγ to form a tetrameric subcomplex 
(Figure 1.9). The decamer is completed through the joining of two tetrameric 
complexes stabilised by a homodimer of eIF2Bα (Figure 1.9) (Wortham and Proud, 
2015; Wortham et al., 2016). Studies in yeast first revealed that the eIF2B regulatory 
subunits share high sequence homology, particularly in their C terminal domains 
(Figure 1.10) (Bushman et al., 1993; Paddon et al., 1989) which are highly conserved 
from yeast to mammalian cells (Price et al., 1996).  The hydrophobicity of the C 
terminal domains facilitates the dimerization of eIF2Bα subunits to form homodimers, 
and the dimerization of eIF2Bβ and eIF2Bδ to form heterodimers (Bogorad et al., 2014; 
Kuhle et al., 2015). An eIF2Bα homodimer and two eIF2B(βδ) heterodimers form a 
hexameric structure within the decamer, facilitated by the arrangement of the C 
terminal domains into the decameric core (Kuhle et al., 2015). In this arrangement the 
N terminal domains are accessible for interactions with eIF2α (Figure 1.8) (Kashiwagi et 
al., 2016; Tsai et al., 2018; Zyryanova et al., 2018).   
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Figure 1.8 The crystal structure of mammalian eIF2B.  
The structure was solved by Kenner et al. (2019) PDB code 6O81 and was drawn here 
using PYMOL (DeLano, 2002). In its native conformation eIF2B exists as a decamer 
comprised of two copies of each of its 5 subunits. Two copies of each of the regulatory 
subunits (α, β, and δ) reside in the centre of the decamer, forming a hexameric 
regulatory core. The core is flanked on either side by a heterodimer of the catalytic 
subunits (γ and ε).  
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Figure 1.9 Schematic of eIF2B decamer assembly.  
A model for the assembly of decameric eIF2B was proposed by Wortham et al., 2015. 
eIF2Bɛ and eIF2Bγ subunits first bind to form a catalytic heterodimer. eIF2Bβ and 
eIF2Bδ subunits then bind the eIF2B catalytic heterodimer to form an eIF2B tetrameric 
subcomplex. Two eIF2B tetrameric subcomplexes are then bound by an eIF2Bα 
homodimer to complete the decameric conformation.  
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Figure 1.10 Schematic representation of regions of sequence homology within the 
eIF2B subunits. The catalytic subunits of eIF2B share domains of high sequence 
homology with each other, but also with nucleotidyl transferases (NT) and acyl 
transferases (AT). The regulatory subunits of eIF2B share domains of high sequence 
homology within their C terminal domains.  
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1.4.2.1 eIF2B subcomplexes 
In mammalian cells eIF2B(βδγε) tetrameric subcomplexes have been shown to exist 
(Figure 1.11) and in vitro GEF assays suggest they function at approximately 50 % the 
activity of the decameric complex (Liu et al., 2011; Wortham et al., 2014). Additionally, 
functional eIF2B(γε) catalytic subcomplexes have been identified in yeast and 
mammalian cells (Figure 1.11) and in vitro GEF assays suggest they harbour 
approximately 20 % of the activity of the decameric complex (Liu et al., 2011; Pavitt et 
al., 1998). Whether these subcomplexes are present as intermediates in decamer 
formation or are themselves functionally important complexes in cellular regulation is 
unknown. Due to the requirement of the eIF2B regulatory subunits to mediate the 
inhibitory effects of phosphorylated eIF2α, the presence of subcomplexes harbouring 
different arrangements of subunits could facilitate different responses to cellular 
stress. This could perhaps provide a highly controlled level of eIF2B regulation within 
the cell. 
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Figure 1.11 eIF2B complexes identified in mammalian cells.  
eIF2B forms a decameric complex in its native form composed of two copies of each of 
its five subunits. eIF2B has also been shown to form tetrameric complexes that contain 
one copy of each subunit except for the α subunit and heterodimers of one copy of 
each of the catalytic subunits; γ and ɛ.  
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1.4.3 eIF2B mediated regulation of translation initiation 
1.4.3.1 Regulation by phosphorylated eIF2α 
The initiation step of the translation pathway is rate limiting and therefore the 
inhibition of eIF2B by phosphorylated eIF2α (serine residue 51) provides an important 
mechanism through which translation can be controlled. Levels of eIF2B within the cell 
are lower than eIF2 and thus even partial phosphorylation is sufficient for the down-
regulation of protein synthesis. Although phosphorylated eIF2α has been known to 
inhibit eIF2B since 1982 (Siekierka et al., 1982), the exact mechanism through which 
phosphorylated eIF2 induces this inhibition has remained largely unknown. Recent 
structural studies have solved structures of eIF2B bound to both phosphorylated and 
non-phosphorylated eIF2α, providing the first insight into this precise mechanism 
(Adomavicius et al., 2019; Bogorad et al., 2017; Gordiyenko et al., 2018; Kashiwagi et 
al., 2019; Kenner et al., 2019). Although the structure of eIF2B is highly conserved 
(Kashiwagi et al., 2016; Tsai et al., 2018; Zyryanova et al., 2018), phosphorylated eIF2α 
appears to inhibit eIF2B via distinct mechanisms within yeast and mammalian cells.  
In yeast, both phosphorylated and non-phosphorylated eIF2α share a binding pocket 
(Figure 1.12). eIF2α binds to the C terminal domains of eIF2Bα and eIF2Bδ and has 
minor contacts with eIF2Bβ. This binding positions eIF2β and eIF2γ in close proximity 
to the catalytic domain of eIF2B, facilitating nucleotide exchange. Upon 
phosphorylation of eIF2α, conformational changes in the structure of eIF2α 
surrounding the phosphorylation site are believed to enhance the binding of eIF2α to 
eIF2Bα and eIF2Bδ. This results in a conformational change in eIF2B that displaces the 
catalytic domain from its original close proximity to eIF2β and eIF2γ inhibiting 
nucleotide exchange (Adomavicius et al., 2019; Gordiyenko et al., 2018). Similarly to 
yeast two molecules of eIF2 are able to bind mammalian eIF2B, however the binding 
site of eIF2 is not conserved from yeast to mammalian eIF2B. Mammalian eIF2α binds 
to decameric eIF2B by bridging across the two eIF2B(βδγɛ) tetrameric arrangements, 
binding to eIF2Bβ resident within one eIF2B(βδγɛ) tetramer of the decamer and eIF2Bδ 
resident within the opposite eIF2B(βδγɛ) tetramer (Figure 1.12). This arrangement 
positions eIF2γ in an orientation appropriate for catalytic exchange by eIF2Bɛ (Kenner 
et al., 2019). In yeast eIF2α interacts with each eIF2B(βδγɛ) tetramer independently, 
and the main contact between eIF2α and eIF2B is mediated by eIF2Bα (Adomavicius et 
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al., 2019; Kenner et al., 2019). Furthermore, unlike in yeast, in mammalian cells there 
is no overlap between the binding sites of eIF2α in its unphosphorylated and 
phosphorylated forms. Phosphorylation of eIF2α induces N terminal refolding, 
exposing hydrophobic residues that facilitate interactions with eIF2Bα and eIF2Bδ 
(figure 1.12). Binding of phosphorylated eIF2α to eIF2Bα and eIF2Bδ is non-productive 
for eIF2B GEF activity and blocks the binding site for non-phosphorylated eIF2, 
inhibiting eIF2B GEF activity (Kenner et al., 2019).  
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Figure 1.12 Crystal structures of mammalian and S. cerevisiae eIF2B bound to eIF2 
and eIF2α[P]. The mammalian structure was solved by Kenner et al. (2019) PDB code 
6O81 and the S. cerevisiae structure was solved by Adomavicius et al. (2019) PDB code 
6I3M. The structures here were drawn using PYMOL (DeLano, 2002). eIF2B is 
comprised of two eIF2B(βδγε) tetramers stabilised by an eIF2Bα homodimer. The 
binding pocket for mammalian eIF2 is formed by residues of eIF2Bδ and residues of 
eIF2Bβ present in opposite eIF2B(βδγε) tetramers. In its phosphorylated form the 
binding pocket for eIF2 is comprised of residues present in eIF2Bδ and eIF2Bα. The 
binding pocket of S.cerevisiae eIF2 is formed mainly from residues of eIF2Bα and 
eIF2Bδ. In its phosphorylated form eIF2 also binds to eIF2B through this binding 
pocket.     
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1.4.3.2 Regulation of eIF2B through binding of ISRIB 
The small molecule ISRIB was recently identified to reverse ISR-induced translational 
repression through restoration of eIF2B activity and appears to be a promising 
therapeutic, as discussed in Section 1.3.2.2. ISRIB is a small molecule that restores 
eIF2B activity through bridging two eIF2B(βδγɛ) tetramers to promote decamer 
formation (Sidrauski et al., 2015b; Tsai et al., 2018; Zyryanova et al., 2018) (Figure 
1.10). ISRIB binds between the N termini of eIF2Bδ and eIF2Bβ within the tetrameric 
structure, as ISRIB is a symmetrical molecule it can bind two tetramers in this way 
promoting the stabilisation of two tetramers to form an eIF2B(βδγɛ)2 octamer (Tsai et 
al., 2018; Zyryanova et al., 2018). The interface formed between the two eIF2B 
tetramers favours the binding of eIF2Bα homodimers when compared to single 
tetramers. Through stabilising this tetrameric interface, ISRIB promotes decameric 
formation (Tsai et al., 2018). The presence of ISRIB does not disrupt binding of 
phosphorylated eIF2 and consequently phosphorylated eIF2α is still capable of 
inhibiting eIF2B in the presence of ISRIB. The ability of ISRIB to restore translation 
within a cell is dependent on the levels of phosphorylated eIF2. In the absence of 
phosphorylated eIF2 ISRIB does not enhance eIF2B activity, however during episodes 
of mild cellular stress, associated with moderate phosphorylation of eIF2, ISRIB is able 
to enhance eIF2B activity (Rabouw et al., 2019; Sidrauski et al., 2015a). This is likely 
through stabilising the decameric conformation of eIF2B to increase the overall level of 
eIF2B activity within the cell. Decameric eIF2B harbours two eIF2 binding sights and is 
approximately twice as efficient at performing GEF activity when compared to 
tetrameric eIF2B which harbours only one eIF2 binding site (Kenner et al., 2019; Liu et 
al., 2011). During episodes of extreme cellular stress, associated with high levels of 
phosphorylated eIF2, ISRIB is no longer capable of rescuing eIF2B activity  (Rabouw et 
al., 2019; Sidrauski et al., 2015a). This is likely a consequence of the stabilised 
decameric complexes of eIF2B becoming saturated by the high level of phosphorylated 
eIF2 present within the cell when compared to non-phosphorylated eIF2.   
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Figure 1.13 ISRIB promotes eIF2B decameric assembly.  
ISRIB binds to eIF2Bβ and δ subunits within two distinct eIF2B(βδγɛ) tetramers, 
stabilising the binding of the two tetramers and forming an eIF2B(βδγɛ)2 octamer. The 
octameric conformation of eIF2B favours the binding of an eIF2Bα homodimer, 
promoting the assembly of the eIF2B decamer.   
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1.4.4 Cellular localisation of eIF2B 
In yeast eIF2B has been shown to localise to cytoplasmic foci which have been termed 
eIF2B bodies (Campbell et al., 2005; Moon and Parker, 2018; Noree et al., 2010; Taylor 
et al., 2010). eIF2B bodies are cytoplasmic granules formed of accumulations of eIF2B 
and eIF2. Morphologically eIF2B bodies commonly exist as a filamentous-like structure 
(Campbell et al., 2005; Noree et al., 2010). This morphology appears common in yeast 
with a number of other enzymes also documented to localise to filaments, including 
glutamine synthetase (GS) and Cytidine triphosphate synthetase (CTPS) (Noree et al., 
2010). Studies investigating the filamentous nature of GS and CTPS synthase have 
linked this localisation to enzyme inactivation and adverse cellular conditions (Noree et 
al., 2014; Petrovska et al., 2014). eIF2B bodies however appear somewhat different to 
these filamentous structures. Campbell et al., (2005) demonstrated that eIF2 
dynamically interacted with the eIF2B body at a rate that correlated with eIF2B GEF 
activity, suggesting that eIF2B bodies are sites of enzyme activity.  
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1.5 Vanishing White Matter disease 
The importance of eIF2B function within the cell is highlighted by the fact that 
mutations in any of the five subunits of eIF2B lead to the fatal neurological disorder, 
leukoencephalopathy with vanishing white matter (VWM). VWM is also known as 
childhood ataxia with central nervous system hypomyelination (CACH), and although it 
is a rare disease it is regarded as the most prevalent childhood leukodystrophy and is 
associated with a very poor prognosis (Bugiani et al., 2010). Clinically the disease is 
characterised by a mutation in any of the five subunits of eIF2B accompanied by 
chronic degradation of the cerebral white matter. The affected white matter appears 
thinned and porous due to dispersal by vacuoles and MRI imaging reveals 
cerebrospinal fluid filled areas where white matter has been largely degraded (van der 
Knaap et al., 1998). Phenotypically, symptoms and disease progression vary 
dramatically. This is likely due to the genetic complexity of VWM with currently around 
200 mutations, across the 5 eIF2B subunits, characterised as causative of VWM 
according to the Human Gene Mutation Database. There is no cure for VWM and 
elucidating common pathophysiological mechanisms across the broad spectrum of 
causative mutations remains difficult.  
1.5.1 Patient symptoms and clinical progression 
VWM disease has a wide clinical spectrum and the severity of disease appears to 
inversely correlate with age of onset (Hamilton et al., 2018). In classical cases of VWM, 
disease onset occurs in childhood and is symptomatically characterised by cerebellar 
ataxia, spasticity, mild mental decline and less commonly loss of vision and epilepsy 
(Hanefeld et al., 1993; Schiffmann et al., 1994; van der Knaap et al., 1997). In addition 
to neurological symptoms some patients also present with ovarioleukodystrophy 
(Boltshauser et al., 2002; Hamilton et al., 2018; van der Knaap et al., 2006). Exposure 
to stressful episodes including, fever, head trauma and acute fright can cause disease 
onset and can also contribute to episodes of rapid neurological deterioration, which 
influence disease progression. During these episodes patient motor function rapidly 
declines and recovery is usually incomplete. Patient prognosis is poor with severe 
episodes commonly resulting in comas which are often fatal (Maletkovic et al., 2008; 
van der Knaap et al., 1998). 
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 Milder cases of VWM appear to be associated with onset in adolescence or adulthood, 
where episodes of rapid deterioration are less prominent but cognitive problems are 
more apparent (Hamilton et al., 2018; Labauge et al., 2009; Van Der Knaap et al., 
2004). Early infantile and antenatal cases of VWM are associated with severe disability 
and higher mortality (Francalanci et al., 2001; Hamilton et al., 2018). In these early 
onset cases of VWM involvement of organs other than the brain and ovaries have been 
documented and patients often suffer symptoms including, cataracts, pancreatitis and 
kidney hypoplasia (van der Knaap et al., 2003).  
1.5.2 Pathophysiology and genotype-phenotype link 
VWM is a genetically complex disease. It is caused by autosomal recessive mutations, 
most commonly missense mutations that may exist in homozygous or heterozygous 
states (Pavitt and Proud, 2009). Frameshift and nonsense mutations occur less 
frequently (Li et al., 2004) and have never been observed in the homozygous state 
likely due to their association with severe VWM phenotypes (Pavitt and Proud, 2009). 
Figure 1.14, adapted from Shimada et al., (2015), demonstrates the distribution of 
over 100 characterised VWM mutations across the genes ecoding the eIF2B subunits. 
Mutations arise most frequently in EIF2B5 (encoding eIF2Bɛ), dispersed across the 
gene but largely sparing the 3' end which encodes the catalytic domain of eIF2B; 
mutations in this region would likely be fatal (Gomez and Pavitt, 2000; Gomez et al., 
2002). eIF2Bγ shares high sequence homology with eIF2Bɛ and mutations occuring in 
EIF2B3 (encoding eIF2Bγ), generally cluster around areas of sequence homology to 
EIF2B5. Additionally, mutations affecting the regulatory subunits also appear to cluster 
in regions of homology. The regulatory subunits of eIF2B (α,β and δ) share high 
sequence homology in their C terminal domains. VWM mutations identified in EIF2B1, 
EIF2B2 and EIF2B4 (encoding eIF2B α,β and δ respectively) in general cluster towards 
the 3' portion of the genes.  
Biochemical analyses have investigated the functional effects of VWM mutations on 
eIF2B. Some mutations destabilise interactions between eIF2B subunits affecting 
complex formation, whereas other mutations affect the GEF activity of eIF2B either 
directly or indirectly through impairing eIF2 binding (de Almeida et al., 2013; Fogli and 
Boespflug-Tanguy, 2006; Li et al., 2004; Richardson et al., 2004; Scheper et al., 2006; 
Wortham and Proud, 2015). The recent discovery of ISRIB appears a promising avenue 
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in the treatment of VWM mutations that destabilise the decameric conformation of 
eIF2B (Liang Wong et al., 2018; Tsai et al., 2018; Zyryanova et al., 2018). The small 
molecule 2BAct has recently been derived from ISRIB and has similar effects to ISRIB 
on eIF2B activity but improved pharmacodynamic properties. 2BAct prevents disease 
phenotypes in a VWM mouse models harbouring a mutation which effects eIF2B 
complex formation (eIF2Bε R191H mutation - R195H in humans) (Wong et al., 2019), 
demonstrating therapeutic potential for 2BAct in the treatment of eIF2B complex 
destabilising VWM mutants. Mutations have also been identified that affect neither 
complex formation nor eIF2B activity in vitro but cause some of the most severe forms 
of VWM in vivo (Liu et al., 2011; Wortham and Proud, 2015). The mechanisms of these 
mutations remain elusive and therefore the development of treatments for these 
particular mutations is difficult.  
Although eIF2B is a global regulator of protein synthesis, glial cells appear to be 
selectively vulnerable to eIF2B mutations, and VWM disease presents with populations 
of immature astrocytes and an increased number of oligodendrocyte progenitor cells 
(Dooves et al., 2016). Patient glial cells commonly exhibit an elevated ISR (Abbink et 
al., 2018; van der Voorn et al., 2005; van Kollenburg et al., 2006) and PERK induced 
induction of the ISR in mouse models has been found to recreate this glial cell 
phenotype (Lin et al., 2014). Primary fibroblast cells isolated from VWM disease 
patients have been shown to have a heightened stress response, characterised by a 
hyper-induction of the downstream ISR transcription factor ATF4, whereas patient 
lymphoblast cells appear to maintain normal levels of ATF4 induction following 
exposure to stress (Horzinski et al., 2010; Kantor et al., 2005). Although the exact role 
of the ISR is unclear in VWM pathophysiology these data suggest it may be linked to 
the tissue-specificity of VWM and is a key area for future research.   
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Figure 1.14 The distribution VWM mutations across the genes encoding the 5 eIF2B 
subunits adapted from Shimada et al., (2015).  
VWM mutations have been identified across all 5 subunits of eIF2B. Mutations most 
frequently occur in EIF2B5 and reside throughout the gene, except for the 3’ domain 
which is mostly spared. Mutations in EIF2B3 most commonly cluster within areas of 
the 5’ and 3’ ends of the gene which have high sequence homology to EIF2B5. 
Mutations in the genes encoding the regulatory eIF2B subunits, EIF2B1, EIF2B2 and 
EIF2B4 rarely occur within the 5’ sequences of the genes and cluster more within the 
central region and the 3’ end of the genes.  
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1.6 Project overview 
The functional localisation of eIF2B has not previously been investigated in mammalian 
cells. This thesis aims to elucidate localisation patterns of eIF2B in mammalian cells 
and determine the functional significance of this localisation under normal cellular 
conditions and during conditions of cellular stress. Currently the pathophysiology of 
VWM remains elusive, with the functional impact that mutations have on eIF2B, 
correlating poorly with disease severity and progression. It could be hypothesised that 
the localisation of eIF2B within a cell may contribute to VWM pathology. This study 
aims to characterise eIF2B localisation in cells affect by VWM pathology and explore 
the function of eIF2B localisation during conditions of cellular stress. 
The cellular localisation of eIF2B will be investigated under normal cellular conditions 
in cell types linked to VWM pathology. In yeast eIF2B localises to cytoplasmic bodies, 
termed eIF2B bodies. Here we aim to determine if eIF2B bodies exist in mammalian 
cells. It can be hypothesised that eIF2B will localise to eIF2B bodies in mammalian cells. 
In order to observe mammalian eIF2B localisation, a plasmid encoding a fluorescently 
tagged eIF2B subunit will be transiently expressed in mammalian cells and the 
phenotypic localisation of the eIF2B subunit will be visualised by confocal microscopy. 
ICC will be used to study the localisation of the other 4 subunits of eIF2B in relation to 
the fluorescently tagged subunit.  
If eIF2B is found to localise to cytoplasmic bodies in mammalian cells the relationship 
of eIF2 and the eIF2B body will be investigated. In yeast eIF2 exists as a mobile 
component of the eIF2B body and this mobility is manipulated by the modulation of 
eIF2B GEF activity. It is hypothesised that eIF2 will form a mobile component of eIF2B 
bodies and we aim to determine if the mobility will correlate to the activity of eIF2B 
within the cell. Fluorescent recovery after photobleaching (FRAP) analysis will be used 
as a tool to analyse the movement of eIF2 within eIF2B bodies and treatments with Tg 
and SA will be used to induce cellular stress as a method to decrease eIF2B activity 
within the cell.  
In recent years several small molecules have been found to relieve cellular stress 
induced translational repression (Sidrauski et al. 2015a; Halliday et al. 2017). If the 
dynamics between eIF2 and mammalian eIF2B bodies are found to be altered during 
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conditions of cellular stress, the impact of these molecules on eIF2B body dynamics 
will be assessed. To determine if this event occurs FRAP analysis will be used to 
investigate the movement of eIF2 within the eIF2B bodies. Transient expression of a 
fluorescently tagged eIF2B subunit coupled with ICC will be used to study eIF2B 
subunit distribution patterns.  
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2. Materials and Methods 
2.1 Cell culture 
2.1.1 Cell culture conditions 
U373 astrocytoma cells were cultured in Minimum Essential Medium (MEM), 
supplemented with 10 % (v/v) Fetal Bovine Serum (FBS), 1 % (w/v) non-essential amino 
acids, 1 % (w/v) sodium pyruvate, 1 % (w/v) glutamine and 1 % (w/v) 
penicillin/streptomycin, all purchased from Life Technologies Co. (New York, USA). 
Primary human astrocytes were cultured in Astrocyte Medium (AM) supplemented 
with 10 % (v/v) FBS, 1 % (v/v) astrocyte growth supplement and 1 % (w/v) 
penicillin/streptomycin, all purchased from ScienCell Research Laboratories 
(Buckingham, UK). MG-63 cells were cultured in Roswell Park Memorial Institute 
medium (RPMI) supplemented with 10 % (v/v) FBS and 1 % (w/v) 
penicillin/streptomycin. HEK293 and HepG2 cells were cultured in Dulbecco's Modified 
Eagle's Medium (DMEM) supplemented with 10 % FBS (v/v) and 1 % (w/v) 
penicillin/streptomycin. CHO-C30 cells and CHO-C30 cells harbouring the L180F 
mutation within the eIF2B4 gene (Sekine et al., 2015) were a kind gift from Prof D Ron 
(Cambridge Institute for Medical Research). Cells were cultured in Nutrient Mixture 
F12 Ham medium (Sigma, Dorset, UK) supplemented with 10 % Fetal calf serum 
(FetalClone II, Thermo) and 1 % (w/v) penicillin/streptomycin, (Life Technologies Co. 
(New York, USA)). All cells were maintained at 37°C under 5 % CO2 and were routinely 
tested for contamination with MycoAlert™ Mycoplasma Detection Kit purchased from 
Lonza (Slough, UK).   
2.1.2 Transient transfections 
One day prior to transfection, primary human astrocytes or CHO cells were seeded at a 
density of 1 x 105 cells, and all other cells were seeded at a density of 8 x 104 cells in a 
6-well plate or fluorodish. Transfections were performed by chemical transfection with 
1 mg mL-1 polyethylenimine (PEI) (Sigma, Dorset, UK). 1-3 µg of plasmid DNA was 
diluted in 100 µL of serum and antibiotic free cell culture medium. Diluted DNA was 
mixed with PEI and incubated at room temperature for 10 minutes. The volume of PEI 
used was based on a 3:1 ratio of PEI (µL):plasmid DNA (µg). 600 µL of antibiotic free 
cell culture media was added to the transfection mix, and the total volume added to 
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the cells. Cells were incubated at 37 °C for 23 hours, with an additional 2 mL of 
antibiotic free media added at the 2.5 hour time point. Cell culture media was changed 
to complete media and cells were incubated at 37 °C for 24 to 48 hours prior to 
imaging.  
2.1.3 Cell treatments 
To induce cellular stress, cells were treated with 1 µM Tg for 1 hour, or 125 µM SA for 
30 minutes or 500 µM SA for 1 hour (all purchased from Sigma, Dorset, UK). For drug 
treatments, cells were treated with 200 nM ISRIB, 20 μM DBM or 20 μM Trazodone for 
1 hour (all purchased from Sigma, Dorset, UK).  
2.2 Plasmids  
pCMV6-AC-GFP plasmid vectors encoding, EIF2B5 or EIF2S1 were purchased from 
Origene (Rockville, Maryland, USA). The coding ORF of EIF2B5 from the pCMV6-AC-GFP 
vector was cloned into a pCMV6-AC-RFP vector (Origene). The construct was verified 
by sequencing. The coding ORF of the EIF2S1 pCMV6-AC-GFP plasmid was mutated 
using site directed mutagenesis to generate an S51A mutation. The construct was 
verified by sequencing. pHM2Bε was a kind gift from Dr N Wortham, The University of 
Southampton.   
2.2.1 Site directed mutagenesis  
Site directed mutagenesis was performed using a QuikChange II Site-Directed 
Mutagenesis Kit (Agilent, Stockport, UK) in accordance with manufacturer's 
instructions. In order to increase the efficiency of bacterial transformations with 
mutagenic plasmid DNA, an extra step was performed. Following the DpnI digestion 
step, reactions were concentrated to 1/5 th of their original volume by ethanol 
precipitation. 3 M sodium acetate was diluted 1 in 20 in ice cold 100 % (v/v) ethanol (-
20 °C) and added to the reactions. The reaction mixtures were incubated at -20 °C for 1 
hour and the DNA was then pelleted by centrifugation at 17000 x g for 15 minutes. The 
supernatant was removed, and the DNA was washed once in cold 70 % (v/v) ethanol 
before being centrifuged again for a further 5 minutes. The supernatant was removed, 
and the pellet allowed to air dry at room temperature for 10 minutes. The DNA was 
then resuspended in sterile dH2O to 1/5
th the total volume of the original reaction 
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volume. DNA was stored at 4 °C until transformation following the manufacturer's 
instructions. 
2.2.2 Generating chemically competent E.coli 
XL 10-Gold ultracompetent cells (Fisher Scientific, Loughborough, UK) were inoculated 
in Lysogeny broth (LB) (Sigma, Dorset, UK) and incubated in a shaking incubator at 37 
°C overnight. The following morning the overnight culture was diluted 1 in 100 in LB. 
Cells were grown to an optical density at 600 nm (OD600nm) of between 0.5 and 0.7 and 
then incubated for 15 minutes on ice. Cells were pelleted at 4000 rpm for 5 minutes at 
4 °C and then resuspended in TBF I buffer (0.03 M potassium acetate, 0.05 M 
manganese chloride tetrahydrate, 0.01 M potassium chloride, 0.008 M calcium 
chloride tetrahydrate, 15 % (v/v) glycerol) and incubated for 1 hour on ice. Cells were 
then pelleted at 4000 rpm for 5 minutes at 4 °C and then resuspended in TBF II buffer 
(0.001 M 3-(N-morpholino)propanesulfonic acid, 0.001 M potassium chloride, 0.06 M 
calcium chloride tetrahydrate, 15 % (v/v) glycerol). Cells were aliquoted, flash frozen in 
liquid nitrogen and stored at - 80 °C. 
2.2.3 Bacterial Transformation 
Plasmid constructs were amplified by bacterial transformation. Competent Escherichia 
coli (E.coli) (-80 °C) were defrosted on ice for 30 minutes prior to transformation. 
Competent DH5α cells (generated in Section 2.2.2) were used to transform EIF2S1 
pCMV6-AC-GFP for site directed mutagenesis, and competent JM109 cells (Promega, 
Southampton, UK) were used for all other plasmid transformations. 1 μL of plasmid 
DNA was added to 50 μL competent E.coli and incubated on ice for 1 hour. Following 
incubation cells were heat shocked at 42 °C for 90 seconds. Transformations were then 
incubated on ice for 2 minutes prior to plating on LB Agar plates containing 50 mg mL-1 
carbenicillin, which were then incubated at 37 °C overnight.  
2.2.4 Extracting plasmid DNA from transformed E.coli 
Transformed bacteria were inoculated in LB containing 50 mg mL-1 carbenicillin and 
incubated in a shaking incubator at 37 °C overnight. Plasmid DNA was extracted from 
cultures using a GeneJET plasmid Miniprep kit (Fisher Scientific, Loughborough, UK) 
according to the manufacturers instructions. The concentration of the purified 
plasmids was determined using a NanoDrop 1000 Spectrophotometer.  
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2.3 Protein analysis 
2.3.1 Extraction of protein from cultured cells 
Culture media was removed, and cells were washed with phosphate buffered saline 
(PBS) (Sigma, Dorset UK). Cells were lysed in Cell Lytic M containing 1 % (v/v) protease 
inhibitor cocktail (Sigma, Dorset, UK), for 15 mins shaking at room temperature. Cell 
extracts were harvested by scraping flasks with a cell scraper. Cellular debris was 
pelleted by centrifugation at 12,000 x g for 12 minutes at 4 °C. Protein extracts were 
either subject to dot blot analysis or, for western blot analysis, the concentration of 
the extracts were quantified. 
2.3.2 Dot blot analysis 
For dot blot analysis 1 μL of protein sample was applied to a nitrocellulose membrane 
and allowed to air dry. Membranes were blocked in Tris-buffered saline supplemented 
with 0.1 % (v/v) Tween 20 (TBST) and 5 % (w/v) nonfat milk (Premier Foods, London, 
UK) for 1 hour. Primary antibodies were diluted in block solution and incubated with 
membranes overnight at 4 °C. The following antibodies were used: eIF2Bɛ (1:500 
dilution, ARP61329_P050; Aviva Systems Biology, San Diego, USA), eIF2Bγ (1:500 
dilution, sc-137248; Santa Cruz, California, USA), eIF2Bδ (1:100 dilution, sc-271332; 
Santa Cruz Biotechnology, California, USA) and β-actin (1:1000 dilution, ab8224, 
Abcam, Cambridge, UK). Membranes were then washed in TBST and incubated for 1 
hour with appropriate LiCor secondary antibodies diluted 1:10,000 in 5 % (w/v) nonfat 
milk in TBST. Dot blots were visualised on a LiCor Odyssey Scanner with Image Studio 
Lite software. 
2.3.3 Quantification of protein extracts  
Protein extracts were subject to a Bicinchoninic Acid (BCA) protein assay to determine 
the protein concentration for western blot analysis. Bovine Serum Albumin (BSA) 
(Sigma, Dorset, UK) was diluted in Cell Lytic M to generate a set of protein standards 
ranging from 0.1 mg mL-1 to 4 mg mL-1. Protein samples and standards were incubated 
in a 96-well plate with BCA reagent (0.4 % (w/v) copper sulphate in BCA) at 1:20 ratio 
for 30 minutes. The absorbance was determined using a Victor2 1420 multi-label 
counter (Wallac) at a wavelength of 570 nm.   
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2.3.4 Concentrating protein samples 
For western blot analysis protein samples were concentrated using 10 kDa MWCO Viva 
spin 2 columns (Fischer Scientific, Loughborough, UK), in accordance with the 
manufacturer's instructions.  
2.3.5 Western blot analysis 
Concentrated protein extracts were diluted in 4 x SDS-PAGE sample buffer (Expedeon, 
Swavesey, UK) and incubated at 95 °C for 4 minutes. 60 μg of total protein was 
resolved on a 10 % polyacrylamide gel, and electroblotted onto nitrocellulose 
membrane. Membranes were blocked in TBST supplemented with either 5 % (w/v) 
nonfat milk or 5 % (w/v) BSA for 1 hour. Primary antibodies were diluted in block 
solution and incubated with membranes overnight. The following antibodies were 
used: eIF2Bɛ (1:500 dilution, ARP61329_P050; Aviva Systems Biology, San Diego, USA), 
eIF2α (1:100 dilution, sc-11386; Santa Cruz Biotechnology, California, USA) and 
phospho-eIF2α (ser51) (1:1000 dilution, 44728G, Invitrogen, Fisher Scientific). In order 
to quantify levels of proteins detected by western blot a β-actin antibody (1:1000 
dilution, ab8224, Abcam, Cambridge, UK) was used as a loading control. Following 
primary antibody incubations, membranes were then washed with TBST, and then 
incubated for 1 hour with appropriate LiCor secondary antibodies diluted 1:10,000 in 
block solution (goat-anti-rabbit IRDye 680RD P/N 925-68071 and goat-anti-mouse 
IRDye 800CW P/N 925-32210) (LiCor, Cambridge, UK). Following secondary antibody 
incubations, membranes were washed with TBST and then visualised on a LiCor 
Odyssey Scanner with Image Studio Lite software.  
2.3.6 Puromycin incorporation assays  
For puromycin incorporation assays, cells were seeded at a density of 6.7 x 105 cells in 
T75 flasks. One day later, culture media was replaced with fresh media. Cells were 
then either untreated or treated as outlined in Section 2.1.3. For puromycin labelling, 
cells were incubated with 91 µM puromycin (Fisher Scientific, Loughborough, UK) and 
208 µM emetine (Sigma, Dorset, UK) for 5 minutes. Cells were then washed twice in ice 
cold PBS containing 355 µM cycloheximide (Sigma, Dorset, UK) and protein extracts 
were prepared as outlined in Section 2.3.1. Western blot analysis was performed on 
protein extracts as outlined in Section 2.3.5. For detection of puromycin, a primary 
puromycinylated protein antibody (1:500 dilution, clone 12D10, MABE343, Millipore, 
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Watford, UK) was used. In order to quantify levels of puromycin a primary antibody for 
β-actin (1:2000 dilution, ab8227, Abcam, Cambridge, UK) was used as a loading 
control. 
2.4 Immunocytochemistry 
Cells were grown on coverslips in 6 well plates and transfected as described in Section 
2.1.2. Cells were fixed in ice cold methanol (Fischer Scientific, Loughborough, UK) at -
20 °C for 15 minutes. Following fixation, cells were washed with PBS supplemented 
with 0.5 % (v/v) Tween 20 (PBST), and then blocked in PBS supplemented with 1 % 
(w/v) BSA. Cells were then washed with PBST, and probed with primary antibodies 
diluted in PBS supplemented with 1 % (w/v) BSA, overnight at 4 °C. The following 
antibodies were used: eIF2Bα (1:25 dilution, 18010-1-AP; Proteintech, Manchester, 
UK), eIF2Bβ (1:25 dilution, 11034-1-AP; Proteintech, Manchester, UK), eIF2Bδ (1:50 
dilution, sc-271332; Santa Cruz Biotechnology, California, USA), eIF2Bγ (1:50 dilution, 
sc-137248; Santa Cruz, California, USA), eIF2Bγ (1:100 dilution, 11296-2-AP, 
Proteintech, Manchester, UK), eIF2Bɛ (1:500 dilution, ARP61329_P050; Aviva Systems 
Biology, San Diego, USA), eIF2α (1:20 dilution, FL-315 sc-11386; Santa Cruz 
Biotechnology, California, USA), phospho-eIF2α (ser51) (1:100 dilution, ab32157; 
Abcam, Cambridge, UK),  myc (1:100 diltuion, ab18185, Abcam, Cambridge, UK), G3BP 
(1:100 dilution, ab56574, Abcam, Cambridge, UK), eIF3b (1:100 dilution, ab40799, 
Abcam, Cambridge, UK), polyubiquitinylated conjugates; FK1 (1:100 dilution, BML-
PW8805, Enzo Life Sciences, Exeter, UK). Following primary antibody incubation, cells 
were washed with PBST and then probed with an appropriate AlexaFLuor conjugated 
secondary antibody (Fisher Scientific, Loughborough, UK), diluted in PBS supplemented 
with 1 % (w/v) BSA, for 1 hour at room temperature. Cells were then washed with 
PBST and mounted using VECTASHIELD HardSet Antifade Mounting Medium with DAPI 
(Vector Laboratories, California, USA). Cells were viewed on a Zeiss LSM 510 or Zeiss 
LSM 800 confocal microscope.  
2.5 Confocal Microscopy 
2.5.1 Zeiss LSM 510 
The LSM 510 confocal was used with Zeiss 2009 software. All samples were imaged 
using a 40 X plan-apochromat oil objective. In order to image fluorophores excited at 
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488 nm and 568 nm, an argon laser with a maximum output of 25 mW at 55 % laser 
transmission was used. Fluorophores excited at 633 nm were imaged using a HeNe 
laser with a maximum output at 5mW at 100 % laser transmission.  
2.5.2 Zeiss LSM 800 
The LSM 800 confocal was used with Zen Blue software. All samples were imaged using 
a 40 X plan-apochromat oil objective, except in the case of Airyscan super resolution 
imaging where a 63 X plan-apochromat oil objective was used. To image DAPI staining 
a 405 nm diode laser with a maximum output of 5 mW was used. For imaging of 
fluorophores excited at 488 nm, a 488 nm diode laser with a maximum output of 10 
mW was used. In order to image fluorophores excited at 633 nm, a 640 nm diode laser 
with a maximum output of 5 mW was used. All lasers were used at 0.2 % laser 
transmission. 
2.5.3 FRAP analysis 
2.5.3.1 Imaging 
FRAP experiments performed for Chapter 3, Chapter 4 and Section 5.2.5 of Chapter 5 
were carried out on the LSM 510 confocal microscope. Bleaching was carried out with 
23 iterations at 100 % laser power (488 nm argon laser). An image was captured 
before bleaching and then after bleaching, 12 images were captured for 589.82 msec. 
For Chapter 3 FRAP experiments, a 600 msec interval between images was carried out. 
These timings were optimised to better represent the recovery period. For the FRAP 
experiments performed for Chapter 4 and Chapter 5, Section 5.2.5, images were 
captured without an interval. FRAP experiments performed for all other sections of 
Chapter 5 were carried out on the LSM 800. Bleaching was carried out with 23 
iterations at 100 % laser power (488 nm diode laser). An image was captured before 
bleaching and then after bleaching, 48 images were captured for 118 msec, with no 
interval between images. 
2.5.3.2 Analysis 
Pre-bleach, bleach and recovery images from each experiment were analysed in 
accordance to the methodology by Campbell and Ashe (2007). FRAP curves were fitted 
using GraphPad Prism software. The data was entered into a XY table and plotted. The 
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data was fitted to a one phase association model (below) where '𝑦0' is the 𝑦 value 
when 𝑥 is zero, 'Plateau' is the 𝑦 value at infinite values of 𝑥 and '𝐾' is the rate 
constant. The data was fitted using nonlinear regression. 
𝑦 = 𝑦0 + (𝑃𝑙𝑎𝑡𝑒𝑢 − 𝑦0). (1 − 𝑒
(−𝐾.𝑥)) 
The percentage of eIF2 recovery was determined as the mobile phase of the recovery 
curve represented as the plateau of the FRAP recovery curves.    
2.6 Analysing populations of eIF2B bodies 
2.6.1 Calculating percentages of different sized bodies 
Using confocal microscopy, different size populations of eIF2B bodies were observed. 
In order to categorise these bodies by size, Image J software was used to measure the 
area of the bodies. Scale bars were used to set the number of pixels per μm and the 
freehand line tool was used to draw around the eIF2B bodies in order to calculate the 
area. Three categories were determined, large bodies; ≥10 µm2, medium bodies; ≥ 3 
µm2 ≤ 9.99 µm2 and small bodies ≤ 2.99 µm2. Having determined the size categories for 
the different populations of eIF2B bodies, counts were performed by eye using the 
images of each sized body that had been measured on image J as a reference. In order 
to minimise human error, for all counts at least 50 cells were analysed and counts 
were performed blind. For each experiment, the number of bodies that had been 
counted were converted into percentages and graphs were plotted using GraphPad 
Prism software.  
2.6.2 Determining co-localisation of antibody staining with eIF2B 
bodies 
eIF2B bodies were counted as described in Section 2.6.1. eIF2B bodies were classed as 
positive for co-localisation when the eIF2B body signal and antibody signal overlapped 
completely.  
2.7 Statistical analysis 
In order to determine statistically significant differences within the groups of data 
presented in this thesis, all data was first subject to a shapiro wilk test for normality. 
Data was considered parametric when p < 0.05. All groups of data were found to be 
non-parametric. For the comparison of three or more groups of data a Kruskal-Wallis 
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test was performed followed by a Conover Inman post-hoc test, using StatsDirect 
Statistical Analysis software. Differences in data were considered significant when p < 
0.05.  
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3. Cellular localisation of mammalian eIF2B subunits 
3.1 Introduction 
The cytoplasm of a cell is highly organised and contains numerous intracellular 
structures. The process of translating protein is highly energy consuming and thus 
requires tight regulation within the cell. The accumulation and concentration of 
specific cellular components at precise foci allows for compartmentalisation of the 
various biochemical reactions that take place in the cytosol, allowing cells to function 
in an energy efficient manner. A number of translation associated factors have been 
well documented to accumulate into cytoplasmic granules, and these granules can 
function as sites of translational control.  
Under normal cellular conditions the translation of mRNA transcripts is initiated 
following the recruitment of the 80 S ribosome to an appropriate start codon, in a 
process facilitated by a number of eIFs (Chapter 1, Section 1.2.1). In response to 
conditions of cellular stress, global translation is downregulated to preserve energy 
and the translation of specific stress responsive mRNAs is upregulated to promote 
homeostasis in a process known as the ISR (Chapter 1, Section 1.3.1). One of the best 
characterised classes of translation factor containing granules are SGs and the 
assembly of SGs is driven by the ISR. The ISR is activated by the phosphorylation of 
eIF2α at serine 51, by a family of eIF2α kinases that serve as sensors to environmental 
stress (Donnelly et al., 2013). This phosphorylation of eIF2 results in the inhibition of 
eIF2B activity. eIF2B acts as a GEF for eIF2 and is required within the cell to restore 
levels of eIF2-GTP following successive rounds of translation (Chapter 1, Section 1.4). 
eIF2-GTP is required for efficient recruitment of the 80 S ribosome to an appropriate 
start codon and thus the reduced availability of eIF2-GTP stalls translation initiation 
within the cell. Preinitiation complexes and their associated mRNA transcripts are 
assembled into SGs (Kedersha et al., 2002) by specific RNA-binding proteins including 
G3BP (Tourrière et al., 2003) (Chapter 1, Section 1.3.1.1.1). SGs function as a reservoir 
of partly translated mRNA molecules that can return to the translating pool upon 
restoration of cellular homeostasis (Kedersha and Anderson, 2002). In cases where 
high levels of cellular stress remain, mRNA transcripts are degraded by the cell. P-
bodies are another class of cytoplasmic granule that contain translation associated 
factors. Like SGs, P-bodies form during conditions of cellular stress (although 
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phosphorylation of eIF2α is not necessary) and contain translationally repressed 
mRNAs. P-bodies however also contain mRNA decay machinery and were initially 
hypothesised to be cellular sites of mRNA decay (Kedersha et al., 2005; Sheth and 
Parker, 2003). More recent studies have challenged this hypothesis through 
demonstrating that mRNA molecules present in P-bodies can return to the translating 
pool (Brengues et al., 2005) and that mRNA decay can occur in the absence of P-bodies 
(Decker et al., 2007; Eulalio et al., 2007). The exact role of P-bodies is still unclear, but 
it is currently hypothesised they function as storage granules (Luo et al., 2018). 
eIF2B bodies are another class of translation associated cytoplasmic granules that have 
been shown to exist in yeast (Campbell, Hoyle and Ashe, 2005; Noree et al., 2010; 
Taylor et al., 2010; Moon and Parker, 2018). eIF2B bodies are less well characterised 
when compared to SGs and currently eIF2B and eIF2 are the only known components 
(Campbell et al., 2005; Noree et al., 2010; Taylor et al., 2010). The Ashe lab group first 
identified eIF2B bodies in Saccharomyces cerevisiae (S. cerevisiae) and demonstrated 
that eIF2B is a stable component of the body whereas the association of eIF2 is 
dynamic (Campbell et al., 2005). Furthermore, eIF2 moves through the bodies at a rate 
that correlates to eIF2B GEF activity suggesting that the bodies are sites of eIF2 
guanine nucleotide exchange (Campbell et al., 2005). It was predicted that if these 
bodies were sites of eIF2B GEF activity they may have an important role in translation 
initiation. Seemingly it was demonstrated that eIF2B bodies exist in readily translating 
cells, and that inhibition of translation resulted in the dispersal of the eIF2B bodies 
(Campbell et al., 2005). A more recent study from the Parker group demonstrated 
eIF2B body assembly to only occur in response to cellular stress conditions in 
S.cerevisiae (Moon and Parker, 2018). These results are very much contradictory and 
further research into the role of eIF2B bodies during conditions of cellular stress may 
provide a clearer insight into their role.  
Mutations in eIF2B lead to the neurological disorder VWM (Leegwater et al., 2001; van 
der Knaap et al., 2002). The functional impact of eIF2B mutations correlate poorly with 
the severity of the patient phenotype (Liu et al., 2011) (Chapter 1, Section 1.5.2). eIF2B 
bodies are yet to be characterised in higher eukaryotes. Characterising the cellular 
localisation of eIF2B could offer further insight into the possible disease mechanisms of 
VWM. This chapter aims to explore eIF2B localisation patterns in mammalian cells. The 
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pathological effects of VWM are predominately observed within patient glial cells and 
therefore these cell types are of particular interest for exploring eIF2B localisation. The 
ɛ subunit of eIF2B has previously been documented to localise to SGs (Kimball et al., 
2003) and therefore eIF2B localisation in relation to SGs and P-bodies will also be 
explored.  
It can be hypothesised that as in yeast, eIF2B will localise to discrete cytoplasmic 
bodies in mammalian cells. In order to determine if eIF2B localises to cytoplasmic 
bodies in mammalian cells, a plasmid encoding eIF2Bε C-terminally tagged with GFP 
will be expressed in the glial cell line U373 (astrocytoma cells). The cellular localisation 
of the eIF2Bε-GFP construct will be analysed by confocal microscopy. To determine the 
localisation of the other eIF2B subunits in relation to eIF2Bε-GFP, cells expressing 
eIF2Bε-GFP will be fixed and ICC will be performed using primary antibodies directed 
against the other eIF2B subunits. Primary antibody signals will be detected by 
fluorescently tagged secondary antibodies and the localisation of these signals 
analysed by confocal microscopy. In order to investigate eIF2B localisation in relation 
to SGs and P-bodies, cells expressing eIF2Bε-GFP will be fixed and ICC will be 
performed using primary antibodies directed against key components of SGs and P-
bodies. Primary antibody signals will be detected by fluorescently tagged secondary 
antibodies and the localisation of these antibody signals analysed by confocal 
microscopy. 
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3.2 Results 
3.2.1 Transiently expressed eIF2Bε localises to a heterogeneous 
population of different sized cytoplasmic bodies in mammalian 
cells 
In order to study the cellular localisation of mammalian eIF2B in live cells, eIF2Bɛ 
bearing a C-terminal GFP tag was transiently transfected into the astrocytoma cell line, 
U373. This cell line was chosen as glial cells are the cell type predominately affected in 
VWM (Bugiani et al., 2018; Dooves et al., 2016). Western blot analysis was used to 
confirm the expression of the eIF2Bɛ-GFP construct (Figure 3.1A). Expression of eIF2Bɛ 
has been shown to stabilise expression levels of eIF2Bγ within the cell (Wortham et al., 
2016). To provide an indication as to whether the overexpression of eIF2Bɛ-GFP 
affected expression levels of eIF2Bγ dot blot analysis was performed on transfected 
and untransfected cells. Normalisation of the dot blot signal indicated that eIF2Bγ 
expression was not increased in transfected cells (Figure 3.1B). Confocal analysis of 
cells expressing eIF2Bɛ-GFP revealed that eIF2Bε-GFP either adopted a dispersed 
cytoplasmic localisation (11 % of cells) or localised to cytoplasmic bodies which were 
termed eIF2B bodies (89 % of cells) (Figure 3.2). The size and abundance of the eIF2B 
bodies within individual cells varied. To better understand the pattern of eIF2Bε-GFP 
localisation, the eIF2B bodies were classified by size: large (≥10 µm2), medium (≥ 3 µm2 
≤ 9.99 µm2) or small (≤ 2.99 µm2). Cells exhibiting 4 phenotypes for eIF2Bε-GFP 
localisation were observed: eIF2Bε-GFP localised to only large (Figure 3.2B i), only 
medium (Figure 3.2B ii) or only small (Figure 3.2B iii) or a mixture of large medium or 
small eIF2B bodies (Figure 3.2B iv). To determine the abundance of these different 
localisation phenotypes counts were carried out across 100 cells expressing eIF2Bε-
GFP (Figure 3.2C i). Cells displaying eIF2Bε-GFP localised to a mixture of large, medium 
or small eIF2B bodies were the predominant phenotype (60 %), and contained on 
average 1 large, 2 medium and >15 small eIF2B bodies (Figure 3.2C ii). The second 
most frequent phenotype was cells displaying eIF2Bε-GFP localised to only small eIF2B 
bodies (25 %). Cells displaying eIF2Bε-GFP localised to only medium eIF2B bodies were 
less frequent again (4 %), and cells that displayed eIF2Bε-GFP localised to only large 
eIF2B bodies were the least frequent (1 %).    
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Figure 3.1 Expression levels of eIF2Bε-GFP in U373 cells and its influence on eIF2Bγ 
expression levels.  
(A) Western blot analysis of eIF2Bε expression in U373 cells, untransfected or 
transfected with eIF2Bε-GFP. β-actin has been included as a loading control. (B) U373 
cells transfected with eIF2Bε-GFP were sorted into transfected and non-transfected 
populations by fluorescence-activated cell sorting (FACs). Expression levels of eIF2Bε 
and eIF2Bγ were examined by dot blot analysis. 
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Figure 3.2 eIF2Bɛ-GFP expressed in U373 cells localises to cytoplasmic bodies.  
(A) Live cell confocal images of U373 cells expressing eIF2Bε-GFP localised to (i) only 
large (≥10 µm2), (ii) only medium (≥ 3 µm2 ≤ 9.99 µm2), (iii) only small (≤ 2.99 µm2), or 
(iv) a mixture of large, medium or small eIF2B bodies. (B) (i) The median percentage of 
cells, in a population of 100 cells, expressing eIF2Bε-GFP dispersed throughout the 
cytoplasm or localised to only large, only medium, only small or a mixture of large, 
medium or small eIF2B bodies (n=3), (ii) within the population of cells containing a 
mixture of large, medium or small eIF2B bodies, the mean number of large, medium 
and small eIF2B bodies.  
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3.2.2 The GFP tag is not responsible for the observed localisation of 
eIF2Bε-GFP to cytoplasmic bodies 
In order to ensure that the observed localisation of eIF2Bε-GFP was not caused by 
aggregation of the GFP tag, localisation of transiently expressed eIF2Bε with an 
alternative C-terminal tag (myc-tag) was also observed in U373 cells. U373 cells were 
transiently transfected with eIF2Bε-myc, fixed in methanol and immunocytochemistry 
(ICC) was performed with an anti-myc-tag antibody. Confocal microscopy revealed that 
similarly to eIF2Bɛ-GFP (Figure 3.2), eIF2Bɛ-myc was either dispersed within the 
cytoplasm of cells or localised to cytoplasmic bodies (Figure 3.3). The cytoplasmic 
bodies varied in size and number between cells and populations of cells with eIF2Bε-
myc localised to only large (≥10 µm2 ) (Figure 3.3A i), only medium (≥ 3 µm2 ≤ 9.99 
µm2) (Figure 3.3A ii), only small  (≤ 2.99 µm2) (Figure 3.3A iii) or a mixture of large, 
medium or small (Figure 3.3A iv) eIF2B bodies were observed. Counts were carried out 
across a population of 50 transfected cells to determine the percentage of each of the 
observed localisation phenotypes (Figure 3.3B i). eIF2Bε-myc was dispersed 
throughout the cytoplasm in 34 % of cells. In the remaining 66 % of cells eIF2Bε-myc 
localised to eIF2B bodies and showed a similar localisation pattern to that observed for 
eIF2Bɛ-GFP. 34% of cells contained a mixture of large, medium or small eIF2B bodies, 
and on average these cells contained 0 large, 2 medium and 13 small eIF2B bodies 
(Figure 3.3B ii). 22 % of cells contained only small eIF2B bodies, 8 % of cells contained 
only medium eIF2B bodies and 2 % of cells contained only large eIF2B bodies.  
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Figure 3.3 eIF2Bɛ-myc expressed in U373 cells localises to cytoplasmic bodies and 
shows a similar localisation pattern to eIF2Bε-GFP expressed in U373 cells.  
U373 cells were transfected with eIF2Bε-myc, fixed in methanol and subjected to ICC 
with a primary anti-myc-tag antibody. Antibody staining was visualised using an 
appropriate secondary antibody conjugated to Alexa Fluor 488.  (A) Confocal images of 
U373 cells expressing eIF2Bε-myc, (i) showing localisation to only large (≥10 µm2), (ii) 
only medium (≥ 3 µm2 ≤ 9.99 µm2), (iii) only small (≤ 2.99 µm2), or (iv) a mixture of 
large, medium or small eIF2B bodies. (B) (i) The median percentage of cells, in a 
population of 100 cells, exhibiting eIF2Bε-myc dispersed throughout the cytoplasm or 
localised to, only large, only medium, only small, or a mixture of different sized eIF2B 
bodies (n=3), (ii) within the population of cells containing a mixture of different sized 
eIF2B bodies, the mean number of large, medium and small eIF2B bodies is shown.  
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3.2.3 Endogenous eIF2B subunits localise to cytoplasmic bodies in 
mammalian cells 
In order to confirm the observed localisation of eIF2B to cytoplasmic bodies was not a 
result of the eIF2Bε overexpression, the cellular localisation of endogenous eIF2B 
subunits was investigated. U373 cells were fixed in methanol and ICC was carried out 
individually for each of the five subunits of eIF2B. All subunits of eIF2B were found to 
localise to cytoplasmic bodies, of varying size and number (Figure 3.4).  
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Figure 3.4 Confocal images of endogenous eIF2B subunits localising to cytoplasmic 
bodies in U373 cells.  
U373 cells were fixed in methanol and subject to ICC with (A) anti-eIF2Bα, (B) anti-
eIF2Bβ, (C) anti-eIF2Bδ, (D) anti-eIF2Bγ or (E) anti-eIF2Bε. Primary antibodies were 
visualised using appropriate secondary antibodies conjugated to Alexa Fluor 488 and 
imaged using confocal microscopy.  
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3.2.4 eIF2Bε-GFP bodies do not co-localise with polyubiquitin 
Overexpression of proteins can become toxic to the cell. If protein levels reach a toxic 
level the cell may direct these proteins into cytoplasmic aggregates which are targeted 
for degradation by the proteasome (Bolognesi and Lehner, 2018). Due to the large size 
of the observed eIF2Bε-GFP bodies (sometimes ≥ 10 μM2) it was important to ensure 
that these bodies were not aggregates of protein targeted for degradation.  The cell 
targets proteins for degradation by tagging the proteins with ubiquitin. While 
ubiquitination can target proteins for a number of functions, only the addition of poly-
ubiquitin directs proteins for degradation by the proteasome (Kleiger and Mayor 
2014). In order to provide an insight as to whether the eIF2Bɛ-GFP bodies observed in 
this study were polyubiquitinated immunofluorescence analysis was performed. U373 
cells expressing eIF2Bɛ-GFP were fixed in methanol and ICC was performed using a 
poly-ubiquitin FK1 antibody (Danielson and Hope, 2013). eIF2B bodies did not co-
localise with the poly-ubiquitin antibody signal suggesting that they are not protein 
aggregates targeted for degradation (Figure 3.5). 
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Figure 3.5 eIF2B bodies do not co-localise with poly-ubiquitin.  
Confocal images of U373 cells transfected with eIF2Bε-GFP, fixed in methanol and 
subject to ICC with a primary anti-poly-ubiquitin antibody. Primary antibody signals 
were visualised using an appropriate Alexa Fluor 633 conjugated secondary antibody. 
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3.2.5 eIF2Bɛ-GFP bodies are distinct from stress granules and P-
bodies 
Previously eIF2Bε has been shown to localise to SGs in mammalian cells (Kimball et al., 
2003). It was therefore important to determine whether the eIF2Bε-GFP bodies 
identified in this study were spatially discrete from SGs. Additionally, P-bodies are 
another class of cytoplasmic granule that contain translation associated factors (Luo et 
al., 2018). Although eIF2B has not previously been associated with P-bodies, the 
localisation of P-bodies was also analysed to determine if any co-localisation existed 
between P-bodies and the eIF2Bε-GFP bodies identified. U373 cells expressing eIF2Bε-
GFP were exposed to either ER stress, through treatment with Tg, or to oxidative 
stress, through treatment with SA, in order to induce SG or P-body assembly. Cells 
were then fixed in methanol and subject to ICC with primary antibodies to SG and P-
body specific markers. Confocal microscopy confirmed that eIF2B bodies are spatially 
distinct from G3BP containing SGs (Figure 3.6), eIF3B containing SGs (Figure 3.7) and 
GW182 containing P-bodies (Figure 3.8).  
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Figure 3.6 eIF2Bε-GFP bodies do not co-localise with G3BP containing stress granules. 
U373 cells were transfected with eIF2Bε-GFP and either (A) untreated, or treated with 
(B) 1 μM Tg, (C) 125 μM SA or (D) 500 μM SA. Cells were fixed in methanol, and subject 
to ICC with a primary anti-G3BP antibody. The anti-G3BP antibody was visualised using 
an appropriate Alexa Fluor 633 conjugated secondary antibody and imaged using 
confocal microscopy. 
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Figure 3.7 eIF2Bε-GFP bodies do not co-localise with eIF3b containing SGs.  
U373 cells were transfected with eIF2Bε-GFP and either (A) untreated, or treated with 
(B) 1 μM Tg, (C) 125 μM SA or (D) 500 μM SA. Cells were fixed in methanol, and subject 
to ICC with a primary anti-eIF3b antibody. The anti-eIF3b antibody was visualised using 
an appropriate Alexa Fluor 633 conjugated secondary antibody and imaged using 
confocal microscopy. 
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Figure 3.8 eIF2Bε-GFP bodies do not co-localise with GW182 containing P-bodies. 
U373 cells were transfected with eIF2Bε-GFP and either (A) untreated, or treated with 
(B) 1 μM Tg, (C) 125 μM SA or (D) 500 μM SA. Cells were fixed in methanol, and subject 
to ICC with a primary anti-GW182 antibody. The anti-GW182 antibody was visualised 
using appropriate Alexa Fluor 633 conjugated secondary antibody and imaged using 
confocal microscopy. 
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3.2.6 eIF2Bε-GFP localises to cytoplasmic bodies in primary human 
astrocytes 
Studying the cellular localisation of eIF2B may provide a tool to assess the functional 
impact that VWM mutations have on eIF2B function. Astrocytes are one of the main 
cell types affected by VWM (Bugiani et al., 2018; Dooves et al., 2016). Having 
determined that transiently expressed eIF2Bε localises to eIF2B bodies in the human 
astrocytoma cell line, U373, the cellular localisation of eIF2Bε in primary human 
astrocytes was investigated. eIF2Bε-GFP was transiently transfected into primary 
human astrocytes and the localisation was observed by confocal microscopy. eIF2Bε-
GFP was found to either localise to a number of different sized eIF2B bodies (75 % of 
cells) or remain dispersed throughout the cell cytoplasm (15 % of cells) (Figure 3.9). To 
better characterise the localisation of eIF2Bɛ-GFP to eIF2B bodies, counts were carried 
out to determine the percentage of cells that displayed eIF2Bε-GFP localised to only 
large (≥10 µm2), only medium (≥ 3 µm2 ≤ 9.99 µm2), only small (≤ 2.99 µm2) or a 
mixture of large, medium or small eIF2B bodies (Figure 3.9B i). Cells displaying eIF2Bε-
GFP localised to only small eIF2B bodies were found to be the predominant phenotype 
(41 % of cells). Cells displaying eIF2Bɛ-GFP localised to a mixture of different sized 
eIF2B bodies were the second most frequent phenotype (35 % of cells), with cells on 
average containing contained 1 large, 1 medium and 25 small eIF2B bodies (Figure 
3.9B ii). Cells displaying eIF2Bε-GFP localised to only medium eIF2B bodies were the 
third most frequent phenotype (8 % of cells) and cells that displayed eIF2Bɛ-GFP 
localised to only large eIF2B bodies were the least frequent phenotype (5 % of cells).   
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Figure 3.9 eIF2Bɛ-GFP localises to cytoplasmic bodies in primary human astrocytes. 
(A) Live cell confocal images of primary astrocyte cells transiently expressing eIF2Bε-
GFP, (i) showing localisation to only large (≥10 µm2), (ii) only medium (≥ 3 µm2 ≤ 9.99 
µm2), (iii) only small (≤ 2.99 µm2), and (iv) a mixture of large, medium or small eIF2B 
bodies. (B) (i) The median percentage of cells, in a population of 100 cells, exhibiting 
eIF2Bε-GFP dispersed throughput the cytoplasm or, localised to only large, only 
medium, only small or a mixture of different sized eIF2B bodies (n=3), (ii) within the 
population of cells containing a mixture of different sized eIF2B bodies, the mean 
number of large, medium and small eIF2B bodies.  
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3.2.7 eIF2Bε-GFP localises to cytoplasmic bodies in various 
mammalian cell lines 
Mutations in eIF2B have been shown to have different effects on the function of eIF2B 
dependent upon the cell type they are expressed in (Horzinski et al., 2010; Kantor et 
al., 2005). In order to determine if eIF2B bodies were a specific feature of astrocytic 
cells or a general feature of mammalian cells, the cellular localisation of eIF2Bε-GFP in 
various human cell lines was investigated. eIF2Bε-GFP was transiently expressed in 
liver hepatocellular carcinoma cells (HepG2), human osteosarcoma cells (MG-63), and 
human embryonic kidney cells (HEK293) and the cellular localisation was observed 
using confocal microscopy. Similarly to the localisation patterns observed in astrocytic 
cells, for each of the cell lines analysed, eIF2Bɛ-GFP was either dispersed throughout 
the cytoplasm (40 % of cells for HepG2, 36 % of cells for MG-63 and 46 % of cells for 
HEK293) or localised to a number of different sized eIF2B bodies (60 % of cells for 
HepG2, 64 % of cells for MG-63 and 54 % of cells for HEK293) (Figure 3.10). To better 
characterise the localisation of eIF2Bɛ-GFP to different sized eIF2B bodies within these 
cell lines, counts were performed. Within a population of 100 cells, the percentage of 
cells displaying eIF2Bε-GFP localised to only large (≥10 µm2), only medium (≥ 3 µm2 ≤ 
9.99 µm2), only small (≤ 2.99 µm2) or a mixture of large, medium or small eIF2B bodies 
was determined. For all cell lines similar trends were observed. Cells displaying a 
mixture of large, medium or small eIF2B bodies was found to be the most frequently 
observed phenotype for each cell line (30 % for HepG2, 28 % for MG-63 and 28% for 
HEK293). In the case of HepG2 cells, cells displaying only small eIF2B bodies were 
equally as frequent (30 % of cells). For MG-63 and HEK293 cells, cells displaying only 
small eIF2B bodies presented as a less frequent phenotype (26 % and 22 % of cells 
respectively). For HEK293 cells, 6 % of cells displayed eIF2Bε-GFP localised to only 
medium eIF2B bodies and 2 % displayed eIF2Bε-GFP localised to only large eIF2B 
bodies. Cells displaying eIF2Bε-GFP localised to only large, or only medium, eIF2B 
bodies were not observed for HepG2 and MG-63 cells.     
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Figure 3.10 eIF2Bε-GFP localises to cytoplasmic bodies in mammalian cell lines. 
(A) HepG2, MG-63 and HEK293 cells expressing eIF2Bε-GFP were observed via confocal 
microscopy and representative images are displayed in the panels. (B) The median 
percentage of cells, in a population of 100 cells, displaying eIF2Bε-GFP dispersed 
throughout the cytoplasm, or localised to only large (≥10 µm2), only medium (≥ 3 µm2 
≤ 9.99 µm2), only small (≤ 2.99 µm2) or a mixture of large, medium or small eIF2B 
bodies (n=3).  
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3.2.1 eIF2B(α-γ) subunits display unique localisation patterns to 
different sized eIF2Bε-GFP bodies in mammalian cells 
Having shown that transiently expressed eIF2Bε-GFP localised to cytoplasmic bodies in 
mammalian cells, it was important to determine if the other subunits of eIF2B also 
localised to these foci. U373 cells expressing eIF2Bε-GFP were fixed in methanol and 
subjected to ICC with antibodies against eIF2Bα, β, δ and γ subunits individually.  
Confocal microscopy revealed that eIF2Bα, β, δ and γ antibody signals co-localised with 
a proportion of eIF2Bε-GFP bodies (Figure 3.11). To better characterise the degree of 
co-localisation between eIF2Bα, β, δ or γ antibody signals and eIF2Bε-GFP bodies, 
counts were performed. Firstly, within a population of 50 cells, the percentage of cells 
that showed antibody signal co-localised to at least one eIF2Bε-GFP body was 
determined for each eIF2B subunit independently (Figure 3.12A). These cells were 
classified as displaying a degree of co-localisation between antibody signal and eIF2Bɛ-
GFP bodies. For eIF2Bα, 52 % of cells displayed a degree of co-localisation. For eIF2Bβ, 
66 % of cells displayed a degree of co-localisation. For eIF2Bδ, 78 % of cells displayed a 
degree of co-localisation and for eIF2Bγ 98 % of cells displayed a degree of co-
localisation. The degree of co-localisation varied between subunits. This raised the 
question, could the size of the eIF2Bε-GFP bodies correlate with the eIF2B subunits 
present. To investigate this, counts were performed within the population of cells that 
had been found to display a degree of co-localisation between antibody signal and 
eIF2Bε-GFP bodies.  The percentage of each sized eIF2B body (large, medium and 
small) that had an antibody signal co-localised was determined for each eIF2B subunit 
(α, β, δ, γ) (Figure 3.12B). For large eIF2Bε-GFP bodies, eIF2Bα co-localised with 87 %, 
eIF2Bβ co-localised with 88 %, eIF2Bδ co-localised with 94 % and eIF2Bγ co-localised 
with 100 %. For medium eIF2Bε-GFP bodies, eIF2Bα co-localised with 36 %, eIF2Bβ co-
localised with 51 %, eIF2Bδ co-localised with 74 % and eIF2Bγ co-localised with 89 %. 
For small eIF2Bε-GFP bodies, eIF2Bα co-localised with 0 %, eIF2Bβ co-localised with 1 
%, eIF2Bδ co-localised with 14 % and eIF2Bγ co-localised with 65 %. 
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Figure 3.11 eIF2B(α-γ) subunits co-localise with eIF2Bε-GFP bodies.  
Confocal images of U373 cells transfected with eIF2Bε-GFP, fixed in methanol and 
subject to ICC with primary (A) anti-eIF2Bα, (B) anti-eIF2Bβ, (C) anti-eIF2Bδ and (D) 
anti-eIF2Bγ antibodies. All antibodies were visualised using appropriate secondary 
antibodies conjugated to Alexa Fluor 568. 
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Figure 3.12 The degree to which eIF2B(α-γ) subunits co-localise with eIF2Bε-GFP 
bodies varies between different sized bodies.  
U373 cells were transfected with eIF2Bε-GFP, fixed in methanol and subject to ICC with 
primary anti-eIF2Bα, anti-eIF2Bβ, anti-eIF2Bδ or anti-eIF2Bγ antibodies. All primary 
antibodies were visualised using appropriate secondary antibodies conjugated to Alexa 
Fluor 568. (A) For eIF2Bα, eIF2Bβ, eIF2Bδ or eIF2Bγ subunits, the percentage of cells 
with antibody signal co-localising to at least one eIF2Bε-GFP body; these cells were 
classified as displaying a degree of co-localisation (n = 3 counts of 50 cells). (B) For each 
eIF2B subunit (α-γ), within the population of cells that showed a degree of co-
localisation, the median percentage of co-localisation between antibody signal and 
large, medium or small eIF2Bε-GFP bodies, (n=3 counts of 50 cells).  
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3.3 Discussion 
Previous work in the yeasts S. cerevisiae and Candida albicans (C. albicans) has shown 
that eIF2B localises to cytoplasmic foci that have been termed eIF2B bodies (Campbell 
et al., 2005; Egbe et al., 2015). The cellular localisation of mammalian eIF2B has not 
previously been investigated. Understanding the function of mammalian eIF2B 
localisation could be a potential tool to provide further insights into the mechanisms of 
VWM disease. In the present study the cellular localisation of eIF2B has been analysed 
in U373 cells, a cell type linked to the phenotypic effects of VWM disease (Bugiani et 
al., 2018; Dooves et al., 2016). The ε subunit of eIF2B bearing a C-terminal GFP tag was 
transiently expressed in U373 cells to analyse eIF2B localisation in live cells. To confirm 
that this localisation was not a result of the eIF2Bε overexpression or self-aggregation 
of the GFP tag, ICC was used to analyse the localisation of endogenous eIF2B subunits. 
The data presented here demonstrates that as in yeast (Campbell et al., 2005; Noree et 
al., 2010) all 5 subunits of mammalian eIF2B localise to cytoplasmic foci (Figure 3.4), 
however this localisation appears to be more complex in mammalian cells. In yeast 
eIF2B has been shown to localise to a single cytoplasmic body, whereas the data 
presented here shows mammalian eIF2B localising to a number of different sized 
cytoplasmic bodies (Figure 3.4). These mammalian eIF2B bodies were present under 
normal cellular conditions. The cellular conditions under which eIF2B localises to 
cytoplasmic bodies within yeast has been debated. eIF2B bodies have been 
documented under normal growth conditions (Campbell et al., 2005; Noree et al., 
2010) however other studies have documented that eIF2B bodies only form in 
response to conditions of cellular stress (Moon and Parker, 2018). The data presented 
here suggests that cellular stress is not required to stimulate mammalian eIF2B body 
assembly (Figure 3.4). 
To better characterise the localisation of mammalian eIF2B bodies, the bodies were 
classified by size and counts performed to determine the average number of bodies 
present within cells for each size category. eIF2B bodies ≥10 µm2 were classified as 
large, bodies ≥ 3 µm2 ≤ 9.99 µm2 were classified as medium and bodies ≤ 2.99 µm2 
were classified as small. On average eIF2Bε-GFP localised to 1 large, 2 medium and ˃ 
15 small eIF2B bodies in U373 cells (Figure 3.2). eIF2Bε-GFP was also expressed in 
primary human astrocytes (Figure 3.9). The distribution of different sized eIF2B bodies 
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was found to differ between U373 astrocytoma cells and primary human astrocytes, 
with the primary astrocytes harbouring higher numbers of small eIF2B bodies. The 
functional relevance of these different sized bodies is further explored in Chapter 4. In 
order to determine if this localisation was a specific feature of astrocytes, eIF2Bε-GFP 
was expressed in HepG2, MG-63, and HEK293 cells. eIF2Bε-GFP localised to different 
sized cytoplasmic foci in all three cell lines (Figure 3.10) demonstrating that eIF2B 
bodies are not a specific feature of astrocytes.  
Having shown that eIF2B localises to cytoplasmic bodies in mammalian cells it was 
important to determine whether these foci were distinct from other well-known 
translation-associated granules. SGs are one of the best characterised translation-
associated granules. They consist primarily of stalled 48S preinitiation complexes. 
eIF2Bɛ was shown to co-localise with SGs in embryonic mouse cells (Kimball et al., 
2003) however more recent studies in yeast suggest eIF2B localises to foci distinct 
from SGs  (Moon and Parker, 2018). In keeping with this, the data presented here 
demonstrates that mammalian eIF2B bodies are spatially discrete from SGs (Figure 3.6, 
Figure 3.7). P-bodies are another class of cytoplasmic granule to which translational 
machinery has been documented to localise. The data presented here shows eIF2B 
bodies are also spatially discrete from P-bodies (Figure 3.8), supporting eIF2B bodies 
are a unique cytoplasmic assembly.  
In its native form eIF2B exists as a heterodecamer (Gordiyenko et al., 2014; Kashiwagi 
et al., 2016; Kashiwagi et al., 2017; Wortham et al., 2014), however subcomplexes of 
eIF2B have also been found to exist in mammalian cells, namely eIF2B(βδγε) tetramers 
and eIF2B(γε) heterodimers (Wortham et al., 2014). The data presented in this study 
highlight an increased complexity of the localisation of eIF2B within mammalian cells 
when compared to yeast. In yeast all five eIF2B subunits have been shown to localise 
to a single cytoplasmic body (Campbell et al., 2005; Noree et al., 2010). It was 
hypothesised that the increased number of eIF2B bodies within mammalian cells 
observed in this study may be linked to the presence of eIF2B subcomplexes. Indeed, a 
relationship between eIF2B body size and the eIF2B subunits present was observed in 
U373 cells. All subunits of eIF2B were found to localise to large and medium sized 
eIF2B bodies to some degree, supporting that eIF2B decameric or tetrameric 
complexes may reside within these foci. However, for small eIF2B bodies only the 
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catalytic eIF2B subunits predominately localised indicating that eIF2B heterodimers 
may makeup small eIF2B bodies (Figure 3.12). The GEF activity of eIF2B heterodimers 
is not regulated by cellular stress, due to the absence of eIF2B regulatory subunits 
which are required to confer stress sensitivity (Elsby et al., 2011; Fabian et al., 1997; 
Krishnamoorthy et al., 2001; Pavitt et al., 1998). Additionally in vitro biochemical 
assays have shown subcomplexes of eIF2B have reduced activity when compared to 
the full complex containing all five subunits (Liu et al., 2011). It could therefore be 
hypothesised that the different sized populations of eIF2B bodies identified here may 
function differently within the cell, and this may be important to the regulation of 
eIF2B activity.  
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4. Functionality of mammalian eIF2B bodies 
4.1 Introduction 
The most well studied mechanism of eIF2B regulation is the integrated stress response 
(ISR); an adaptive pathway highly conserved amongst eukaryotes (Chapter 1, Section 
1.3.1). The core event in the ISR is the phosphorylation of eIF2α at serine 51, 
stimulated by stress-responsive eIF2α kinases (Wek et al., 2006). In mammalian cells 
there are four eIF2α kinases and although these kinases share homologous catalytic 
domains for the phosphorylation of eIF2α, they each have unique regulatory domains 
stimulated by distinct environmental or physiological stresses. Phosphorylation of 
eIF2α converts it from a substrate to a competitive inhibitor of eIF2B (Dever et al., 
1995; Rowlands et al., 1988) preventing 5' cap-dependent translation, and thus leading 
to the downregulation of global protein synthesis. Paradoxically, the translation of a 
subset of ISR-responsive mRNAs that contain short upstream open reading frames 
(uORF) or internal ribosome entry sites (IRES) are upregulated (Chapter 1, Section 
1.3.1.2) (Palam et al., 2011; Vattem and Wek, 2004). Increased translation of these 
mRNAs promotes pro-survival mechanisms to alleviate the cellular stress and restore 
homeostasis. However, in cases of long-term exposure or induction of chronic stress 
the ISR promotes translation of mRNAs involved in cell death signalling (Pakos-
Zebrucka et al., 2016).  
eIF2B exists as a decamer with hexameric regulatory core, comprised of two copies of 
each of the regulatory subunits; eIF2Bα, eIF2Bβ and eIF2Bδ. The catalytic activity of 
eIF2B is carried out by two heterodimers of eIF2Bγ and ε subunits which reside upon 
opposite sides of the hexameric core (Kashiwagi et al., 2016; Tsai et al., 2018; 
Zyryanova et al., 2018). The stress-induced inhibition of eIF2B by phosphorylated eIF2α 
is mediated by the eIF2B regulatory subunits (Dever et al., 1993; Fabian et al., 1997; 
Hannig et al., 1990; Kimball et al., 1998; Pavitt et al., 1997) (Chapter 1, Section 1.4.3.1). 
Under normal cellular conditions, eIF2Bε interacts with eIF2γ and catalyses the release 
of GDP. This reaction is further catalysed by interactions between eIF2α and the β and 
δ subunits of eIF2B (Kashiwagi et al., 2019; Kenner et al., 2019). In mammalian cells 
stress-induced phosphorylation of eIF2α induces a conformational rearrangement that 
alters the eIF2 binding site (Kashiwagi et al., 2019; Kenner et al., 2019). In its 
phosphorylated form eIF2α binds to the α and δ subunits of eIF2B (Kashiwagi et al., 
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2019; Kenner et al., 2019). This conformation results in eIF2γ docking onto the γ 
subunit of eIF2B, preventing eIF2Bε from catalysing GDP release.  
In yeast eIF2 shuttles through eIF2B bodies at a rate that correlates to the GEF activity 
of eIF2B. Stimulation of the ISR through phosphorylation of eIF2α decreases the rate 
eIF2 shuttles through the bodies suggesting that they are sites where eIF2B GEF 
activity can be regulated (Campbell et al., 2005; Egbe et al., 2015). The function of 
mammalian eIF2B bodies has not yet been investigated. In recent years 
phosphorylation of eIF2α and dysregulation of the ISR have emerged as common 
pathways in several neurodegenerative diseases including; Alzheimer's (Ma et al., 
2013), schizophrenia (Trinh et al., 2012), amyotrophic lateral sclerosis (Kim et al., 2014) 
and VWM (Abbink et al., 2018; van der Voorn et al., 2005). Understanding how the 
activity of mammalian eIF2B bodies is regulated could provide a platform to better 
understand the pathological mechanisms of neurodegenerative disease. 
This chapter aimed to determine the functional relationship between eIF2 and the 
mammalian eIF2B bodies identified in Chapter 3, both under normal cellular conditions 
and during the ISR. It was hypothesised that eIF2 would localise to the eIF2B bodies 
and that as in yeast, these bodies would be sites of eIF2B regulation. The localisation of 
eIF2 will be investigated using ICC techniques on cells expressing eIF2Bε-GFP bodies. 
To determine the dynamics between eIF2B and any eIF2 that localises to eIF2B bodies, 
FRAP analysis will be performed. In yeast the movement of eIF2 through eIF2B bodies 
correlated to eIF2B regulation, it was therefore hypothesised eIF2 would be mobile 
within mammalian eIF2B bodies and this movement would be affected by cellular 
stress. The movement of eIF2B within eIF2B bodies will be analysed in cells expressing 
eIF2Bε-GFP. For the assessment of eIF2 movement within eIF2B bodies, cells 
expressing the alpha subunit of eIF2, GFP tagged, will be used. eIF2Bε tagged with RFP 
will also be co-expressed in these cells to mark eIF2B bodies as this subunit is known 
localise to SGs. FRAP analysis will be performed on GFP tagged proteins only. This is 
due to high levels of background generated when using RFP fluorophores for FRAP 
experiments. In order to analyse the relationship between eIF2 and eIF2B bodies 
during cellular stress, two different inducers of the ISR will be used; Tg, an inducer of 
ER stress and SA, an inducer of oxidative stress.  
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4.2 Results 
4.2.1 eIF2 localises to eIF2B bodies 
In yeast eIF2 has been shown to co-localise to eIF2B bodies (Campbell et al., 2005; 
Noree et al., 2010). In order to determine if eIF2 localises to eIF2B bodies in 
mammalian cells, U373 cells transiently expressing eIF2Bε-GFP were fixed in methanol 
and ICC was carried out to visualise the cellular localisation of eIF2α.  
Confocal microscopy demonstrated that eIF2α co-localises with all mammalian eIF2Bɛ-
GFP bodies, independent of size (Figure 4.1A). Super-resolution microscopy of these 
bodies highlighted in greater detail that eIF2α and eIF2Bɛ-GFP co-localised. The close 
proximity of these two protein complexes suggests that the proteins may be 
interacting (Sekar and Periasamy, 2003). 
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Figure 4.1 eIF2α co-localises with eIF2B bodies.  
U373 cells were transfected with eIF2Bε-GFP, fixed in methanol and subject to ICC with 
a primary anti-eIF2α antibody. Primary antibody signal was visualised using an 
appropriate Alexa Fluor 568 conjugated secondary antibody. (A) Confocal images of 
eIF2α localised to eIF2Bε-GFP bodies. (B) Airyscan Super-resolution images of eIF2α 
localised to an eIF2Bɛ-GFP body captured on a Zeiss LSM 800 Confocal.  
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4.2.2 eIF2 can rapidly shuttle into eIF2B bodies 
In yeast, the movement of eIF2 through eIF2B bodies correlates with eIF2B GEF 
activity, with many conditions or scenarios that reduce GEF activity leading to reduced 
eIF2 mobility (Campbell et al., 2005; Singh et al., 2011; Taylor et al., 2010). To assess 
the dynamics between eIF2 and eIF2B bodies in mammalian cells, fluorescent recovery 
after photobleaching (FRAP) was carried out. FRAP analysis can be used to measure 
the movement of fluorescently tagged proteins into a region of interest within the cell. 
This technique utilises the fact that photobleaching of fluorophores is irreversible and 
has no impact upon protein function. As outlined in Figure 4.2, a region of interest 
containing fluorescently tagged protein is selected and bleached (in this case an eIF2B 
body). The bleached region is then analysed over time to measure any recovery of 
fluorescence and this is plotted as a FRAP recovery curve. As bleaching of a 
fluorophore is irreversible the only way recovery of fluorescence can occur is if 
fluorescently tagged protein from another region of the cell moves into the region of 
interest.  
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Figure 4.2 Fluorescence recovery after photobleaching technique.  
A region of interest (ROI) containing a fluorescently tagged protein is selected. Using 
confocal microscopy, the fluorophores present within the ROI can be bleached. Over 
time images are taken of the ROI and the intensity of fluorescence signal within the 
ROI of interest is measured. The intensity of fluorescence signal can be normalised 
against the intensity of the pre-bleach fluorescence signal. This percentage of 
fluorescence recovery is plotted against the time the image was taken to generate a 
FRAP recovery curve. The total percentage of protein recovery is calculated as the 
plateau of the FRAP recovery curve.  
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U373 cells were transfected with eIF2Bɛ-GFP or eIF2α-GFP and eIF2Bɛ-RFP (to mark 
the eIF2B body) and FRAP analysis was carried out on large, medium and small eIF2B 
bodies. Following photobleaching eIF2Bε-GFP did not recover to any size eIF2B body, 
demonstrating that eIF2B is a resident component of eIF2B bodies (Figure 4.3). eIF2 
however was found to recover to all sized eIF2B bodies following photobleaching 
indicating that eIF2 is a mobile component of the eIF2B bodies (Figure 4.3).  
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Figure 4.3 eIF2α-GFP is mobile within eIF2B bodies.  
(A) FRAP analysis was carried out on the GFP fluorophore in U373 cells transiently 
expressing (i) eIF2α-GFP or (ii) eIF2Bε-GFP in addition to eIF2Bε-RFP to mark the eIF2B 
body. Panels show representative prebleach, bleach and recovery images. (B) 
Normalised FRAP curves for eIF2α-GFP and eIF2Bε-GFP recovery to (i) Large, (ii) 
Medium and (iii) Small eIF2B bodies. FRAP analysis was performed on 10 bodies (n=3). 
The percentage recovery is presented as mean ± s.e.m.  
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4.2.3 Phosphorylated eIF2α localises to eIF2B bodies during 
conditions of cellular stress  
In response to various stress conditions, protein kinases phosphorylate eIF2α at serine 
51, converting it from a substrate into a competitive inhibitor of eIF2B GEF activity 
(Dever et al., 1995; Rowlands et al., 1988). In yeast the movement of eIF2 through 
eIF2B bodies is decreased in response to cellular stress, suggesting the bodies are sites 
of eIF2B GEF activity (Campbell et al., 2005). Having shown that eIF2 is mobile within 
mammalian eIF2B bodies, the impact of cellular stress on this movement was 
investigated to determine if, as in yeast, the movement of eIF2 through mammalian 
eIF2B bodies correlates with levels of eIF2B GEF activity.  
Phosphorylated eIF2α tightly binds to eIF2B and induces a conformational change 
which is unfavourable for performing GEF activity (Kenner et al., 2019). If 
phosphorylated eIF2α inhibits the GEF activity of eIF2B bodies, it would be expected 
that phosphorylated eIF2α would localise to the eIF2B bodies. The localisation of stress 
induced phosphorylated eIF2α in relation to eIF2B bodies was investigated. Two 
different cellular stress stimuli were used to induce eIF2α phosphorylation; Tg (1 μM), 
an ER stress, and SA, an oxidative stress at a lower and higher concentration (125 μM 
and 500 μM). The levels of phosphorylated eIF2α induced by Tg treatment and 
treatment with SA, at the two different concentrations, were analysed by western blot 
(Figure 4.4A). Under normal condtions cells had low levels of phosphorylated eIF2α 
present. All stress treatments induced a significant increase in levels of phosphorylated 
eIF2α, with Tg treatment inducing the lowest levels and the higher SA concentration 
(500 μM) inducing the highest levels. A puromycin incorporation assay was used to 
measure levels of global protein synthesis in response to Tg (1 μM) and SA (500 μM) 
stress treatments (Figure 4.4B). Global protein synthesis was found to decrease in a 
manner inversely correlating to levels of phosphorylaed eIF2α. 
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Figure 4.4 Thapsigargin and sodium arsenite treatments induce eIF2α 
phosphorylation (serine 51) and decrease protein synthesis.  
(A) Western blot analysis of the expression level of total eIF2α and eIF2α 
phosphorylated at serine 51 (p[S51]) in U373 cells treated with 1 µM Tg , 125 μM SA  or 
500 μM SA to induce cellular stress. Levels of eIF2α p[S51] were normalised to levels of 
total eIF2α and presented as mean ± SD (n=3). P-values are derived from a Kruskal-
Wallis test (p = 0.0156), followed by a Conover-Inman analysis; * p ≤ 0.05. (B) 
Puromycin incorporation assays were carried out on U373 cells, either untreated or 
treated with 1 μM Tg or 500 μM SA, β-actin was used as a loading control (n=1).  
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Having determined that Tg and SA treatments induced phosphorylation of eIF2α, the 
cellular localisation of phosphorylated eIF2α was investigated following these 
treatments. eIF2B complexes containing the regulatory subunits are known to display a 
higher affinity for eIF2 when present in its phosphorylated form (Kashiwagi et al., 
2017; Pavitt et al., 1998).  As the regulatory subunits of eIF2B were found to 
predominately localise to the large and medium eIF2B bodies (Figure 3.12) it was 
hypothesised that phosphorylated eIF2α would predominately localise to these bodies. 
In order to explore this hypothesis, U373 cells transiently expressing eIF2Bε-GFP were 
subject to treatment with Tg (1 μM) and SA at two different concentrations (125 μM 
and 500 μM). The cells were fixed in methanol and ICC was carried out to visualise the 
cellular localisation of phosphorylated eIF2α. Confocal microscopy revealed that 
phosphorylated eIF2α localised to a proportion of eIF2B bodies following treatment 
with Tg and SA at both concentrations (Figure 4.5). Super-resolution microscopy 
highlighted phosphorylated eIF2α localised to an eIF2B body in cells treated with the 
higher concentration of SA (500 μM) (Figure 4.6).  
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Figure 4.5 Phosphorylated eIF2α localises to eIF2B bodies.  
Confocal microscopy images of U373 cells, transfected with eIF2Bε-GFP and either (A) 
untreated or treated with (B) 1 µM Tg, (C) 125 μM SA or (D) 500 μM SA. Cells were 
fixed in methanol, and subject to ICC with a primary anti-eIF2α p[S51] antibody. The 
anti-eIF2α p[S51] antibody was visualised using an appropriate Alexa Fluor 568 
conjugated secondary antibody. 
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Figure 4.6 Super-resolution microscopy of phosphorylated eIF2α co-localised to eIF2B 
bodies.  
U373 cells were transfected with eIF2Bε-GFP, and either (A) untreated or (B) treated 
with 500 μM SA. Cells were fixed in methanol, and subject to ICC with a primary anti-
eIF2α p[S51] antibody. The anti-eIF2α p[S51] antibody was visualised using an 
appropriate Alexa Fluor 568 conjugated secondary antibody and imaged using the Airy 
scan super-resolution functionality on a Zeiss LSM 800 confocal microscope. 
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To better characterise the proportion of eIF2B bodies that phosphorylated eIF2α 
localised to following treatment with Tg (1 μM), SA (125 μM) or SA (500 μM), counts 
were carried out (Figure 4.7). As hypothesised a significantly higher proportion of large 
and medium eIF2B bodies had phosphorylated eIF2α localised to them when 
compared to small eIF2B bodies. This is consistent with eIF2B complexes containing 
the regulatory subunits having a higher affinity for eIF2 in its phosphorylated form 
(Kashiwagi et al., 2017; Pavitt et al., 1998). In untreated cells, phosphorylated eIF2α 
localised to 2 % of small eIF2B bodies, and 20 % of large and medium bodies. Induction 
of cellular stress through treatment with Tg (1 μM) lead to an increase in the 
percentage of large and medium bodies that phosphorylated eIF2α localised to (35 %), 
however no significant difference in the percentage of small bodies to which 
phosphorylated eIF2α localised was observed. Induction of higher levels of eIF2α 
phosphorylation through treatment with SA induced a greater increase in the 
percentage of large and medium eIF2B bodies to which phosphorylated eIF2α 
localised. In cells treated with 125 µM SA, phosphorylated eIF2α localised to 71 % of 
large and medium bodies and in cells treated with 500 µM SA, phosphorylated eIF2α 
localised to 68 % of large and medium bodies. A significant increase in localisation of 
phoshorylated eIF2α to small bodies was also observed under these SA treatments. In 
cells treated with 125 µM SA phosphorylated eIF2α localised to 13 % of small bodies 
and in cells treated with 500 µM SA, phoshorylated eIF2α localised to 27 % of small 
bodies.  
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Figure 4.7 Phosphorylated eIF2α localises to eIF2B bodies in a size-dependent 
manner.  
U373 cells expressing eIF2Bε-GFP were fixed in methanol and subject to ICC with an 
anti- eIF2α p[S51] antibody. The median percentage of anti-eIF2α p[S51] co-localised 
to large and medium or small eIF2Bε-GFP bodies was determined in a population of 50 
cells (n=3). P-values are derived from a Kruskal-Wallis test (P = 0.0011), followed by a 
Conover-Inman analysis; * p ≤ 0.05. 
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4.2.4 The movement of eIF2 into large and medium eIF2B bodies is 
impaired during cellular stress 
Binding of phosphorylated eIF2α sequesters eIF2B GEF activity (Pavitt et al., 1998; 
Ramaiah et al., 1994). It was therefore hypothesised that the increased presence of 
phosphorylated eIF2α localised to large and medium bodies during cellular stress 
would reduce the GEF activity of eIF2B within these bodies. In yeast, the movement of 
eIF2 through eIF2B bodies correlates to eIF2B activity (Campbell et al., 2005; Taylor et 
al., 2010). FRAP analysis was used to measure the movement of eIF2 through large and 
medium eIF2B bodies during cellular stress as an indirect measure of eIF2B activity. 
FRAP analysis was carried out on eIF2α-GFP localised to large and medium eIF2B 
bodies in U373 cells (marked by the expression of eIF2Bɛ-RFP), either untreated as a 
control, or treated with Tg (1 μM) or SA (125 μM and 500 μM) to induce cellular stress. 
A significant decrease in the recovery of eIF2 to large and medium eIF2B bodies was 
observed following all stress treatments (Figure 4.8).  The greatest decrease in 
recovery was observed for the higher concentration of SA (500 μM) (21 %) (Figure 4.8) 
followed by the lower concentration of SA (125 μM) (14 % decrease), and then Tg (1 
μM) (8 % decrease). Interestingly the observed decrease in eIF2 movement following 
these three treatments inversely correlated to the levels of phosphorylated eIF2α 
induced by these treatments (Figure 4.4A).  
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Figure 4.8 Conditions of cellular stress decrease the movement of eIF2 through large 
and medium eIF2B bodies.  
FRAP analysis was carried out on eIF2α-GFP localised to large and medium eIF2B 
bodies in U373 cells transfected with eIF2α-GFP, and eIF2Bε-RFP to mark the eIF2B 
bodies. (A) Normalised FRAP recovery curves were plotted for cells treated with (i) 1 
µM Tg, (ii) 125 μM SA or (iii) 500 μM SA to induce cellular stress.  (B) The mean ±s.e.m 
percentage of eIF2α-GFP recovery was determined from the normalised FRAP recovery 
curves. FRAP analysis was performed on 10 bodies (n=3). P-values are derived from a 
Kruskal-Wallis test (P = 0.021), followed by a Conover-Inman analysis; * p ≤ 0.05. 
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In order to confirm that the phosphorylation of eIF2α was responsible for the observed 
reduction in the movement of eIF2 through the large and medium eIF2B bodies, FRAP 
analysis was performed with an eIF2α mutant where serine 51 is replaced by Alanine 
(eIF2α S51A). This mutant cannot be phosphorylated, as confirmed by western blot 
(Figure 4.9A). FRAP analysis following stress treatment with the higher concentration 
of SA (500 µM) revealed that the eIF2α S51A mutant could move through large and 
medium eIF2B bodies (marked by the expression of eIF2Bɛ-RFP), while the movement 
of wild type (wt) eIF2α was severely reduced (Figure 4.9B). These data suggest that the 
movement of eIF2 through large and medium eIF2B bodies is specifically influenced by 
eIF2α phosphorylation.    
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Figure 4.9 eIF2α S51A moves through large and medium eIF2B bodies during SA 
induced cellular stress.  
U373 cells were transfected with either wt eIF2α-GFP or mutant eIF2α-GFP (S51A). 
Cells were either untreated of subject to treatment with SA (500 μM) to induce cellular 
stress. (A) Western blot analysis was performed to determine the phosphorylation 
status of wt eIF2α-GFP and mutant eIF2α-GFP (S51A). (B) FRAP analysis was carried out 
for wt and mutant (S51A) eIF2α-GFP localised to large and medium eIF2B bodies in the 
presence and absence of 500 μM SA.  FRAP analysis was performed on 10 bodies (n=2) 
and (i) plotted as normalised FRAP recovery curves. (ii) The mean ± s.e.m percentage 
of eIF2α-GFP recovery was determined from the normalised FRAP recovery curves.  
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4.2.5 The movement of eIF2 into small eIF2B bodies is increased 
during cellular stress but is dependent on levels of eIF2α 
phosphorylation 
The movement of eIF2 through large and medium eIF2B bodies decreased in the 
presence of phosphorylated eIF2α (Figure 4.8). The regulatory subunits of eIF2B are 
required to mediate phosphorylated eIF2α induced inhibition of eIF2B 
(Krishnamoorthy et al., 2001; Pavitt et al., 1997) and it was hypothesised that as the 
regulatory subunits localised to the large and medium eIF2B bodies (Figure 3.12) these 
were responsible for this decreased movement of eIF2. The small eIF2B bodies 
identified in this study primarily presented with only eIF2B catalytic subunits (eIF2Bγ 
and eIF2Bε) localised to them, with less than 15 % presenting with regulatory subunits 
also co-localised (Figure 3.12). It was therefore hypothesised that the movement of 
eIF2 through these bodies would not be downregulated by cellular stress treatments. 
FRAP analysis was carried out on eIF2α-GFP localised to small eIF2B bodies in U373 
cells (marked by the expression of eIF2Bɛ-RFP), either untreated as a control, or 
treated with Tg (1 μM) or SA (125 μM and 500 μM) to induce cellular stress. 
Surprisingly, treatment with both Tg (1 μM) and the lower concentration of SA (125 
µM) significantly increased the movement of eIF2α-GFP into these bodies (Figure 
4.10A i and ii) and B). In contrast, a decrease in the percentage recovery of eIF2 was 
observed for the higher concentration of SA (500 µM) (Figure 4.10A iii and B).  
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Figure 4.10 Cellular stress modulates the movement of eIF2 through small eIF2B 
bodies.  
FRAP analysis was carried out on eIF2α-GFP localised to small eIF2B bodies in U373 
cells transfected with eIF2α-GFP and eIF2Bε-RFP to mark the eIF2B bodies. Cells were 
treated with (i) 1 µM Tg, (ii) 125 μM SA or (iii) 500 μM. FRAP analysis was performed 
on 10 bodies (n=3) and plotted as normalised FRAP recovery curves. (B) The mean ± 
s.e.m percentage of eIF2α-GFP recovery was determined from the normalised FRAP 
recovery curves. P-values were derived from a Kruskal-Wallis test (P = 0.0082), 
followed by a Conover-Inman analysis; * p ≤ 0.05. 
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4.2.6 Localisation of eIF2Bδ to small eIF2B bodies increases during 
cellular stress 
The movement of eIF2 through small eIF2B bodies in the presence of low levels of 
phosphorylated eIF2α (Figure 4.10), suggests the GEF activity within these bodies is 
increased under these conditions. Increased GEF activity of eIF2B has been linked to 
subunit composition, specifically the presence of regulatory subunits (Dev et al., 2010; 
Fabian et al., 1997; Liu et al., 2011; Williams et al., 2001). To address whether the 
stress treatments had any impact upon the localisation of regulatory subunits within 
the small eIF2B bodies, U373 cells transfected with eIF2Bε-GFP were either untreated, 
or treated with Tg (1 μM) or SA (125 μM and 500 μM). Cells were then fixed in 
methanol and subject to ICC with antibodies to the eIF2B regulatory subunits. 
Interestingly, for all stress treatments, the percentage of eIF2Bδ co-localising to small 
eIF2B bodies increased by over 40 %, however no increase in the percentage co-
localisation of eIF2Bα or eIF2Bβ to small eIF2B bodies was observed (Figure 4.11).  
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Figure 4.11 eIF2Bδ localises to an increased percentage of small eIF2B bodies during 
cellular stress.  
U373 cells were transfected with eIF2Bε-GFP, and treated with 1 µM Tg, 125 μM SA or 
500 μM. Cells were fixed in methanol and subject to ICC with primary (A) anti-eIF2Bα, 
(B) anti-eIF2Bβ or (C) anti-eIF2Bδ antibodies and visualised using an appropriate 
secondary antibody conjugated to Alexa Fluor 568. Within a population of 50 cells, the 
median percentage of co-localisation between anti-eIF2Bα, anti-eIF2Bβ or anti-eIF2Bδ 
and large and medium or small eIF2B bodies was determined (n=2 for eIF2Bα and β; 
n=3 for eIF2Bδ). P-values were derived from a Kruskal-Wallis test (p = 0.0434), 
followed by a Conover-Inman analysis; * p ≤ 0.05. 
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4.2.7 The size and distribution of eIF2B bodies is altered during 
cellular stress 
Having shown that the subunit composition of small eIF2B bodies is altered during 
cellular stress, it seemed important to determine if stress also impacted upon the size 
and distribution of eIF2B bodies. Firstly, counts were carried out on U373 cells 
expressing eIF2Bε-GFP to determine the number of large and medium, and small eIF2B 
bodies during cellular stress (Tg 1 μM, SA 125 μM or SA 500 μM). The number of small 
eIF2B bodies was found to increase for Tg (1 μM) and SA (125 μM and 500 μM) 
induced cellular stress, however the number of large and medium sized bodies was not 
changed (Figure 4.12A). Under Tg treatment the average number of small bodies per 
cell increased by 14, and for treatment with the two concentrations of SA, the average 
number of small bodies per cell increased by 7 and 8 respectively. Next the size of 
large eIF2B bodies was analysed under stress treatments to determine if stress could 
affect the size of eIF2B bodies. The average size of the large eIF2B bodies was found to 
significantly increase for all stress treatments (Figure 4.12B). 
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Figure 4.12 During cellular stress the number of small eIF2B bodies increases and the 
size of large eIF2B bodies increases.  
(A) U373 cells were transfected with eIF2Bε-GFP, and treated with 1 µM Tg, 125 μM SA 
or 500 μM. Counts were performed to determine the median number of large and 
medium or small eIF2B bodies within a population of 50 cells (n=3). (B) (i) Cells 
containing large eIF2B bodies were imaged by confocal microscopy and Image J was 
used to determine the median area of the large eIF2B bodies (25 eIF2B bodies, n=3). 
(ii) Representative images are shown in the panels. P-values were derived from a 
Kruskal-Wallis test (A p = 0.0047; B p = < 0.0001), followed by a Conover-Inman 
analysis, * p ≤ 0.05. 
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4.2.8 The size and distribution of eIF2B bodies in primary astrocytes 
displays a similar phenotype to stressed U373 cells 
The induction of cellular stress in U373 cells correlated with an increase in the number 
of small eIF2B bodies and an increase in the size of large eIF2B bodies (Figure 4.12). 
The average number of small eIF2B bodies in primary astrocytes under normal cellular 
conditions was found to be greater than that of U373 cells; 25 small bodies and 18 
small bodies respectively (Figure 3.9). The average number of small eIF2B bodies in 
primary astrocytes under normal conditions was therefore similar to the average 
number of small bodies observed in U373 cells experiencing cellular stress (Figure 
4.12). In order to determine if the eIF2B body phenotype in primary astrocytes may 
share other similarities with stressed U373 cells, the size of the large bodies in primary 
astrocytes was analysed (Figure 4.13). Similar to the trend observed for U373 cells 
subjected to cellular stress, the size of large bodies in primary astrocytes was 
significantly increased compared to untreated U373 cells.  
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Figure 4.13 The area of large eIF2B bodies is greater in primary human astrocyte cells 
than in U373 cells.  
(A) U373 cells and primary astrocyte cells were transfected with eIF2Bε-GFP, and cells 
containing large eIF2B bodies were imaged by confocal microscopy. (B) Image J was 
used to determine the median area of large eIF2B bodies in U373 cells and primary 
astrocytes (25 eIF2B bodies, n=3). P-values were derived from a Kruskal-Wallis test (p = 
< 0.0001), followed by a Conover-Inman analysis, * p ≤ 0.05. 
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From the changes observed in eIF2B body size and distribution in U373 cells treated 
with Tg and SA (Figure 4.12) it was hypothesised that phosphorylation of eIF2α may 
impact upon the size and distribution of eIF2B bodies. The levels of phosphorylated 
eIF2α were therefore analysed in U373 cells and primary astrocytes under normal 
conditions and during conditions of cellular stress (Figure 4.14). These experiments 
were only performed once but provide an indication that primary astrocytes may have 
a higher level of basal eIF2α when compared to U373 cells. Additionally, the induction 
of cellular stress appeared to induce higher levels of phosphorylated eIF2α in primary 
human astrocytes, when compared to U373 cells. These experiments should be 
repeated before conclusions are drawn.  
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Figure 4.14 Primary human astrocytes appear to express higher levels of 
phosphorylated eIF2α when compared to U373 cells.  
(A) Western blot analysis of the level of eIF2α and eIF2α p[S51] expression in (i) U373 
cells and (ii) primary astrocytes either untreated or treated with 1 µM Tg or 500 μM SA 
to induce cellular stress. Levels of phosphorylated eIF2α were normalised to levels of 
total eIF2α (n=1). 
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4.3 Discussion 
Previous work in the yeasts Saccharomyces cerevisiae and Candida albicans has shown 
that eIF2 localises to eIF2B bodies and is mobile within these bodies. Three different 
strategies to decrease the GEF activity of eIF2B all inhibited eIF2 movement into the 
bodies, showing that in yeast, the measurement of eIF2 movement into the eIF2B body 
correlates precisely with eIF2B GEF activity (Campbell et al., 2005). The data presented 
in this study demonstrates that similarly to yeast, eIF2 localises too and is mobile 
within mammalian eIF2B bodies.  
The functional importance of eIF2 mobility within eIF2B bodies was assessed using 
cellular stress as a tool to modulate eIF2B activity. Stress-induced phosphorylation of 
eIF2α converts eIF2 into a competitive inhibitor of eIF2B activity (Rowlands et al., 
1988; Dever et al., 1995) and the regulatory subunits of eIF2B (α, β and δ) are essential 
for mediating this inhibition (Krishnamoorthy et al., 2001; Pavitt et al., 1997). In 
chapter 3 of this study the regulatory subunits of eIF2B where found to predominately 
localise to eIF2B bodies with an area ≥ 3 µm2; classified as large and medium eIF2B 
bodies (Figure 3.12). It was therefore hypothesised that the GEF activity of eIF2B 
localised to large and medium bodies would be downregulated upon the induction of 
eIF2α phosphorylation. In support of this hypothesis, FRAP analysis revealed that the 
movement of eIF2 through large and medium eIF2B bodies was attenuated in response 
to ER and oxidative stress, induced by Tg and SA respectively (Figure 4.8). Furthermore, 
this decreased movement of eIF2 through the large and medium eIF2B bodies 
correlated with an increase in the localisation of phosphorylated eIF2 to the eIF2B 
bodies (Figure 4.5 and 4.7). FRAP analysis with an eIF2α S51A mutant (resistant to 
stress-induced phosphorylation) confirmed that the movement of eIF2 through large 
and medium eIF2B bodies is directly influenced by eIF2α-phosphorylation (Figure 4.9). 
These data therefore provide evidence to suggest that mammalian eIF2B bodies are 
sites of eIF2B GEF activity.  
In addition to the large and medium sized bodies identified in chapter 3, a population 
of eIF2B bodies with an area of ≤ 2.99 µm2 were also observed and these were 
classified as small eIF2B bodies. ICC revealed that these small eIF2B bodies 
predominately consisted of the catalytic subunits of eIF2B (γ and ε), with the 
regulatory subunits being either absent or present in a very low percentage of these 
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bodies (Figure 3.12). In vitro GEF assays, in both yeast and mammalian systems, have 
shown that eIF2Bγε heterodimers exhibit guanine nucleotide exchange activity that is 
unregulatable by phosphorylated eIF2α (Li et al., 2004; Pavitt et al., 1998). It was 
therefore hypothesised that the activity of eIF2B within these bodies would be 
unaffected upon induction of eIF2α phosphorylation. Intriguingly, the movement of 
eIF2 through the small eIF2B bodies was in fact significantly increased by cellular stress 
induced by both Tg, and a low concentration of SA (125 µM) (Figure 4.10). Biochemical 
assays in yeast have demonstrated that increasing the expression of eIF2B regulatory 
subunits can enhance the GEF activity of eIF2B (Dev et al., 2010; Fabian et al., 1997; Liu 
et al., 2011; Williams et al., 2001). Interestingly, an increase in the localisation of 
eIF2Bδ to the small eIF2B bodies under stress treatment was observed (Figure 4.11) 
and thus may be responsible for the observed increase in movement of eIF2. This 
increased localisation of eIF2Bδ to small eIF2B bodies during stress is suggestive of the 
formation of a currently unidentified eIF2B subcomplex, containing eIF2Bδ, γ and ε 
subunits. This complex may not have been identified in previous studies (which have 
analysed eIF2B subcomplexes) as such studies did not observe cells under stress 
conditions (Wortham et al., 2014). At higher levels of SA induced cellular stress (500 
µM), an increase in the localisation of eIF2Bδ to small bodies was also observed (Figure 
4.11), however the movement of eIF2 through these bodies was decreased (Figure 
4.10). Phosphorylated eIF2α exhibits a greater affinity for eIF2B than 
unphosphorylated eIF2α (Rowlands et al., 1988). The favoured explanation for these 
results is that in the presence of high levels of phosphorylated eIF2α, eIF2B is 
saturated by phosphorylated eIF2 and thus all eIF2B complexes become inhibited 
independent of subunit make up. 
In recent years, low levels of cellular stress have been shown to induce a protective 
phenotype. Cells that are preconditioned through the induction of sub-toxic levels of 
phosphorylated eIF2α have been shown to respond to and overcome episodes of 
cellular stress more successfully than unconditioned cells (Lewerenz and Maher, 2009; 
Lu et al., 2004a). The data presented here suggests that small eIF2B bodies have 
increased eIF2B GEF activity in the presence of low levels of phosphorylated eIF2α. A 
number of recent studies have demonstrated that treatment of cells with activators of 
eIF2B activity to enhance the GEF activity of eIF2B within a cell can protect the cell 
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against cellular stress (Sekine et al., 2015; Sidrauski et al., 2015b). It could therefore be 
hypothesised that this increase in the GEF activity of small eIF2B bodies may provide a 
protective phenotype through increasing the overall activity of eIF2B within the cell. 
Future studies investigating this hypothesis may provide insight into the protective 
mechanisms of preconditioning cells with low levels of phosphorylated eIF2α. The N-
terminus of eIF2Bδ has previously been shown to be important in mediating cellular 
stress responses (Martin et al., 2010). Mutational analysis of this region of eIF2Bδ may 
provide insight into the mechanisms by which phosphorylated eIF2 modulates small 
eIF2B body dynamics.  
In addition to the changes to the subunit make-up of the small eIF2B bodies observed 
during cellular stress, the number of small eIF2B bodies was found to increase, and the 
size of the large eIF2B bodies was also increased (Figure 4.12). Interestingly, primary 
human astrocytes displayed a similar localisation phenotype for eIF2B under non-
stressed conditions (Figure 3.9 and Figure 4.13). Although U373 cells and primary 
astrocytes are both of astrocytic lineages, immortalisation can alter cell metabolism 
(Kaur and Dufour, 2012; Mulukutla et al., 2010) possibly explaining the differences 
seen between the cell types. Levels of phosphorylated eIF2α in unstressed primary 
astrocytes appeared to be similar to levels of phosphorylated eIF2α induced by Tg 
treatment in U373 cells (Figure 4.14). If this localisation phenotype was found to 
contribute to a cell's ability to overcome episodes of cellular stress, as hypothesised 
earlier, studying eIF2B localisation phenotypes could be an interesting avenue to 
explore. Decreased basal levels of phosphorylated eIF2α have been documented in 
VWM mouse brain from mice homozygous for eIF2Bδ (R484W) or eIF2Bɛ (R191H) 
VWM mutations or heterozygous for eIF2Bδ (R484W) and eIF2Bɛ (R191H) VWM 
mutations (Abbink et al., 2018). Analysis of the phenotypic distribution of eIF2B bodies 
within these cells could perhaps provide insight into VWM disease mechanisms and 
cell-type specificity.  
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5. The impact of small molecules on eIF2B localisation and 
functionality 
5.1 Introduction 
The activation of the ISR in response to conditions of cellular stress can promote cell 
survival and recovery. Consequently, dysregulation of the ISR has important 
pathological implications and has been linked to a number of disorders (Bi et al., 2005; 
Chou et al., 2017; Eizirik et al., 2008; Santos-Ribeiro et al., 2018). Neurodegenerative 
diseases in particular commonly present with impairment of the ISR (Hetz and Saxena, 
2017) and thus pharmacological modulation of the ISR is an attractive therapeutic 
strategy (Chapter 1, Section 1.3.2). PERK is an eIF2α kinase that is activated in response 
to ER stress, commonly caused by the unfolding or misfolding of proteins (Pavitt and 
Ron, 2012). It has become a favourable pharmacological target due to an increase in 
the identification of misfolded proteins in the brains of neurodegenerative disease 
patients over the last decade (Smith and Mallucci, 2016). GSK2606414 was developed 
as a small molecule to inhibit PERK activity in cells subject to ER stress (Axten et al., 
2012), and has been shown to be neuroprotective in mouse models of frontotemporal 
dementia, Parkinson's disease and prion disease (Mercado et al., 2018; Moreno et al., 
2013; Radford et al., 2015). However, in addition to its neuroprotective role, 
GSK2606414 has been shown to induce pancreatic toxicity (Moreno et al., 2013), 
highlighting that complete ISR inhibition is lethal in specific tissue types; GSK2606414 
is therefore not a suitable therapeutic.  
Similarly to PERK inhibitors, the small molecule ISRIB reverses stress induced 
translational repression (Halliday et al., 2015; Sidrauski et al., 2013; Sidrauski et al., 
2015a). ISRIB functions downstream of eIF2α kinases and restores translation by 
enhancing the GEF activity of eIF2B (Sidrauski et al., 2015b). Structural studies have 
revealled that ISRIB interacts with the β and δ subunits of eIF2B, promoting the 
assembly of two eIF2B(βδγɛ) tetramers into an octomeric conformation (Tsai et al., 
2018; Zyryanova et al., 2018). In this octomeric conformation, eIF2B has high affinity 
for eIF2Bα homodimers and in this way, ISRIB favours the formation of decameric 
eIF2B (Tsai et al., 2018). Unlike PERK inhibitors, ISRIB does not cause pancreatic toxicity 
(Halliday et al., 2015). Through increasing eIF2B activity rather than preventing eIF2B 
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inhibition (through inhibiting eIF2α phosphorylation), ISRIB is only capable of restoring 
translation below a precise threshold of phosphorylated eIF2α, ensuring that the 
cytoprotective effects of the ISR are still accessible to the cell during periods of severe 
stress (Rabouw et al., 2019).  
ISRIB has emerged as a promising therapeutic that has been shown to promote a 
neuroprotective phenotype in mouse models of neurodegenerative disease (Chou et 
al., 2017; Halliday et al., 2015). Of particular interest is the therapeutic potential of 
ISRIB for the treatment of VWM. VWM is a leukodystrophy that is directly caused by 
mutations in eIF2B (Chapter 1, Section 1.5). A number of VWM mutations manifest 
through structural destabilisation of the decameric eIF2B complex (Li et al., 2004; Liu 
et al., 2011; Wortham and Proud, 2015). In vitro biochemical assays have confirmed 
that ISRIB can stabilise decameric eIF2B harbouring these mutations, increasing their 
GEF activity (Liang Wong et al., 2018). Furthermore, ISRIB has been shown to relieve 
VWM pathology in mouse models of VWM harbouring an eIF2Bδ (R483W) complex 
destabilising mutation (Abbink et al., 2018). The promising effects of ISRIB have led to 
the development of the molecule 2BAct, a small molecule that like ISRIB activates 
eIF2B but has improved solubility and pharmacokinetics (Wong et al., 2019). Long term 
treatment with 2BAct has been shown to prevent all pathological signs of VWM in 
mouse models harbouring an eIF2Bɛ (R191H) complex destabilising mutation, 
demonstrating that like ISRIB, 2BAct has potential to be an effective treatment for 
VWM. 
The development of new drugs for the treatment of human disease is a costly and 
time-consuming process, with only 8 % of drugs that enter clinical trials gaining 
approval. Drug repurposing is an attractive field. Recently, the currently FDA approved 
drugs, DBM and trazodone were found to have similar properties to ISRIB (Halliday et 
al., 2017). Both drugs reversed stress-induced translational repression and induced 
neuroprotective phenotypes in mouse models of neurodegenerative disease (Halliday 
et al., 2017). Although these drugs seem to have similar effects to ISRIB, the 
mechanisms through which they reverse stress-induced translational repression 
remain largely unknown. Current evidence suggests that unlike ISRIB, trazodone and 
DBM do not stabilise eIF2B in its decameric conformation (Halliday et al., 2017). 
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Having shown that the functional and phenotypic localisation of eIF2B is affected by 
conditions of cellular stress (Chapter 4), it was of interest to determine if small 
molecules that modulate the cellular stress response would have any impact on eIF2B 
localisation. This chapter therefore aimed to investigate the phenotypic localisation of 
eIF2B and the dynamics between eIF2 and eIF2B bodies in the presence of ISRIB, DBM 
and trazodone, under normal conditions and conditions of cellular stress. It is 
hypothesised that ISRIB, DBM and Trazodone will reverse the effects that cellular 
stress was found to have on the movement of eIF2 through eIF2B bodies in Chapter 4. 
To analyse the impact of the small molecules on the movement of eIF2 through eIF2B 
bodies, FRAP analysis will be performed on cells expressing eIF2α-GFP and eIF2Bε-RFP. 
To investigate whether the small molecules have an impact on the phenotypic 
localisation of eIF2B, eIF2B subunit localisation will be analysed. Cells expressing 
eIF2Bε-GFP will be fixed and ICC used to detect the presence of the other subunits of 
eIF2B in relation to the eIF2Bε-GFP bodies.  
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5.2 Results 
5.2.1 ISRIB reverses stress induced translational depression in a 
manner that is dependent on levels of eIF2α phosphorylation 
Recently the small molecule ISRIB has been shown to increase global translation in 
cells subject to sub-lethal levels of cellular stress (Rabouw et al., 2019; Sidrauski et al., 
2015a). In Chapter 4 of this study Tg and SA treatments were used to induce cellular 
stress through the phosphorylation of eIF2α. Treatment of cells with 1 µM Tg induced 
lower levels of eIF2α phosphorylation than treatment with 500 µM SA (Figure 4.4). 
Both treatments were found to impact upon the functionality of eIF2B bodies in a 
manner that correlated to levels of phosphorylated eIF2α (Figure 4.8, Figure 4.9 and 
Figure 4.10). It was therefore of interest to determine if ISRIB affected the functionality 
of eIF2B bodies in the presence of the different levels of phosphorylated eIF2α induced 
by Tg and SA treatment. To address this, firstly the ability of ISRIB to restore translation 
under the conditions of cellular stress induced by Tg and SA treatments was assessed. 
Puromycin incorporation assays were carried out on U373 cells subject to these 
stresses in the presence or absence of ISRIB (Figure 5.1). Tg treatment decreased levels 
of global translation by 65 %, compared to untreated cells, and SA treatment 
decreased levels of translation by 93 %, compared to untreated cells, reflecting the 
higher levels of phosphorylated eIF2α induced by the SA treatment (Figure 4.4). The 
addition of ISRIB to Tg treated cells significantly enhanced translation levels to near 
normal (92 % of that of untreated cells) (Figure 5.1). In contrast, the addition of ISRIB 
to SA treated cells did not restore normal levels of translation, although ISRIB did 
increase levels of translation in SA treated cells by 18 % (Figure 5.1).  
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Figure 5.1 ISRIB treatment restores translation in cells treated with 1 μM Tg but not 
in cells treated with 500 µM SA.  
Puromycin incorporation assays were carried out on U373 cells treated with 200 nM 
ISRIB and 1 μM Tg or 500 μM SA either alone, or in combination with 200 nM ISRIB. 
Levels of puromycin where normalised to β-actin and are presented as mean ± SD for 
each treatment normalised to control cells (n=3). P-values were derived from a 
Kruskal-Wallis test (P = 0.0101), followed by a Conover-Inman analysis, * p ≤ 0.05. 
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5.2.2 ISRIB rescues eIF2 mobility within large and medium eIF2B 
bodies during stress dependent on levels of eIF2α 
phosphorylation 
The decameric eIF2B complex has increased GEF activity compared to eIF2B 
subcomplexes (Liu et al., 2011). ISRIB promotes eIF2B decameric formation, increasing 
the GEF activity of eIF2B, and enabling cells to overcome low levels of cellular stress 
(Sidrauski et al., 2015b). All subunits of eIF2B localised to some degree with large and 
medium eIF2B bodies (area of ≥ 3 µm2) (Figure 3.12), it was therefore hypothesised 
that ISRIB would affect the GEF activity of these bodies. To investigate this hypothesis, 
FRAP analysis was used to measure the movement of eIF2 into large and medium 
eIF2B bodies during stress in the presence and absence of ISRIB, as an indirect 
measure of eIF2B activity. As shown previously in Figure 4.8, cellular stress induced by 
treatment with Tg (1 μM) and SA (125 μM and 500 μM), decreased movement of eIF2 
into large and medium eIF2B bodies. Treatment of ISRIB alone did not impact upon the 
movement of eIF2 through these bodies (Figure 5.2). In cells treated with 1 µM Tg, the 
addition of ISRIB significantly enhanced the movement of eIF2 through the large and 
medium eIF2B bodies (12 % increase in eIF2 recovery), restoring the percentage 
recovery of eIF2 to that observed in unstressed cells (Figure 5.2A). A similar trend was 
observed in cells treated with a low concentration of SA (125 µM) (Figure 5.2B). The 
addition of ISRIB increased the percentage recovery of eIF2 by 6 %. In contrast ISRIB 
was not able to rescue the movement of eIF2 through large and medium eIF2B bodies 
in the presence of a higher concentration of SA (500 µM), with no changes in the 
percentage recovery of eIF2 observed (Figure 5.2C). A DMSO vehicle control confirmed 
that these observed changes to the movement of eIF2 through the eIF2B bodies were 
a direct result of ISRIB (Figure 5.3).   
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Figure 5.2 ISRIB can reverse the effect that cellular stress has on the movement of 
eIF2 into large and medium eIF2B bodies dependent on the levels of cellular stress.  
FRAP analysis was carried out on eIF2α-GFP localised to large and medium eIF2B 
bodies in U373 cells transfected with eIF2α-GFP and eIF2Bε-RFP to mark the eIF2B 
bodies. Cells were treated with 200 nM ISRIB alone or in combination with (A) 1 µM Tg, 
(B) 125 μM SA or (C) 500 μM SA. (i) FRAP recovery curves were plotted and (ii) the 
mean ± s.e.m percentage of eIF2α-GFP recovery was determined. FRAP analysis was 
performed on 10 bodies (n=3). P-values were derived from a Kruskal-Wallis test (P = 
0.0922), followed by a Conover-Inman analysis * p ≤ 0.05. 
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Figure 5.3 DMSO does not influence the movement of eIF2 through large and 
medium eIF2B bodies.  
FRAP analysis was carried out on eIF2α-GFP localised to large and medium eIF2B 
bodies in U373 cells transfected with eIF2α-GFP and eIF2Bε-RFP to mark the eIF2B 
bodies. Cells were treated with DMSO as a vehicle control for ISRIB. (A) FRAP recovery 
curves were plotted and (B) the mean ±s.e.m percentage of eIF2α-GFP recovery was 
determined. FRAP analysis was performed on 10 bodies (n=3). 
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5.2.3 Treatment with ISRIB increases the movement of eIF2 into 
small eIF2B bodies 
The mechanism of action of ISRIB relies upon stabilisation of eIF2B in its decameric 
form to enhance eIF2B GEF activity (Sidrauski et al., 2015b; Tsai et al., 2018; Zyryanova 
et al., 2018). In Chapter 3, eIF2B bodies with an area ≤ 2.99 µm2, classified as small 
eIF2B bodies, primarily presented with only the catalytic subunits of eIF2B (eIF2Bγ and 
eIF2Bε) localised to them. As all subunits of eIF2B are required to form the decameric 
conformation, it was hypothesised that ISRIB would not impact upon the GEF activity 
of eIF2B localised to these bodies. In order to investigate this hypothesis, FRAP analysis 
was used to measure the movement of eIF2 into small eIF2B bodies as an indirect 
measure of eIF2B activity. The FRAP analysis was carried out on untreated cells or cells 
treated with ISRIB (Figure 5.4). Rather surprisingly, the percentage recovery of eIF2 to 
small eIF2B bodies was found to significantly increase (8 % increase in eIF2 recovery) in 
the presence of ISRIB (Figure 5.4A). A DMSO vehicle control confirmed that this 
observed increase in the movement of eIF2 was a direct result of ISRIB (Figure 5.4B).   
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Figure 5.4 The movement of eIF2 into small eIF2B bodies is enhanced during ISRIB 
treatment.  
FRAP analysis was carried out on eIF2α-GFP localised to small eIF2B bodies in U373 
cells transfected with eIF2α-GFP and eIF2Bε-RFP to mark the eIF2B bodies. Cells were 
either untreated or treated with (A) 200 nM ISRIB or (B) a DMSO vehicle control. (i) 
FRAP recovery curves were plotted and (ii) the mean ± s.e.m percentage of eIF2α-GFP 
recovery was determined. FRAP analysis was performed on 10 bodies (n=3). P-values 
were derived from a Kruskal-Wallis test (p = 0.0495), followed by a Conover-Inman 
analysis * p ≤ 0.05. 
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5.2.1 The localisation of eIF2Bδ to small eIF2B bodies is increased 
during ISRIB treatment 
Although the γ and ε subunits of eIF2B are sufficient to perform eIF2B GEF activity, 
eIF2B complexes that contain the regulatory eIF2B subunits display enhanced GEF 
activity (Dev et al., 2010; Fabian et al., 1997; Liu et al., 2011; Williams et al., 2001). 
Chapter 3 of this study demonstrated that the regulatory subunits of eIF2B 
predominately localise to large and medium eIF2B bodies with very few small eIF2B 
bodies co-localising with regulatory subunits (Figure 3.12). To address whether the 
increased movement of eIF2 into small eIF2B bodies induced by ISRIB could be linked 
to a change in the subunit composition of these bodies ICC analysis was carried out. 
Cells transiently expressing eIF2Bɛ-GFP were either untreated or treated with ISRIB, 
and then subjected to ICC with primary antibodies to eIF2Bα, eIF2Bβ or eIF2Bδ. Using 
confocal microscopy counts were carried out across a population of 50 cells to 
determine the percentage of large and medium or small eIF2B bodies that eIF2Bα, 
eIF2Bβ or eIF2Bδ localised to. No changes were observed for eIF2Bα or eIF2Bβ upon 
addition of ISRIB, however a significant increase in the median localisation of eIF2Bδ to 
small eIF2B bodies (39 %) was observed (Figure 5.5). No significant difference in the 
percentage of large and medium bodies that eIF2Bδ localised too was observed in the 
presence of ISRIB (Figure 5.5).   
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Figure 5.5 eIF2Bδ localises to an increased percentage of small eIF2B bodies 
following treatment with ISRIB.  
U373 cells were transfected with eIF2Bε-GFP and either untreated or treated with 200 
nM ISRIB. Cells were fixed in methanol and subject to ICC with a primary (A) eIF2Bα, 
(B) eIF2Bβ or (C) eIF2Bδ antibodies and visualised using an appropriate secondary 
antibody conjugated to Alexa Fluor 568. Within a population of 50 cells, the median 
percentage of co-localisation between anti-eIF2Bα, anti-eIF2Bβ or anti-eIF2Bδ and 
large and medium or small eIF2Bε-GFP bodies was determined (n=2 for eIF2Bα and 
eIF2Bβ; n=3 for eIF2Bδ). P-values were derived from a Kruskal-Wallis test (p = 0.0156), 
followed by a Conover-Inman analysis * p ≤ 0.05. 
140 
 
In order to determine if the increased percentage of small eIF2B bodies with eIF2Bδ 
co-localised was a direct effect of ISRIB interacting with eIF2Bδ, the localisation of 
eIF2Bδ was analysed in CHO cells harbouring eIF2Bδ (L180F) mutation. This mutation 
resides within the ISRIB binding pocket of eIF2B and prevents ISRIB from enhancing 
eIF2B activity (Sekine et al., 2015; Tsai et al., 2018; Zyryanova et al., 2018). eIF2Bɛ-RFP 
was expressed in CHO cells containing wt eIF2Bδ or mutant eIF2Bδ (L180F), cells were 
either untreated or treated with ISRIB and then subject to ICC with a primary eIF2Bδ 
antibody (Figure 5.6). To ensure that the eIF2Bδ mutant did not affect antibody 
recognition, dot blot analysis was carried out (Figure 5.7A). Analysis of extracts 
prepared from both the wt and the mutant cells showed eIF2Bδ was recognised by the 
antibody. Using confocal microscopy, counts were performed across a population of 25 
cells to determine the percentage of large and medium or small eIF2B bodies that 
showed eIF2Bδ localisation (Figure 5.7B).  Upon ISRIB treatment, an increase in eIF2Bδ 
localisation to small eIF2B bodies was observed for the wt eIF2Bδ. Interestingly, in the 
mutant cells, no increase in distribution of mutant eIF2Bδ (L180F) to small bodies was 
observed.   
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Figure 5.6 Localisation of eIF2Bδ to small eIF2B bodies in the presence of ISRIB is 
decreased by an eIF2Bδ ISRIB-resistant mutation.  
CHO cells harbouring wt eIF2Bδ or mutant eIF2Bδ (L180F) were transfected with 
eIF2Bε-RFP and treated with 200 nM ISRIB. Cells were fixed in methanol and subject to 
ICC with a primary anti-eIF2Bδ antibody, detected using an appropriate secondary 
antibody conjugated to Alexa Fluor 568. The localisation of eIF2Bδ was visualised by 
confocal microscopy. 
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Figure 5.7 Localisation of eIF2Bδ to small eIF2B bodies is a direct consequence of 
ISRIB interacting with eIF2Bδ.  
(A) CHO cells containing wt eIF2Bδ or mutant eIF2Bδ (L180F) were subject to dot blot 
analysis for anti-eIF2Bδ. (B) CHO cells containing wt eIF2Bδ or mutant eIF2Bδ (L180F) 
were transfected with eIF2Bε-RFP and either untreated or treated with 200 nM ISRIB. 
Cells were fixed in methanol and subject to ICC with a primary anti-eIF2Bδ antibody, 
detected using an appropriate secondary antibody conjugated to Alexa Fluor 568. 
Using confocal microscopy, the median percentage of co-localisation between anti-
eIF2Bδ and large and medium or small eIF2Bε-RFP bodies was determined in the 
presence or absence of ISRIB treatment (25 cells, n=3). P-values were derived from a 
Kruskal-Wallis test (p = 0.4125), followed by a Conover-Inman analysis, * p ≤ 0.05. 
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5.2.2 The size and distribution of eIF2B bodies is altered during ISRIB 
treatment 
The influence of ISRIB on small eIF2B body composition and activity reflects the 
changes that low levels of cellular stress were observed to have on small eIF2B bodies 
in Chapter 4 of this study (Figure 4.10 and Figure 4.11). Cellular stress was found to 
also increase the number of small eIF2B bodies and the size of large eIF2B bodies 
(Figure 4.12). In order to determine if ISRIB may also affect the number of small eIF2B 
bodies, U373 cells expressing eIF2Bɛ-GFP were either untreated or treated with ISRIB 
and then using confocal microscopy counts were carried out to determine the median 
number of large and medium or small eIF2B bodies across a population of 50 cells 
(Figure 5.8A). ISRIB treatment significantly enhanced the median number of small 
eIF2B bodies (44 % increase) when compared to untreated cells. No significant change 
to the number of large and medium eIF2B bodies was observed.  
In order to determine if ISRIB also influenced the size of large eIF2B bodies, eIF2Bɛ-GFP 
was expressed in U373 cells and cells containing large eIF2B bodies were imaged. The 
area of the large eIF2B bodies were measured using Image J software in both ISRIB 
treated and untreated cells (Figure 5.8B). ISIRB treatment significantly increased the 
area of large eIF2B bodies by approximately 2-fold.  
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Figure 5.8 Following treatment with ISRIB the number of small eIF2B bodies 
increased and the size of large eIF2B bodies increased.  
U373 cells were transfected with eIF2Bε-GFP and either untreated or treated with 200 
nM ISRIB. (A) Using confocal microscopy counts were performed to determine the 
median number of large and medium or small eIF2B bodies within a population of 50 
cells (n=3). (B) (i) Cells containing large eIF2B bodies were imaged by confocal 
microscopy and image J was used to determine the median area of large eIF2B bodies 
(25 eIF2B bodies, n=3). (ii) Representative images confocal images are shown. P-values 
were derived from a Kruskal-Wallis test ((A) p = 0.0156; (B) p = < 0.0001), followed by a 
Conover-Inman analysis, * p ≤ 0.05.  
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5.2.3 DBM appears to increase translation under normal cellular 
conditions and during cellular stress 
DBM is a naturally occurring structural analogue of curcumin, with widely reported 
anti-cancer properties (Oo Khor et al., 2009) that has recently been shown to also 
restore translation under conditions of cellular stress induced by Tg (Halliday et al., 
2017). In order to determine if DBM could enhance translation during the conditions of 
cellular stress used in this study (specifically Tg treatment) a puromycin incorporation 
assay was carried out on U373 cells to measure levels of global protein synthesis.  Cells 
were treated with 1 µM Tg, in the presence or absence of 20 µM DBM (Figure 5.9). Tg 
treatment alone decreased levels of global translation by approximately 45 % while the 
addition of DBM to the Tg treated cells appeared to enhance translation back to 
normal levels. Interestingly, in contrast to ISRIB treatment, DBM treatment alone also 
appeared to increase translation levels (42 % increase in puromycin incorporation). It 
should be noted this experiment was only performed once and future experiments 
repeating this should be performed to confirm the trend.   
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Figure 5.9 DBM treatment increases translation in cells under normal growth 
conditions and can restore translation rates in cells during Tg induced cellular stress. 
Puromycin incorporation assays were carried out on U373 cells untreated or treated 
with 20 µM DBM or 1 μM Tg alone, or in combination. Levels of puromycin where 
normalised to β-actin and are presented as mean ± SD for each treatment (n=1). 
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5.2.4 DBM cannot rescue the movement of eIF2 into Large and 
Medium eIF2B bodies during cellular stress 
The mechanism through which DBM restores translation is currently unknown. Unlike 
ISRIB, DBM does not stabilise eIF2B in its decameric conformation (Halliday et al., 
2017), however both drugs do share the same downstream effect of restoring 
translation in stressed cells. Having shown ISRIB modulates eIF2B bodies in a number 
of different ways (Figure 5.2, Figure 5.4 and Figure 5.5) we were intrigued to 
determine if DBM may also have an impact upon the properties of eIF2B bodies. 
Firstly, the effect of DBM on the activity of eIF2B localised to large and medium eIF2B 
bodies in stressed cells was investigated. FRAP analysis was used as a tool to measure 
the movement of eIF2 into eIF2B bodies as an indirect measurement of eIF2B activity. 
Cells were subject to Tg-induced cellular stress either in the presence, or the absence 
of DBM (Figure 5.10). Similarly to ISRIB, treatment with DBM alone did not impact 
upon the movement of eIF2 through the large and medium eIF2B bodies in untreated 
cells (Figure 5.10). However, in contrast to ISRIB, in cells treated with Tg, DBM also had 
no impact upon the movement of eIF2 through large and medium eIF2B bodies (Figure 
5.10). These data suggest that DBM does not restore translation in stressed cells 
through increasing the activity of eIF2B localised to large and medium eIF2B bodies.  
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Figure 5.10 DBM cannot rescue the decreased movement of eIF2 through large and 
medium eIF2B bodies during Tg induced cellular stress.  
FRAP analysis was carried out on eIF2α-GFP localised to large and medium eIF2B 
bodies in U373 cells transfected with eIF2α-GFP, and eIF2Bε-RFP to mark the eIF2B 
bodies. Cells were either untreated or treated with 20 µM DBM or 1 µM Tg, either 
alone or in combination (A) FRAP recovery curves were plotted and (B) the mean ± 
s.e.m percentage of eIF2α-GFP recovery was determined. FRAP analysis was 
performed on 10 bodies (n=2).  
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5.2.5 DBM increases the movement of eIF2 into small eIF2B bodies 
These data presented in Figure 5.10 suggests that DBM does not restore translation 
through modulating the activity of eIF2B localised to large and medium eIF2B bodies. 
The data generated in Figure 5.4 suggests that ISRIB treatment enhances the GEF 
activity of small eIF2B bodies. In order to determine if DBM had a similar influence on 
the activity of eIF2B localised to small eIF2B bodies, FRAP analysis was performed as an 
indirect measure of eIF2B activity. U373 cells expressing eIF2α-GFP were either 
untreated or treated with DBM and FRAP analysis performed on eIF2α-GFP localised to 
small eIF2B bodies (eIF2Bɛ-RFP was also expressed to mark the eIF2B bodies) (Figure 
5.11). Interestingly, the percentage recovery of eIF2 to small eIF2B bodies was found 
to increase by 10 % in the presence of DBM.  
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Figure 5.11 The movement of eIF2 through small eIF2B bodies is enhanced during 
treatment with DBM.  
FRAP analysis was carried out on eIF2α-GFP localised to small eIF2B bodies in U373 
cells transfected with eIF2α-GFP and eIF2Bε-RFP to mark the eIF2B bodies. Cells were 
either untreated or treated with 20 µM DBM and FRAP analysis was performed on 10 
small bodies (n=3). (A) FRAP recovery curves were plotted and (B) the mean ± s.e.m 
percentage of eIF2α-GFP recovery was determined. P-values were derived from a 
Kruskal-Wallis test (p = 0.0495), followed by a Conover-Inman analysis, * p ≤ 0.05. 
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5.2.6 DBM promotes an increase in the localisation of eIF2Bδ to small 
eIF2B bodies 
The movement of eIF2 into small eIF2B bodies was found to increase in the presence 
of DBM suggesting that DBM may modulate the GEF activity of eIF2B localised to these 
eIF2B bodies (Figure 5.11). An increase in the movement of eIF2 into small eIF2B 
bodies was also observed in stressed cells (Figure 4.10) and cells treated with ISRIB 
(Figure 5.4). Under these conditions the increased movement of eIF2 correlated with 
an increase in the percentage of small eIF2B bodies to which eIF2Bδ localised (Figure 
4.11 and Figure 5.5). In order to determine if DBM also increased eIF2Bδ localisation to 
small eIF2B bodies, ICC with primary eIF2Bα, eIF2Bβ or eIF2Bδ antibodies was carried 
out on U373 cells expressing eIF2Bɛ-GFP, either in the presence or absence of DBM. 
Counts were carried out across a population of 50 cells to determine the percentage 
co-localisation between eIF2Bδ to large and medium or small eIF2Bɛ-GFP bodies 
(Figure 5.12). A significant increase in the median localisation of eIF2Bδ to small eIF2B 
bodies (49 %) was observed in the presence of DBM. Representative images are shown 
in Figure 5.13. No significant difference in the percentage of large and medium bodies 
that eIF2Bδ localised to was observed in the presence of DBM (Figure 5.12B).   
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Figure 5.12 eIF2Bδ localises to an increased percentage of small eIF2B bodies 
following treatment with DBM.  
U373 cells were transfected with eIF2Bε-GFP and either untreated or treated with 20 
µM DBM. Cells were fixed in methanol and subject to ICC with primary (A) anti-eIF2Bα, 
(B) anti-eIF2Bβ or (C) anti-eIF2Bδ antibodies, visualised using an appropriate secondary 
antibody conjugated to Alexa Flour 568. Within a population of 50 cells, the median 
percentage of co-localisation between anti-eIF2Bδ and large and medium or small 
eIF2Bε-GFP bodies was determined (n=2 for eIF2Bα and eIF2Bβ; n=3 for eIF2Bδ). P-
values were derived from a Kruskal-Wallis test (p = 0.0495), followed by a Conover-
Inman analysis, * p ≤ 0.05. 
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Figure 5.13 eIF2Bδ localises to small eIF2B bodies following treatment with DBM.  
U373 cells were transfected with eIF2Bε-GFP and either untreated or treated with 20 
µM DBM. Cells were fixed in methanol and subject to ICC with a primary anti-eIF2Bδ 
antibody, visualised using an appropriate secondary antibody conjugated to Alexa 
Flour 568. Representative confocal images are presented in the panels.  
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5.2.7 Trazodone partially restores stress induced translational 
depression. 
Similarly to ISRIB and DBM, Trazodone has also been identified as a small molecule 
that  can restore translation in cells subjected to Tg induced cellular stress (Halliday et 
al., 2017). Like DBM, Trazodone is an FDA approved drug. It can modulate the activity 
of serotonin receptors and thus is currently prescribed as an antidepressant (Maj et al., 
1979). The mechanism through which trazodone enhances protein synthesis in 
stressed cells is largely unknown. Having shown that the translation enhancing drugs 
ISRIB and DBM modulate the properties of eIF2B bodies we were intrigued to 
determine if trazodone may also have an impact upon the properties of eIF2B bodies. 
As trazodone has previously been shown to enhance translation in the presence of Tg 
induced cellular stress (Halliday et al., 2017), we focused our study on the impact 
trazodone has on eIF2B bodies during this type of stress. Firstly, it was important to 
determine if trazodone could enhance translation under the conditions of Tg induced 
cellular stress used in this study. Preliminary evidence for this was provided using a 
puromycin incorporation assay carried out on U373 cells subject to treatment with 1 
µM Tg for 1 hour, in the presence or absence of trazodone (Figure 5.14). Tg treatment 
alone decreased levels of global translation to approximately 44 % of untreated cells 
levels. The addition of trazodone to Tg treated cells enhanced translation back to 69 % 
of untreated levels. Interestingly, unlike DBM but similar to ISRIB, trazodone treatment 
alone did not enhance translation (Figure 5.14). It should be noted this experiment was 
only performed once and future experiments repeating this should be performed to 
confirm the trend.   
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Figure 5.14 Trazodone treatment partially restores translation in cells during Tg 
induced cellular stress.  
Puromycin incorporation assays were carried out on U373 cells untreated or treated 
with 20 µM trazodone or 1 μM Tg either alone, or in combination. Levels of puromycin 
where normalised to β-actin and are presented as mean ± SD for each treatment (n=1). 
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5.2.8 During cellular stress trazodone increases the movement of 
eIF2 through large and medium eIF2B bodies 
Having determined that trazodone enhanced translation in cells subject to Tg induced 
cellular stress, the effect of trazodone on the GEF activity of large and medium eIF2B 
bodies was investigated. FRAP analysis was used as a tool to measure the movement 
of eIF2 into eIF2B bodies as an indirect measurement of eIF2B activity. FRAP analysis 
was carried out on eIF2α-GFP localised to large and medium eIF2B bodies in cells that 
were subjected to Tg-induced cellular stress either in the presence, or the absence of 
trazodone (Figure 5.15). Treatment with trazodone alone did not impact upon the 
movement of eIF2 through the large and medium eIF2B bodies (Figure 5.15). In cells 
treated with Tg, the movement of eIF2 was decreased by 7 %. The addition of 
trazodone to Tg treated cells increased movement of eIF2 through large and medium 
eIF2B bodies by 2 % (Figure 5.15).   
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Figure 5.15 Trazodone increases the movement of eIF2 through large and medium 
eIF2B bodies during Tg induced cellular stress.  
FRAP analysis was carried out on eIF2α-GFP localised to large and medium eIF2B 
bodies in U373 cells transfected with eIF2α-GFP and eIF2Bε-RFP to mark the eIF2B 
bodies. Cells were treated with 20 µM Trazodone or 1 µM Tg, either alone or in 
combination. FRAP analysis was performed on 10 bodies (n=2). (i) FRAP recovery 
curves were plotted and (ii) the mean ± s.e.m percentage of eIF2α-GFP recovery was 
determined.  
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5.2.9 Trazodone decreases the movement of eIF2 into small eIF2B 
bodies  
The movement of eIF2 through small eIF2B bodies was increased in the presence of 
both ISRIB (Figure 5.4) and DBM (Figure 5.11), suggesting that modulating the GEF 
activity of small eIF2B bodies may be a common trend of translation enhancing drugs. 
In order to determine if trazodone could modulate the activity of eIF2B localised to 
small eIF2B bodies FRAP analysis was performed on eIF2α-GFP localised to small eIF2B 
bodies in untreated cells and cells treated with trazodone (Figure 5.16A).  In contrast 
to the trend observed for ISRIB and DBM treated cells, when cells were treated with 
trazodone, the percentage recovery of eIF2 to small eIF2B bodies was found to 
decrease by approximately 10 % (Figure 5.16B).  
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Figure 5.16 The movement of eIF2 through small eIF2B bodies is decreased during 
treatment with Trazodone.  
FRAP analysis was carried out on eIF2α-GFP localised to small eIF2B bodies in U373 
cells transfected with eIF2α-GFP and eIF2Bε-RFP to mark the eIF2B bodies. Cells were 
treated with 20 µM Trazodone and FRAP analysis was performed on 10 bodies (n=2). 
(A) FRAP recovery curves were plotted and (B) the mean ± s.e.m percentage of eIF2α-
GFP recovery was determined.  
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5.3 Discussion 
Pathological disruption of the ISR is common in a number of different diseases 
including, cancer, diabetes and neurodegenerative diseases (Bi et al., 2005; Chou et al., 
2017; Eizirik et al., 2008). Small molecules that regulate the ISR have therefore 
emerged as promising therapeutic tools and understanding the mechanisms of action 
of these drugs will enhance the likelihood that they will be used as treatments.  
Recently ISRIB was identified as a small molecule that reverses phosphorylated eIF2α 
induced translational repression (Halliday et al., 2015; Sidrauski et al., 2013; Sidrauski 
et al., 2015a), through restoration of eIF2B activity (Sekine et al., 2015; Sidrauski et al., 
2015b). It was therefore of interest to investigate if ISRIB may influence the activity of 
eIF2B localised to eIF2B bodies. ISRIB enhances the GEF activity of eIF2B through 
promoting the assembly of decameric eIF2B complexes (Sidrauski et al., 2015b; Tsai et 
al., 2018; Zyryanova et al., 2018). eIF2B subunit co-localisation data presented in 
Chapter 3 of this study highlighted that all subunits of eIF2B are present to some 
degree in large and medium sized eIF2B bodies, however small bodies mainly consist 
of the catalytic eIF2B subunits (Figure 3.12). This led to the hypothesis that ISRIB would 
increase the GEF activity of eIF2B localised to large and medium bodies during cellular 
stress. Indeed, in cells treated with 1 μM Tg and 125 μM SA an increase in the 
movement of eIF2 through large and medium eIF2B bodies was observed in the 
presence of ISRIB, suggesting that ISRIB increases the GEF actvity of these bodies. ISRIB 
however had no effect on the movement of eIF2 through large and medium bodies in 
cells treated with 500 μM SA. These findings suggest that ISRIB increases the GEF 
activity of large and medium eIF2B bodies when cellular levels of phosphorylated eIF2α 
are below a certain threshold. This is in concordance with recent studies that have 
shown ISRIB can only restore translation in cells exposed to SA at a concentration of 
100 µM or less (Rabouw et al., 2019). The lack of regulatory eIF2B subunits localising to 
small eIF2B bodies led to the hypothesis that ISRIB would have no effect on the GEF 
activity of these bodies, as all subunits are required for decameric assembly. 
Surprisingly, an increase in the movement of eIF2α through these eIF2B bodies was 
observed during ISRIB treatment, in the absence of cellular stress, suggesting that the 
GEF activity of these bodies was increased (Figure 5.4). An increase in the localisation 
of the δ subunit of eIF2B correlated with this increased activity (Figure 5.5). In light of 
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these observations, it has previously been proposed that in addition to the role of 
ISRIB in stabilising the eIF2B decamer, ISRIB may also enhance the basal activity of 
eIF2B by providing a source of eIF2B that is not inhibited by phosphorylated eIF2α 
(Sidrauski et al., 2015b). The data from chapter 4 of this study has highlighted that the 
activity of small eIF2B bodies is not inhibited by phosphorylated eIF2α when low levels 
are present (Figure 4.10). In fact, the GEF activity of small eIF2B bodies appears to be 
increased in the presence of low levels of phosphorylated eIF2, similar to the trend 
observed here for ISRIB. These findings will be discussed further in Chapter 6.  
The drug DBM was recently identified to have similar properties to ISRIB in terms of 
restoring global translation in stressed cells (Halliday et al., 2017). Unlike ISRIB, DBM 
does not promote the stability of decameric complexes of eIF2B (Halliday et al., 2017) 
and its mechanism of action remains unknown. ISRIB was able to restore the 
movement of eIF2 into large and medium bodies during cellular stress. It was 
hypothesised that this was due to all eIF2B subunits localising to these bodies and 
ISRIBs ability to promote decameric formation of eIF2B. In fitting with this hypothesis 
DBM was unable to restore the movement of eIF2 into these eIF2B bodies during 
stress (Figure 5.10). DBM did however modulate the activity of small eIF2B bodies. An 
increased localisation of eIF2Bδ to small bodies (Figure 5.12), accompanied by an 
increase in eIF2 movement through these bodies (Figure 5.11), was observed in cells 
treated with DBM. These data suggest that DBM may share a common mechanism 
with ISRIB whereby promoting the formation of eIF2Bδγε containing subcomplexes 
provides a source of eIF2B with increased activity. 
Trazodone is another translation enhancing drug that has been shown to restore ISR 
induced-translation repression and its mechanism of action is also unknown. 
Trazodone appeared to partially restore the GEF activity of eIF2B localised to large and 
medium bodies during cellular stress (Figure 5.15); a similar trend to that observed for 
treatment with ISRIB. In contrast to ISRIB, trazodone does not promote decameric 
stability of eIF2B (Halliday et al., 2017) and therefore is likely to enhance activity of 
eIF2B localised to these bodies via a different mechanism. In human astrocytes 
trazodone has been shown to activate protein kinase B (AKT), a kinase involved in cell 
growth and survival, and it has been proposed that this is via activation of the 
serotonin 1A receptor (5-HT1A) (Daniele et al., 2015). AKT phosphorylates glycogen 
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synthase kinase 3 (GSK3), inactivating it (Cross et al., 1995). Interestingly, in its active 
form, GSK3 phosphorylates the C-terminal of the ε subunit eIF2B, inhibiting eIF2B 
activity (Welsh and Proud, 1993; Welsh et al., 1998). Investigating the impact of 
trazodone on GSK3 activity and the phosphorylation status of eIF2Bε could be an 
interesting avenue to explore in relation to the increased activity of eIF2B that was 
observed under treatment with trazodone. The effect of trazodone on the GEF activity 
of small eIF2B bodies was less conclusive. An overall trend suggested that Trazodone in 
fact decreased activity of eIF2B within these bodies (Figure 5.16); somewhat 
contradictory to the role of Trazodone in increasing translation. This data however is 
highly variable and should be repeated before conclusions are drawn.  
The three small molecules investigated in this chapter all appear to have an effect on 
the GEF activity of eIF2B bodies. ISRIB appears to enhance the GEF activity of large and 
medium eIF2B bodies during acute stress, likely a consequence of its ability to stabilise 
decameric eIF2B (Sidrauski et al., 2015b; Tsai et al., 2018; Zyryanova et al., 2018). 
Furthermore, the data presented here point towards a secondary affect of ISRIB, 
whereby ISRIB can modulate subunit distribution and activity of small eIF2B bodies. 
DBM appears to also induce these changes to small eIF2B bodies. It could be 
hypothesised that the enhanced activity of these eIF2B bodies could provide a source 
of eIF2B to facilitate low levels of translation during episodes of acute cellular stress. 
Trazodone did not appear to increase the GEF activity of small eIF2B bodies, however it 
did appear to enhance the activity of large and medium bodies during cellular stress. It 
should be considered that eIF2B is the target of a number of cellular pathways to allow 
for tight regulation of translation. The observed effects of these drugs on the GEF 
activity of eIF2B bodies could therefore be indirect and a result of the drugs acting on 
different cellular pathways. 
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6. General Discussion  
eIF2B has an important role in facilitating the initiation step of translation within a cell. 
The loading of the ribosome complex onto a target mRNA transcript requires the 
hydrolysis of a GTP molecule, carried by eIF2. eIF2B catalyses the recycling of eIF2-GDP 
into eIF2-GTP allowing for subsequent rounds of translation to occur. Previous work in 
yeast has shown that eIF2B localises to cytoplasmic foci, termed eIF2B bodies 
(Campbell et al., 2005; Egbe et al., 2015) which appear to be sites of GEF activity 
(Campbell et al., 2005). The functional localisation of eIF2B within mammalian cells 
had not previously been evaluated. Mutations in eIF2B are causative of the 
neurological disorder, VWM. The pathophysiology of VWM remains somewhat elusive 
and thus understanding the cellular localisation of mammalian eIF2B could provide 
insight into the mechanisms of VWM pathology. Although eIF2B is globally expressed, 
VWM primarily manifests as a leukodystrophy, characterised by defective maturation 
of astrocytes and oligodendrocytes (Dooves et al., 2016). An astrocytoma cell line, 
U373, was therefore used in this study as the primary cell type for characterising eIF2B 
localisation.  
The data presented in this study provides the first evidence that eIF2B bodies exist in 
mammalian cells. Unlike in yeast where cells exhibit a single eIF2B body, mammalian 
cells exhibited a number of different sized eIF2B bodies. Structural analysis of eIF2B 
has shown that eIF2B forms a heterodecamer in its native form, comprised of two 
eIF2B(βδγɛ) tetramers stabilised by an eIF2Bα homodimer (Gordiyenko et al., 2014; 
Kashiwagi et al., 2016; Kashiwagi et al., 2017; Wortham et al., 2014). In yeast all 
subunits of eIF2B have been shown to localise to eIF2B bodies and knockdown of 
eIF2Bα disperses the body, suggesting that decameric conformation of eIF2B is key to 
this localisation (Campbell et al., 2005; Noree et al., 2010; Norris et al., 2019). In 
addition to the decameric eIF2B complex, a number of functional subcomplexes have 
also been isolated from mammalian cells overexpressing eIF2B subunits (Liu et al., 
2011; Wortham et al., 2014). It could therefore be hypothesised that the increased 
number of different sized eIF2B bodies observed in mammalian cells could be related 
to the presence of subcomplexes. In support of this, a correlation between the size of 
the mammalian eIF2B body and the subunits of eIF2B present was observed (Figure 
3.12). All five subunits of eIF2B were found to localise to a percentage of eIF2B bodies 
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with an area greater than 3 µm2, referred to as large and medium eIF2B bodies. 
Whereas eIF2B bodies with an area less than 3 µm2, termed small bodies, appeared to 
predominately be formed of only catalytic subunits (γ and ɛ subunits). A schematic 
representation of this data is outline in Figure 6.1.  
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Figure 6.1 Model of eIF2B localisation in mammalian cells.  
The eIF2B subunit localisation data presented in this study suggests that eIF2B subcomplexes 
may localise to different sized eIF2B bodies. All subunits showed a high degree of co-
localisation with large eIF2B bodies suggesting eIF2B(αβδγε)2 decameric complexes may reside 
here. All subunits also showed some degree of co-localisation with medium bodies, however 
eIF2Bα showed the lowest degree of co-localisation suggesting eIF2B(αβδγε)2 decameric and 
eIF2B(βδγε) tetrameric complexes may reside within these bodies. Catalytic subunits localised 
to small eIF2B bodies whereas regulatory subunits showed very low levels of co-localisation 
suggesting eIF2B(γε) heterodimers may localise within these bodies.  
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To assess the functionality of the mammalian eIF2B bodies identified in this study the 
relationship between eIF2 and the eIF2B bodies was analysed. Live cell imaging 
revealed that eIF2 localised to, and was mobile within, eIF2B bodies (Figures 4.1 and 
4.3) suggesting that as in yeast, these bodies may be sites of eIF2B GEF activity (Figure 
6.2A). In order to investigate this, induction of cellular stress was used as a tool to 
manipulate eIF2B activity and the movement of eIF2 was monitored. Activation of the 
ISR by diverse cellular stresses results in the phosphorylation of eIF2α at serine 51. 
Phosphorylated eIF2 is a competitive inhibitor of eIF2B (Rowlands et al., 1988; Dever et 
al., 1995) causing the downregulation of global translation initiation. The eIF2B 
regulatory subunits (α,β and δ) are essential for mediating the control of eIF2B GEF 
activity under stress (Krishnamoorthy et al., 2001; Pavitt et al., 1997), and eIF2B 
complexes containing the regulatory subunits are known to display a higher affinity for 
eIF2 when present in its phosphorylated form (Kashiwagi et al., 2017; Pavitt et al., 
1998). The effects of stress on the movement of eIF2 within eIF2B bodies was 
therefore analysed for the eIF2B bodies to which regulatory subunits localised; large 
and medium eIF2B bodies (Figure 3.12). The movement of eIF2 through large and 
medium eIF2B bodies was attenuated in response to ER and oxidative stress, induced 
by Tg and SA respectively (Figure 4.8). Analysis of the cellular localisation of 
phosphorylated eIF2 under these conditions revealed that phosphorylated eIF2 
localised predominately to these bodies (Figure 4.7). Mutational analysis confirmed 
that the decrease in shuttling of eIF2 through these bodies during stress was directly 
related to the phosphorylation of eIF2 (Figure 4.9). This evidence supports previous 
conclusions in yeast where the movement of eIF2 through eIF2B bodies was relative to 
the GEF activity of eIF2B (Campbell et al., 2005; Taylor et al., 2010). A schematic 
representation of these results is presented in Figure 6.2A and B. 
In vitro GEF assays, in both yeast and mammalian systems, show that eIF2Bγε 
heterodimers exhibit GEF activity that is unregulatable by phosphorylated eIF2α (Li et 
al., 2004; Pavitt et al., 1998). The absence of regulatory eIF2B subunits (α, β and δ) 
localised to small eIF2B bodies (Figure 3.12) led to the hypothesis that the induction of 
eIF2α phosphorylation would not impact upon the movement of eIF2 through these 
bodies. Intriguingly, the movement of eIF2 through small bodies was significantly 
increased by cellular stress induced by both Tg and a low concentration of SA (125 µM) 
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(Figure 4.10), suggesting that these bodies have increased GEF activity during stress 
(Figure 6.2C).  
Biochemical assays in yeast have demonstrated that increasing the expression of 
regulatory eIF2B (α, β and δ) subunits can enhance eIF2B GEF activity (Dev et al., 2010; 
Fabian et al., 1997; Liu et al., 2011; Williams et al., 2001). Interestingly, an increase in 
the localisation of eIF2Bδ to small bodies was also observed in response to cellular 
stress (Figure 4.11), perhaps responsible for the observed increase in eIF2 movement. 
The localisation of eIF2Bδ to the small eIF2B bodies suggests the formation of a 
currently unidentified eIF2B subcomplex comprised of eIF2Bδ, γ, and ε subunits (Figure 
6.2C). This complex may not have been previously identified as characterisation of 
mammalian eIF2B subcomplexes has not been carried out under stress conditions 
(Wortham et al., 2014). However previous work has demonstrated that the knockdown 
of eIF2Bβ leads to a reduction in the expression of all eIF2B subunits with eIF2Bδ 
suffering the greatest reduction (Wortham et al., 2016). These data show that eIF2Bβ 
is required to stabilise the expression of eIF2Bδ and as these subunits are known to 
heterodimerise it could be expected that eIF2Bβ stabilises eIF2Bδ through binding to it. 
These conclusions do not support the data presented here whereby an increase in 
eIF2Bδ localisation was observed in small eIF2B bodies but no change in the 
localisation of eIF2Bβ was observed. Further experiments should be performed to 
confirm the existence of an eIF2B(δγɛ) subcomplex, formed during conditions of 
cellular stress. Investigation into the expression levels of eIF2B β and δ subunits and 
pull-down analysis of these subunits under stress conditions may provide further 
insight.   
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Figure 6.2 Schematic representation of the GEF activity of mammalian eIF2B bodies. 
(A) eIF2 was found to move through eIF2B bodies suggesting they could be sites of GEF 
activity. (B) In response to cellular stress, phosphorylation of eIF2 inhibits the 
movement of eIF2 through large and medium sized eIF2B bodies suggesting a decrease 
in GEF activity within these bodies. (C) In response to cellular stress the movement of 
eIF2 through small eIF2B bodies is increased, suggesting that the GEF activity of these 
bodies is enhanced during cellular stress. This increased movement of eIF2 is 
accompanied by an increase in the percentage of bodies to which eIF2Bδ localises, 
suggesting the formation of an eIF2B(δγε) subcomplex. 
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Low levels of phosphorylated eIF2α have been documented to precondition cells, 
promoting a stress-resistant phenotype (Lewerenz and Maher, 2009; Lu et al., 2004a). 
It could be hypothesised that the increased activity of the small bodies under low 
levels of cellular stress may contribute to this stress-induced protective phenotype, 
through providing a source of eIF2B activity that is not down-regulated during stress. 
This could allow for a low level of translation to occur during low levels of cellular 
stress, enabling the cell to respond and survive. The N-terminal of eIF2Bδ has been 
shown to be required for cells to mediate a response to cellular stress, with the 
expression of an N-terminal truncated isoform rendering cells insensitive to the effects 
of phosphorylated eIF2α (Martin et al., 2010). Mutational analysis of eIF2Bδ may 
provide insight into the importance of eIF2Bδ localisation to the increased movement 
of eIF2 through small bodies and to the cell’s ability to respond to stress.  
The increased movement of eIF2 through small eIF2B bodies was only observed in the 
presence of low levels of phosphorylated eIF2. In the presence of high levels of 
phosphorylated eIF2, eIF2Bδ localised to an increased percentage of small bodies 
(Figure 4.11) however the movement of eIF2 through these bodies was inhibited 
(Figure 4.10). This decrease in the mobility of eIF2 correlated with a significant increase 
in the percentage of small eIF2B bodies to which phosphorylated eIF2 localised. The 
favoured explanation of these results is that eIF2B regulation is lost above a certain 
threshold of phosphorylated eIF2, due to eIF2B saturation. In addition to changes in 
the movement of eIF2 during stress, the number of small eIF2B bodies was found to 
increase. Recent work in S. cerevisiae has observed that induction of stress results in 
an increase in the number of cells harbouring eIF2B bodies (Moon and Parker, 2018); 
supporting the hypothesis that cellular stress impacts upon eIF2B localisation. From 
the data presented here a schematic model of mammalian eIF2B complex formation 
and regulation during cellular stress is proposed in Figure 6.3. 
 
  
170 
 
 
Figure 6.3 Working model for the phenotypic distribution of eIF2B complexes under 
conditions of cellular stress.  
The data presented in this study highlight that under normal cellular conditions eIF2B 
localises to two distinct populations of eIF2B bodies in mammalian cells; larger bodies 
containing all subunits and small bodies containing catalytic subunits (γ and ɛ). In 
response to low levels of cellular stress larger eIF2B bodies are partially inhibited by 
phosphorylated eIF2, whereas the GEF activity and number of small eIF2B bodies is 
increased, accompanied by an increase in the localisation of the eIF2Bδ subunit. It is 
hypothesised that these changes to small eIF2B body dynamics promote a stress-
induced protective phenotype. At high levels of cellular stress all eIF2B complexes are 
inhibited independent of size or subcomplex make up resulting in a stress-inhibited 
phenotype. 
171 
 
Having populations of eIF2B bodies where regulatory subunits are either present or 
absent appears to be linked to eIF2B regulation in U373 cells. If eIF2B bodies share the 
same properties in other cell types, the size and distribution of eIF2B bodies may 
provide an indication of a cell’s ability to function under conditions of cellular stress. 
Intriguingly, primary human astrocytes were found to have a significantly increased 
number of small eIF2B bodies when compared to U373, HepG2, MG-63 and HEK293 
cells (Figure 3.2, Figure 3.9 and Figure 3.10). Although U373 cells are also from an 
astrocytic lineage, these cells are cancerous likely altering their metabolism and 
perhaps explaining differences observed in eIF2B localisation (Hsu and Sabatini 2008). 
In U373 cells the induction of cellular stress and thus increased levels of 
phosphorylated eIF2 correlated to an increase in the number of small eIF2B bodies. 
The basal level of phosphorylated eIF2 was investigated in primary astrocytes and was 
found to be heightened in these cells (Figure 4.15). In U373 cells increased levels of 
phosphorylated eIF2 appeared to correlate with increased GEF activity of small eIF2B 
bodies. These eIF2B bodies therefore represent a source of eIF2B that is not 
downregulated during cellular stress. It was therefore hypothesised the presence of 
these small bodies may be protective through allowing cells to carry out low levels of 
translation in the presence of cellular stress. Astrocytes have a high metabolic turnover 
when compared to other cell types (Weber 2015). The high abundance of small bodies 
in astrocytes could be linked to high levels of translation required by these cells. 
Additionally, astrocytes require high levels of calcium to facilitate signalling within the 
brain (Bazargani and Attwell, 2016; Pivneva et al., 2008). Disturbances to calcium levels 
within the cell reduce the protein folding capacity of the ER and result in ER stress 
(Bahar et al., 2016). The ER plays an important role as an intracellular calcium store 
(Pivneva et al., 2008) and it could therefore be hypothesised that astrocytes require 
the ability to quickly and efficiently respond to ER stress to ensure calcium is readily 
accessible from ER stores.  
Differential localisation and functionality of eIF2B bodies between cell types is of 
particular interest with respect to VWM. Causative mutations in eIF2B are globally 
expressed however astrocytes and oligodendrocytes are the main cell types affected in 
VWM patients. Recent studies have demonstrated that basal levels of phosphorylated 
eIF2 are reduced in VWM mouse and also patient brain (Abbink et al., 2018). Studying 
172 
 
the localisation of VWM mutant eIF2B could provide insight into disease mechanisms. 
Furthermore, previous studies have demonstrated that although VWM mutant 
fibroblast cells, like wild-type cells, respond to cellular stress by decreasing global 
protein synthesis, the downstream transcription factor ATF4 is significantly enhanced 
suggesting that they suffer a heightened stress response (Kantor et al., 2005). 
Interestingly this hyper-induction of ATF4 expression is not observed for VWM mutant 
lymphocytes. These data suggest that the impact of VWM disease mutants on the 
induction of a stress response is cell type dependent (Horzinski et al., 2010). Analysing 
localisation patterns of both wild-type and VWM mutant eIF2B within various cell 
types could provide insight into VWM tissue specificity.  
Biochemically, VWM disease mutations affect eIF2B function in multiple ways (Li et al., 
2004). Although there is currently no treatment for VWM, the small molecule ISRIB 
and its derivative 2BAct have emerged as promising therapeutics for VWM mutations 
that destabilise eIF2B decameric complex formation. ISRIB reverses phosphorylated 
eIF2α induced translational repression (Sidrauski et al., 2013; Halliday et al., 2015; 
Sidrauski et al., 2015a), through increasing the activity of eIF2B by promoting decamer 
formation (Tsai et al., 2018; Zyryanova et al., 2018). The data presented here suggest 
that ISRIB promotes decameric stability in large and medium sized eIF2B bodies. Under 
conditions of cellular stress ISRIB appears to enhance the GEF activity of these eIF2B 
bodies, and subunit localisation data suggests all eIF2B subunits are present (Figure 5.2 
and Figure 3.12).  
ISRIB also impacted upon the dynamics of small eIF2B bodies despite not all subunits 
being present. ISIRB appeared to mimic the effect that low levels of cellular stress had 
on small eIF2B bodies, with a similar increase in the movement of eIF2 and 
redistribution of eIF2Bδ to these bodies observed (Figure 5.4 and Figure 5.5). 
Furthermore, DBM another drug capable of enhancing translation during conditions of 
cellular stress also induced these changes in small body dynamics. It was hypothesised 
that under low levels of cellular stress the increased activity of these bodies represents 
a protective stress-responsive phenotype by providing a source of eIF2B that is not 
downregulated during exposure to cellular stress (Figure 6.3). The observation of this 
phenotype under treatment with drugs that are known to reverse stress induced 
translational depression supports that these bodies may have a role in priming cells to 
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overcome stress.  Further investigation into this phenotype would be an interesting 
avenue to explore with respect to ISRIB and DBM.  
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7. Conclusions 
The data presented in this thesis demonstrates that like in yeast, eIF2B consolidates 
into large cytoplasmic bodies. The situation in mammalian cells appears to be more 
complex. eIF2B bodies of various sizes exist and the size of these bodies correlates 
with their subunit composition. eIF2B bodies with a surface area ≥ 3μm2, termed here 
large and medium eIF2B bodies, harbour regulatory subunits and appear to represent 
sites of GEF activity vulnerable to stress induced repression. eIF2B bodies with an area 
≤ 2.99 μm2, termed here small eIF2B bodies, are mainly composed of catalytic eIF2B 
subunits and the GEF activity of these bodies appears to be up-regulated in response 
to cellular stress. These bodies may therefore provide a level of eIF2B GEF activity 
during stress, allowing cells to respond and survive. The presence of these diverse 
bodies in different abundances may allow different cell types to harbour unique stress 
responses and perhaps contribute to the tissue specificity of VWM; a key area of 
future research.  
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